

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent: **04.09.1996 Bulletin 1996/36**
(51) Int Cl.⁶: **C12Q 1/70, C12Q 1/68, C12P 19/34 // C07H21/04**
(21) Application number: **91116561.1**
(22) Date of filing: **27.09.1991**

(54) **Nucleotide sequences useful as type-specific probes, PCR primers and LCR probes for the amplification and detection of human papilloma virus, and related kits and methods**
Nukleotid-Sequenzen nützlich als typenspezifische Sonden, PCR Primers und LCR Sonden zur Amplifikation und zum Nachweis von humanem Papillomavirus, sowie dazu verwendete Kits und Verfahren
Séquences nucléotidiques utiles comme sondes spécifiques du type amorces de PCR et sondes pour l'amplification et détection du virus-papilloma humain, et kits et procédés utilisés dans ce but

<p>(84) Designated Contracting States: AT BE CH DE DK ES FR GB GR IT LI NL SE</p> <p>(30) Priority: 28.09.1990 US 589948 28.09.1990 US 590105 28.09.1990 US 590253</p> <p>(43) Date of publication of application: 01.04.1992 Bulletin 1992/14</p> <p>(73) Proprietor: ABBOTT LABORATORIES Abbott Park, Illinois 60064-3500 (US)</p> <p>(72) Inventors: • Joseph, Jeffrey L. Cherry Hill, New Jersey 08002 (US) • Bouma, Stanley R. Mundelein, Illinois 60060 (US)</p>	<p>• Marshall, Ronald L. Zion, Illinois 60099 (US) • Laffler, Thomas G. Libertyville, Illinois 60048 (US)</p> <p>(74) Representative: Modiano, Guido, Dr.-Ing. et al Modiano & Associati S.r.l. Via Meravigli, 16 20123 Milano (IT)</p> <p>(56) References cited: EP-A- 0 301 968 EP-A- 0 320 308 EP-A- 0 402 132 EP-A- 0 425 995 WO-A-87/05630 WO-A-89/05357 WO-A-89/09940 WO-A-90/02821 WO-A-91/10675</p>
--	---

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 477 972 B1

Description

This invention relates generally to human papilloma virus, and more particularly, relates to nucleotide sequences of short strands of human papilloma virus which can be amplified and/or used to determine the presence of human papilloma virus products in a test sample, and some of which also can be amplified and/or used to determine the specific type of human papilloma virus of types 16 and 18 present in the test sample.

Human papilloma virus (HPV) is recognized as a venereally-transmitted disease of the anogenital tract which often is associated with the pathogenesis of cervical cancer and its precursor lesions. More than 56 types of HPV have been characterized. Of these, at least 21 types infect the anogenital tract. L. Gregoire et al., *J. Clin. Micro* 27 (12): 2660-2665 (1989). These mucosotropic viruses are associated most frequently with benign condyloma or latent infections. However, the presence of HPV in premalignant lesions and invasive cancers, particularly of the cervix, may reflect the oncogenic potential of these viruses. See P. M. Howley, in *Important Advances in Oncology*, D. T. DeVita, Jr. et al., eds., J. B. Lippincott, Philadelphia, PA (1987) at pages 55-73.

Certain HPV types, namely, HPV type 16 and type 18, and to a lesser extent HPV types 31, 33 and 35, are found in a high proportion of invasive cervical cancers and their metastases. However, many HPV types which infect the anogenital tract, such as HPV types 6 and 11, are found most commonly in benign condyloma and only rarely are found in invasive cancers. HPV detected in the anogenital tract can be classified broadly as low risk papilloma viruses (HPV types 6 and 11), intermediate risk papilloma viruses (HPV types 31, 33 and 35) or high risk papilloma viruses (HPV types 16 and 18), based on the association of the particular HPV type with malignancy. A. T. Lorincz et al., *J. Nat'l Cancer Inst.* 79:671 (1987). Thus, the detection of the presence of HPV and the determination of the specific type of HPV can provide a diagnostic and prognostic tool useful for determining the clinical significance associated with certain HPV types. The early detection of HPV by sensitive and specific reagents and methodologies also could provide earlier therapeutic management and counseling.

A need therefore exists for accurate and reliable methods to identify and type HPV in clinical specimens. However, known polyclonal antisera prepared by immunizing animals with disrupted virions are capable of detecting HPV antigens in only about 30-70% of cutaneous and mucosal warts. Further, the antisera are broadly cross-reactive. Available immunological tests have two major drawbacks. First, only well-differentiated cells apparently are capable of viral antigen expression. HPV-infected tissues which show higher degrees of neoplasia, such as carcinoma *in situ*, rarely contain HPV antigen. Thus, the further the development of the malignancy, the smaller the amount of detectable virus in the tested tissue. Secondly, these immunological tests are unable to identify specific viral types.

It is known that papilloma viruses share amino acid sequences in the major capsid proteins. See, for example, C. C. Baker, in *The Papovaviridae* (Vol. 2), P. M. Howley and N. P. Salzman, eds., Plenum Publ. Corp., New York (1987) at pages 321-385. The DNAs of this virus cross-hybridize, indicating homologous sequences. M. F. Law et al., *J. Virol.* 58:225-229 (1979). Thus, molecular hybridization techniques have been developed as a more sensitive and specific means of detecting and differentiating HPV DNA and RNA in clinical specimens. See A. T. Lorincz, *Obstetrics and Gynecol. Clinics of N. America* 14:451 (1987).

Sequences specific for the DNA and RNA of human papilloma virus are known and have been published. See, for example, PCT application No. WO 89/69940 published October 19, 1989, PCT application No. WO 86/05816 published October 9, 1986 and European Patent Application No. 0 301 968 published February 1, 1989.

The molecular hybridization techniques used to detect homologous DNA sequences are sensitive and can be highly specific if used with probes which bind to nucleic acid sequences which are unique to a particular HPV type. However, the concentration of total viral DNA in a given clinical sample may be below the limit of sensitivity of the test. For example, the amount of viral DNA in dysplastic cervical lesions is reduced with increasing dysplasia.

To overcome this problem of sensitivity, viral DNA sequences can be amplified by using, for example, the polymerase chain reaction (PCR) or the ligase chain reaction (LCR) techniques. The products thus obtained can be identified by using conventional hybridization techniques for identification of virus types, such as Southern blotting. See C. Oste, *Biotechniques* 6:163 (1988), K. B. Mullis, U. S. Patent No. 4,683,202, and EP-A-320 308 (BioTechnica).

Both PCR and LCR serve to amplify the DNA present in a test sample to detectable levels. In practice, the level of sensitivity is about 50 to 100 copies per sample. The next most sensitive technique is dot-blot, which can detect about 10,000 molecules, while Southern blot reliably detects about 100,000 copies of DNA per sample.

Thus, the appropriate diagnosis of HPV may require two steps. In one strategy, the presence of a clinically relevant type of HPV is first detected with a group-specific primer. After the presence of HPV is detected, differentiation between types can be performed by using a type-specific probe having low homology between the HPVs of the group. Alternatively, differentiation can be performed using a mixture of type-specific probes at the outset, provided these probes amplify DNA independently of each other, and that they can be detected independently. In the past, such tasks were attempted using specific antibodies. In general, nucleic acid probes and primers allow greater discrimination among subtypes than do antibodies. The use of DNA-based tests increases both sensitivity and specificity over prior-art antibody-based tests.

It therefore would be advantageous to provide oligonucleotide strands of DNA which could be amplified and used to detect the presence, if any, of HPV in a test sample. It also would be advantageous to provide short oligonucleotide strands of DNA which could be amplified and used to detect the presence, if any, of specific types of HPV in the test sample. The combined use of oligonucleotide strands would be advantageous for allowing for the specific and sensitive in vitro diagnosis of the presence and specific type of HPV present in test samples.

SUMMARY OF THE INVENTION

Oligonucleotides of from about 10 to about 60 nucleotides are provided which can be amplified and used either to detect specific sequences of specific types of human papilloma virus, or consensus regions with high homology among different types. The presence of HPV is determined by contacting the test sample with sequences provided to detect the presence, if any, of HPV types 6, 11, 16, 18, 31, 33 and 61. This may be done with or without prior amplification, for example, by PCR or LCR. Either type-specific or consensus amplification is also possible. Two oligonucleotides are provided if the sequence is to be amplified by PCR, and four oligonucleotides provided if amplification is by LCR, in accordance with these known amplification procedures. After the presence of HPV is detected, the type of HPV present in the sample can be determined by using HPV type-specific probes, by subsequent rounds of PCR, or by LCR. Alternatively, the presence of type-specific HPV can be determined by contacting the test sample directly with type-specific nucleotide sequence provided by the invention for the detection of HPV types 16 and 18. Also provided are methods for using the oligonucleotides and kits for amplifying and detecting the presence of human papilloma virus.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a photograph of a gel following electrophoresis showing the results when the primers PCR 1 and PCR5 were used to amplify selected plasmids wherein HPV 6 is in lane 1, HPV 11 is in lane 2, HPV 16 is in lane 3, HPV 18 is in lane 4, and HPV 31 is in lane 5, HPV 33 is in lane 6, HPV 61 is in lane 7, and molecular weight standards are in lane 8.

FIG. 2 is a photograph of a gel following electrophoresis showing the results when the primers PCR 1, PCR2, PCR3, PCR4 and PCR5 were used to amplify plasmid p65.16.8 (HPV 16). PCR1 and PCR5 are primers according to the invention.

FIG. 3 is a photograph of the ethidium bromide-stained gels wherein PCR 1 4 and PCR15 are used in conjunction with IWDO to obtain amplified PCR product.

FIG. 4 is a graph of results obtained from performing LCR on 10^7 molecules of the selected target using LCR5A, LCR5A', LCR5B and LCR5B'. The rate of reaction of 4-methylumbelliferone is expressed as fluorescence counts/second/second and plotted against the target HPV type.

FIG. 5 is a graph of results obtained from performing LCR on 10^7 molecules of the selected target using LCR6A, LCR6A', LCR6B and LCR6B'. The rate of reaction of 4-methylumbelliferone is expressed as fluorescence counts/second/second and plotted against the target HPV type.

FIG. 6 is a graph of results obtained from performing LCR on 10^7 molecules of the selected target using LCR7A, LCR7A', LCR7B and LCR7B'. The rate of reaction of 4-methylumbelliferone is expressed as fluorescence counts/second/second and plotted against the target HPV type.

FIG. 7 is a graph of results obtained from performing LCR on 10^7 molecules of the selected target using LCR8A, LCR8A', LCR8B and LCR8B'. The rate of reaction of 4-methylumbelliferone is expressed as fluorescence counts/second/second and plotted against the target HPV type.

DETAILED DESCRIPTION OF THE INVENTION

The appropriate diagnosis of HPV requires two sets of conditions. The first enables the detection of all pertinent types, and the second set allows differentiation among them. In the past, such tasks have been attempted using specific antibodies. In general, nucleic acid probes and primers allow greater discrimination among subtypes than do antibodies. Thus, the use of DNA-based tests tends to increase both sensitivity and specificity over antibody-based tests.

U. S. Patents No. 4,683,195 and 4,683,202 teach a method of amplifying DNA sequences by using PCR. This method now is a standard procedure in many molecular biology laboratories. Examples 1-3 which follow below utilize the procedures taught in these two patents and the method as described in the package insert of the commercially-available Gene-Amp™ kit (Document No. 55635-6/89, Perkin-Elmer/Cetus, Emeryville, CA).

In PCR, two complementary polynucleotide strands are amplified by treating the strands with two oligonucleotide primers such that an extension product of each primer is synthesized which is complementary to each nucleic acid strand. The primers are selected such that the extension product of one primer forms a template for the synthesis of an extension product from the other primer once the extension product of the one primer is separated from the template. A chain reaction is maintained by a cycle of denaturing the primer extension products from their templates, treating

the single-stranded molecule generated with the same primers to re-anneal, and allowing the primers to form further extension products. The cycle is repeated for any many times as it takes to increase the target nucleic acid segments to a concentration where they can be detected.

The amplified target sequence can be detected by any of several known techniques; for example, by denaturing the double-stranded products formed by PCR, and treating those products with one or more reporter probes which hybridize with the extension products. The reporter probe has a detectable label, and usually is added in excess. The unhybridized reporter probe, therefore, must be separated from the hybridized reporter probe by involving a separation step. In another method of detecting the extension products without reporter probe and a separation step, the extension products are detected by gels stained with ethidium bromide. The diagnosis can be confirmed by transferring the DNA to nitrocellulose and probing with a probe specific to the HPV type suspected of being present in the sample.

Alternately with PCR, one may take advantage of known restriction sites within the HPV DNA to demonstrate that the amplified DNA contains the expected sequence by examining the cleavage pattern(s) generated with one or more restriction endonucleases. Verifying the authenticity of the amplified sequence may be necessary for two reasons: (1) to ensure that sequences complementary to the amplifying primers are not fortuitously present in cellular DNA which does not contain HPV DNA, and (2), to identify the type of HPV present in the sample. If the sequences chosen for amplification are conserved among HPV types, then the finding of an amplified product does not implicate a particular HPV type. It also should be possible to predict the size of the amplified product based on the binding positions of the two primers. Thus, when that product is found, one reasonably can be assured that HPV is present. However, two different types of HPV may give the same or different size products. Thus, hybridization should be used to confirm the identity of the amplified sequence until confidence is built that the interpretation of the results is reliable. It should be pointed out that the PCR technique will identify only closely related, or type-specific sequences in the absence of highly homologous primers, since only a small portion of the genome is analyzed.

Another particularly useful detection technique is described in EP-A-357 011. In this method, a different reporter molecule, e.g. hapten, is attached to each primer. Following amplification, but before denaturation, duplexes can be detected by "capturing" one hapten (hapten1) with a solid phase coated with anti-hapten1. The separated complex can be detected with a conjugate of label and anti-hapten2, and label associated with the solid phase can be measured.

The Ligase Chain Reaction (LCR) amplifies sections of DNA by copying the section of DNA, and copying the copies of that section of DNA, many times over. This method is described in European Patent Application No. 0 320 308 published June 14, 1989, which is incorporated herein by reference. In this procedure, two probes (for example, A and B) complementary to immediately adjacent regions of a target sequence are hybridized and ligated. This ligated probe then is denatured away from the target, after which it is hybridized with two additional probes (A' and B') of sense opposite to the initial probes A and B. The secondary probes are themselves then ligated. Subsequent cycles of denaturation/hybridization/ligation create the formation of double-length probes of both sense (+) and antisense (-).

In LCR, the nucleic acid of the sample is provided either as single stranded DNA or as double-stranded DNA which is denatured to separate the strands. Four probes are utilized: the first two probes (A and B) are the so-called primary probes, and the second two probes (A' and B') are the so-called secondary probes. The first probe (A) is a single strand capable of hybridizing to a first segment of the primary strand of the target nucleotide sequence. The second probe (b) is capable of hybridizing to a second segment of the primary strand of the target nucleotide sequence. The 5' end of the first segment of the primary strand of the target is positioned relative to the 3' end of the second segment of the primary strand of the target to enable joining of the 3' end of the first probe to the 5' end of the second probe, when the probes are hybridized to the primary strand of the target nucleotide sequence. The third probe (A') is capable of hybridizing to the first probe, and the fourth probe (B') is capable of hybridizing to the second probe (B). The hybridized probes are ligated to form reorganized fused probe sequences. Then, the DNA in the sample is denatured to separate ligated probes from sample DNA. Successive cycles wherein the ligated probes and target DNA undergo the above-described process are performed to increase the amount of detectable DNA in the sample. The amount of cycles performed is dependent upon the sequence used and the sensitivity required of the test. Usually, the cycle can be repeated from 15 to 60 times. At least one of the probes can be conjugated to a signal generating compound.

If the four probes are conjugated to appropriate binding members, the detection of amplified product can be accomplished using standard manual or automated immunoassay procedures known to those skilled in the art. These procedures include, for example, immunochromatography, ELISA, EIA and MEIA. Hybridization also can be accomplished by following standard dot-, slot- or replica-blot procedures which are known to those in the art. The sequences can be labelled with an appropriate signal generating compound (label), which is capable of generating a measureable signal detectable by external means. The various signal generating compounds contemplated include chromogens, catalysts such as enzymes, luminescent compounds such as fluorescein and rhodamine, chemiluminescent compounds, radioactive elements such as ³²P, and other labels known to those of ordinary skill in the art. The selection of a particular label is not critical, but it will be capable of producing a a signal either by itself or in conjunction with one or more additional substances. A variety of different indicator reagents can be formed of label and specific binding member. Either the label or a specific binding member can be varied. Examples of specific binding members which

can be used as a member of the indicator reagent include antibodies, both monoclonal, polyclonal, and fragments thereof; avidin or biotin, biotin and anti-biotin, a carbohydrate or a lectin, a complementary nucleotide sequence, an effector or a receptor molecule, an enzyme cofactor or an enzyme; an enzyme inhibitor or an enzyme; also any antigenic substances, haptens, antibodies, and combinations thereof.

The test sample can be any biological material suspected of containing HPV. Thus, the test sample can be human body tissue, or a test sample which contains cells suspected of containing HPV.

The invention will now be described by way of Examples, which are meant to describe, but not to limit, the spirit and scope of the invention.

The following terms used in the examples are trademarks, tradenames or chemical abbreviations as specified:

TRIS - chemical abbreviation for [tris(hydroxymethyl)aminomethane], used as a buffer.

EDTA - chemical abbreviation for ethylenediaminetetraacetic acid, a chelating agent.

FITC - chemical abbreviation for fluorescein isothiocyanate, a fluorescent hapten derivative.

NHS-ester - chemical abbreviation for N-hydroxysuccinamide ester

MES - chemical abbreviation for [2-(N-morpholino)ethanesulfonic acid], a buffer.

TWEEN®-20 - trademark of Atlas Chemical for polyoxyethylene sorbitan monolaurate, a detergent.

BIS-TRIS - chemical abbreviation for [bis-(2-hydroxyethyl)-amino]tris-(hydroxymethyl)methane, a buffer.

TRITON X- 100® - trademark of Rohm & Haas for nonaethylene glycol octylphenol ether, a detergent.

IMx® - trademark of Abbott Laboratories for an automated instrument for performing microparticle enzyme immunoassay (MEIA).

EXAMPLES

EXAMPLE 1

PCR was performed essentially following the package insert of the commercially available Gene-Amp™ kit (document No. 55635-6/89, available from Perkin-Elmer/Cetus, Emeryville, CA). The following reagents were mixed in a 0.5 mL polypropylene tube and used in performing PCR:

Reagent	Final Concentration
Water	(to give final volume = 50 or 100 µL)
Reaction Buffer	10 mM TRIS pH 8.3
	50 mM KC1
	1.5 mM MgCl ₂
	0.01% gelatin
dNTP mixture	200 µM each of dATP, dCTP, dGTP, and TTP
pCR1	1 µM
pCR2	1 µM
plasmid	10 µL 1 ng/100µL
(or control-human placental DNA (Pooled Placental DNA, catalog D-3287, Sigma Chemical Co, St. Louis MO).	
DNA polymerase, <u>Thermus Aquaticus</u>	25 or 63.9 units/1 mL

After mixing, the reaction mixture was overlaid with 100 µL of mineral oil. The tube then was placed in an instrument capable of incubation at several temperatures, and subjected to 30 or 40 cycles of programmed temperature change. The precise cycle of temperature change used, and the instrument used, varied with the experiment, and is detailed in the descriptions of the figures in Example 3.

EXAMPLE 2

Following the procedure of Example 1, the following sequences were found to amplify sections of papilloma virus types 6, 11, 16, 18, 31, 33, and 61 using PCR.

PCR1: CAGATGTCTC TGTGGCGGCC TAGTG (ID No. 1)

EP 0 477 972 B1

PCR5: AGGTGTCAGG AAAACCAAAT TTATT (ID No. 5)

PCR14: GAATTAGTTA GACCATTAA AAG (ID No. 6)

PCR15: GGGGAAACAC CAGAATGGAT A (ID No. 7)

IWDO: ATCATATGCC CACTGTACCA T (ID No. 8)

Sequence IWDO is derived from a sequence disclosed in International application number PCT/US86/00629 (WO 86/05816).

TABLE 1 shows the sequences and where they map to in the various types.

TABLE 1
SEQUENCES WHICH CAN BE USED AS PROBES OR PCR PRIMERS

PROBE	SEQ ID No.	SEQUENCE	SENSE	MAPS TO:	MAPS TO:	MAPS TO:	MAPS TO:	MAPS TO:	MAPS TO:
				(type 6)	(type 11)	(type 16)	(type 18)	(type 31)	(type 33)
PCR1:	1	CAGATGTCCTGTGCGGCTAGTG	+	5786-5810	5768-5792	5634-5658	5610-5634	5550-5574	5591-5615
PCR2:	2	CGTTTTCCATATTTTTGCAGATG	+	5767-5791	5749-5773	615-5639	5591-5615	5531-5555	5572-5596
OPCR3:	3	AAGTTGTAAGCACCGATGAATATGT	+	5844-5868	5826-5850	695-5719	5671-5695	5611-5635	5652-5676
PCR4:	4	AATGTACCCTAAATACCCTATATTO	-	6008-5984	5990-5966	865-5841	5841-5817	5784-5760	5825-5801
PCR5:	5	AGGTGTCAGGAAAACCAATTTATT	-	6044-6020	6026-6002	5901-5877	5877-5853	5820-5796	5861-5837
PCR14:	6	GAATTAATTAGACCATTTAAAG	+	1495-1517	1495-1517	1524-1546	1595-1617	1462-1484	1518-1540
PCR15:	7	GGGGAAACACCAAGAATGGATA	+	1834-1854	1834-1854	1863-1883	1934-1954	1801-1821	1857-1877
IWDO:	8	ATCATATGCCCACTGTACCAT	-	1931-1911	1931-1911	1960-1940	2031-2011	1898-1878	1954-1934

note: PCR2, PCR3 and PCR4 are not probes or PCR primers of the invention

EXAMPLE 3

Linearized plasmids containing full-length papilloma virus inserts in pGEM3 were used as targets. These were pHPV6.1 (HPV6), pSP65.11.5 (HPV 11), p65.16.8 (HPV16), pHPV18H(HPV18), pG3 HPV31 (HPV31), pLNK322.HPV33 (HPV33), and pBR322.HPV61 (HPV61). The Programmable Cyclic Reactor™ (available from Eri-comp, San Diego) was used as the incubation instrument. Following PCR procedures as described in Example 1, 10 µL aliquots were analyzed by electrophoresis through agarose (comprising a 5:3 ratio of NuSieve®:SeaKem® GTG, available from the FMC Corp., Rockland, ME) in a buffer comprising 0.089 M TRIS, 0.089 M borate, 2 mM EDTA, and 0.5 ppt ethidium bromide.

FIG. 1 is a photograph of an ethidium bromide-stained 1.2% agarose gel showing results using 63.9 units/mL DNA polymerase, in the DNA Thermal Cycler™ (Perkin-Elmer/CETUS, Emeryville, CA). The samples were heated for 5 minutes at 94°C, then subjected to 40 cycles of a temperature program of: 1 minute at 94°C, 2 minutes at 40°C, and 1.5 minutes at 72°C. The PCR primers used in this case were PCR 1 and PCR5 of Example 2. Examination of the gel following electrophoresis showed bands at the expected positions, i.e. 292 bp. Lane 1, HPV6; lane 2, HPV 11; lane 3, HPV16; lane 4, HPV 18; lane 5, HPV31; lane 6, HPV33, lane 7, HPV61; lane 8, pooled human placental DNA (suspected of having HPV infection); lane 9, molecular weight markers-Hae III digest of ΦX174.

FIG. 2 is a photograph of an ethidium bromide-stained 4% agarose gel showing results using 25 units/mL DNA polymerase, in the Programmable Cyclic Reactor™ (Ericomp, San Diego, CA). Samples in this case were subjected to 30 cycles of a temperature program of: 50°C for one (1) minute, 72°C for two (2) minutes and 95°C for one (1) minute. In this case, the primers PCR1, PCR2, PCR3, PCR4 and PCR5 of Example 2 were used to amplify plasmid

EP 0 477 972 B1

p65,16.8(HPV 16). Examination of the gel of Figure 2 shows bands at the expected positions, i.e., PCR 1 and PCR4, 235 bp, lane 2; PCR1 and PCR5, 267 bp, lane 4; PCR2 and PCR4, 254 bp, lane 6; PCR2 and PCR5, 286 bp, lane 8; PCR3 and PCR4, 174 bp, lane 10; PCR3 and PCR5, 206 bp, lane 12; molecular weight marker, 123, 246, 369, 492,... bp ladder, lane 1. Note footnote to Table 1.

FIG. 3 is a photograph of an ethidium bromide-stained 1.2% agarose gel showing results using the same conditions as FIG. 1. In this case, PCR14 and PCR15 were used as primers in conjunction with IWDO. The expected size of the amplified PCR product of PCR 14 and IWDO is 437 bp for all of the HPV types tested. The expected size of the product of PCR 15 and IWDO is 98 bp. Products of these sizes appear in the gels, confirming that PCR14 and PCR15, used in conjunction with IWDO, will amplify HPV DNA of types 6, 11, 16, 18, 31, 33, and 61. Lane 1, Molecular weight marker (Hae III digest of FX 174); PCR 14 + IWDO, lanes 2-9: lane 2, HPV6; lane 3, HPV 11; lane 4, HPV16; lane 5, HPV18; lane 6, HPV31; lane 7, HPV33; lane 8, HPV61; lane 9, human placental DNA suspected of being infected with HPV; PCR 5 + IWDO, lanes 10-17: lane 10, HPV6; lane 11, HPV 11; lane 12, HPV16; lane 13, HPV18; lane 14, HPV31; lane 15, HPV33; lane 16, HPV61; lane 17, human placental DNA suspected of being infected with HPV; lane 18, molecular weight marker (Hae III digest of FX174 and Hind III digest of 1 DNA).

EXAMPLE 4

The following reagents were mixed in a 0.5 mL polypropylene tube as follows for the Ligase Chain Reaction (LCR):

Reagent	Volume	Final Concentration
Water	21 μ L	
Reaction Buffer	10 μ L	50 mM EPPS pH7.8 10 mM NH_4Cl 10 mM MgCl_2 100 mM K^+ (from all sources) 0.001% BSA 1 mM DDT
Nicotine Adenine Dinucleotide (NAD)	0.5 μ L	100 μ L
ProbeA (sense)	4 μ L	5.0×10^{11} molecules
ProbeA' (antisense, 5'-phosphate)	4 μ L	7.5×10^{11} molecules
ProbeB (sense, 5'-phosphate)	4 μ L	7.5×10^{11} molecules
Probe B' (antisense)	4 μ L	5.0×10^{11} molecules
Target (including human placental carrier DNA at 10 μ g/mL)	1.5 μ L	15 ng/50 μ L
DNA ligase, <i>Thermus thermophilus</i>	1 μ L	

This reaction mixture was overlaid with 30 μ L of mineral oil. The tube was placed in an instrument capable of incubation at several temperatures (e.g. thermal cycler from Coy Laboratory Products (Ann Arbor, MI) or the Programmable Cycler Reactor™ (available from Ericomp, San Diego, CA), and then subjected to several cycles of programmed temperature change. Each cycle involved incubation at 50°C for one minute and 85°C for one minute.

EXAMPLE 5

The following procedure was used when performing the Ligase Chain Reaction (LCR), which is described in published European Patent Application No. 0 320 308 A2. The reagents of Example 4 were utilized in the procedure as follows: Two probes (A and B) complementary to immediately adjacent to regions of a target sequence were hybridized and ligated. This ligated probe was denatured away from the target, and hybridized with two additional probes (A' and B') of sense opposite to the initial probes (A and B). The secondary probes then were ligated. Subsequent cycles of denaturation/hybridization/ligation created the formation of double-length probes of both + and - sense.

EXAMPLE 8

The following sequences were determined to be specific for a portion of the E6 region of HPV type 16:

Probe	SEQ ID No.	Sequence	Maps to:
LCR5A	81	GCTGCAAACA ACTATACATG ATATAA	157 - 182
LCR5A'	82	pTTATATCATG TATAGTTGTT TGCAGC	182 - 157
LCR5B	83	pTATTAGAAATG TGTGTACTGC AAGCA	183 - 208
LCR5B'	84	TGCTTGCAGT ACACACATTC TAATA	208 - 157

EXAMPLE 9

Base-denatured plasmids which contained full-length papilloma virus inserts in pGEM3 were used as targets. These plasmids were pG3HPV6(+) (HPV6), pSP 65. 11.5 (HPV11), pSP65.168 (HPV16), p63HPV18H(-)(HPV18), p63:HPV31 (HPV31), pLNK322:HPV33 (HPV33), pBR322:HPV35 (HPV35), pUC19:HPV52 (HPV52), pLNK322:HPV58 (HPV58), pUC9:HPV59 (HPV59) and pBR322:HPV61 (HPV61). All of the oligonucleotides used as probes from Example 8 had chemical labels covalently attached at the ends distal from ligation. These labels were: 5'-fluorescein-LCRSA, 3'-fluorescein-LCRSA', 3'-biotin-LCR5B and 5'-biotin-LCR5B'. Covalent attachment was performed by known methods, i.e., reaction of amine-terminated oligonucleotides with FITC or biotin-NHS-ester essentially following the procedures of Kansal et al., Tet. Letters 29:5537-5540 (1988). The thermal cycler used was obtained from Coy Laboratory Products, Ann Arbor, MI.

Following the LCR procedure of Examples 4 and 5, the mixtures were analyzed using a prototype version of the IM₂ instrument (Abbott Laboratories, Abbott Park, IL), following the protocol for microparticle enzyme immunoassays as follows. A 40μL aliquot of an LCR mixture was diluted 1:1 with distilled water. This diluted mixture was incubated with 50μL anti-fluorescein-conjugated polystyrene microparticles for five (5) minutes to form a suspension of immune complexes on the microparticles. This suspension then was transferred to an inert glass fiber matrix, to which the microparticles became attached. The matrix was washed with buffer (0.3M NaCl, 10 mM TRIS pH8, 0.1%NaN₃). Any immune complexes attached to the glass matrix was detected by using alkaline phosphatase-labeled conjugate that catalyzed the hydrolysis of 4-methylumbelliferone. The rate at which the 4-methylumbelliferone was generated on the matrix was proportional to the concentration of LCR product formed in the reaction mixture.

Referring to FIG. 4, the graph shows the results obtained from performing LCR on 10⁷ molecules of the targets in shown. The rate shown is the rate of generation of 4-methylumbelliferone, and is expressed as fluorescence counts/second/second. Background signal is approximately 10 c/s/s, as shown by the amplification of human placental DNA. The only values above background are those for sample containing HPV16, and those values are about 60 times background signal.

EXAMPLE 10

The following sequences were determined to be specific for a portion of the E6 region of HPV type 18:

Probe	SEQ ID No.	Sequence	Maps to:
LCR6A	85	CTTCACTGCA AGACATACAA ATAA	172 - 195
LCR6A'	86	pTTATTTCTAT GTCTTGCACT GAA	195 - 173
LCR6B	87	pCCTGTGTATA TTGCAAGACA GTAT	196 - 219
LCR6B'	88	TACTGTCTTG CAATATACAC AGG	218 - 196

EXAMPLE 11

Plasmids which contained full-length papilloma virus inserts in pGEM3 were used as targets. The plasmids used were those described in Example 9. All of the oligonucleotides used as probes obtained from Example 10 had chemical labels covalently attached at the ends distal from ligation. The thermal cycler was obtained from Coy Laboratory Products, Ann Arbor, MI.

Following LCR procedure described in Examples 4 and 5, the mixtures were analyzed as described in Example 9 using the prototype version of the IM₂ instrument (Abbott Laboratories, Abbott Park, IL).

Referring to FIG. 5, the graph displays the results obtained from performing LCR on 10⁷ molecules of the targets. The rate shown is the rate of generation of 4-methylumbelliferone, and is expressed as fluorescence counts/second/

EP 0 477 972 B1

second. Background signal is approximately 15 c/s/s, as shown by the amplification of human placental DNA. The only values above background are those for sample containing HPV 8, and those values are about 40 times background signal.

5 EXAMPLE 12

The following sequences were determined to be specific for a portion of the E6 region of HPV type 18:

10	<u>Probe</u>	<u>SEQ ID No.</u>	<u>Sequence</u>	<u>Maps to:</u>
	LCR7A	89	TATATTGCAA GACAGTATTG GAAC	200 - 223
	LCR7A'	90	pGTTCCAATAC TGTCTTGCAA TTTA	223 - 200
	LCR7B	91	pTTACAGAGGT ATTTGAATTT GCATT	224 - 249
15	LCR7B'	92	AATGCAAATT CAAATACCTC TGTAA	249 - 224

EXAMPLE 13

20 Plasmids which contained full-length papilloma virus inserts in pGEM3 were used as targets. The plasmids were those of Example 9. All of the oligonucleotides from Example 12 which were used as probes had chemical labels covalently attached at the ends distal from ligation. The thermal cycler was as described in Example 11.

Following the LCR procedure of Examples 4 and 5, the mixtures were analyzed as described in Example 9 using the prototype version of the IMx instrument (Abbott Laboratories, Abbott Park, IL).

25 Referring to FIG. 6, the graph shows the results obtained from performing LCR on 10^7 molecules of the targets. The rate shown is the rate of generation of 4-methylumbelliferone, and is expressed as fluorescence counts/second/second. Background signal is approximately 15 c/s/s, as shown by the amplification of human placental DNA. The only values above background are those for sample containing HPV 18, and those values are about 80 times background signal.

30 EXAMPLE 14

The following sequences were determined to be specific for a portion of the E6 region of HPV type 16.

35	<u>Probe</u>	<u>SEQ ID No.</u>	<u>Sequence</u>	<u>Maps to:</u>
	LCR8A	93	GTATGGAACA ACATTAGAAC AGCA	352 - 375
	LCR8A'	94	pTGCTGTTCTA ATGTTGTTCC ATAC	375 - 352
40	LCR8B	95	pATACAACAAA CCGTTGTGTG ATTT	376 - 399
	LCR8B'	96	AAATCACACA ACGGTTTGTG GTAT	399 - 376

45 EXAMPLE 15

Plasmids which contained full-length papilloma virus inserts in pGEM3 were used as targets. All of the oligonucleotides from Example 14 used as probes had chemical labels covalently attached at the ends distal from ligation. The thermal cycler was as described in Example 11.

50 Following LCR procedure of Examples 4 and 5, the mixtures were analyzed as described in Example 9 using the prototype version of the IMx instrument (Abbott Laboratories, Abbott Park, IL).

Referring to FIG. 7, the graph details the results obtained from performing LCR on 10^7 molecules of the targets. The rate shown is the rate of generation of 4-methylumbelliferone, and is expressed as fluorescence counts/second/second. Background signal is approximately 10 c/s/s, as shown by the amplification of human placental DNA. The only values above background are those for sample containing HPV 16, and those values are about 36 times background signal.

EXAMPLE 16

The attached Appendix (example 16) discloses the sequences of the invention aligned to known sequences.

5 EXAMPLE 16

APPENDIX

HUMAN PAPILLOMA VIRUS

10

ALIGNMENT of TYPES 6, 11, 16, 18, 31, and 33; with CONSENSUS SEQUENCE

15

The appendix lists the sequences of HPV types 6, 11, 16, 18, 31, and 33. It also shows where the sequences of this invention line up with respect to these HPV sequences. In addition, the appendix shows where other sequences, known to the Inventors as of 28 September 1990, and claimed or disclosed by or unknown to others, line up with respect to these sequences.

1. Sequences and Regions Claimed by Us;

20

PCR = Sequences per examples 1 through 3 (only PCR1, PCR5 PCR14 and PCR15)

LCR = Sequences per examples 4 through 14 only

2. Sequences and Regions Unknown to Others and Not Claimed by Us;

25

PCR = Sequences designated PCR other than those above JJ

LCR = Sequences designated LCR other than those above

30

*3. Sequences and Regions Claimed by Others;
(Italics represents antisense sequences)*

AUS = International application number (Australians) PCT/AU88/00047 (WO 88/06634)

35

WL = International application number (Wayne Lancaster, Wayne State University) PCT/US86/00629
(WO 86/05816)

BE = European Patent Application (Belgians) 89.033834 (X= T or U)

40

C = International application number (CETUS) PCT/US89/03747 (WO 90/C2821)

O = International application number (Oncor) PCT/US89/O1318 (WO 89/09940)

and

45

4. Sequences and Regions Disclosed by Others.

S = Sarkar, F.H. and Crissman. J.D. *Biotechniques* 9 180-184 (1990) *(Italics represents antisense sequences)*

50

55

[illegible]

6 125 GTCTGCAACgAcCAtATAGACCAGTTGTGCAAGACGTTTAATCTaTCTaTGCAtaCgTtGCAAAATTaAtT
11 125 GTCTGCAACAtCtAtATAGACCAGTTGTGCAAGACGTTTAATCTtTCTtTGCACACtCtTGC AAAATT CAGT
5 33 129 aaaACCACGAACaTtTgCatgAtTTGTGCCaAGCAtTtGgAgACAACtATACACAACAttgAAcTACAGT
16 124 gcGACCCaGAAAgTTaCcAcAgTTATGCaCaGagcTgCAAAACAACtATACATGAtATAAtATTgAaT
31 128 aaGACCTcGgAAaTtTgCatGAAcCTAaGCTcGGcAtTtGgAAAtAcCctacgATGAacTAAGATTgAAAtT
10 18 131 gcGACCctacAAgcTaCctGAtCTgtGCaCGGaActGaAcActtCactgcAaGAcATaGaAaTaAcctT
con g-gacCaagaa--tTacat-AgtTgtGCa-ggc-tTgaA-a-atCtatgcAt-a-aTa-aAaTaaa-T
GTCTGCAAC-AUS1 AUS7-GCAAGACGTTTAATCT-AUS7
AAGACCTC-C67 C74-ACACTCTGCAAAATTCAGT
15 010-GCGACCCTACAAGCTACCTGATCTGTGCACGGAACtGAACACTTCACTGCAAGACATAGAAAATACCT-010
024-GCGACCcAGAAAGTTACCACAGTtATGCACAGAGCTGCAAAACAACtATACATGATATAATATTAGAAT-024
S4-CTGGGTCTTTCAATGGTGTCAATA-S4
6 193 GtGTGTTTTGCAaGAATGCACTGACCACaGcAGAGATtTATtCATATGCaTATAAAcACCTTAgGtC
11 193 GCGTGTtTTGCAgGAATGCACTGACCACcGCAGAGATATATGCATATGCcTATAAGaACCTAAAGGTT
20 33 197 GCGTGgAatGCAAAaAAACCTtTGCAaCGAtCTGAGGTATATGAtTTTGCAtTTTgCaGATTTAaCaGTT
16 192 GTGTGTACTGCAAgcAACAGTTACTgCGAcgTGAGGTATATGAcTTTGcTTTcgGATTtAtgcATA
31 196 GTGTcTACTGCAaAggtCAGTTAacAgaAACAGAGGTATtAGAtTTTGcATTtAcAGATTTAaCaATA
25 18 199 GTGTaTAtTGCAAgacagtaTTggaActtACAGAGGTATTTGAAtTTGCATTTAaAGATTtAttgTg
con GtGTgtatTGCAagaa--catTgacac-a-caGAGgTaTatgaaTtTGCaTtTaaagAttTaa--gT-
AUS2-TACGTGACTGGTGGCCGTCTC-AUS2 C73-ACACCTAAAGGTC
GC-C74 AUS3-TGAGGTATATGACTTTTGCTTTT-AUS3
30 C60-GAGGTATWTGAHTTTGC-C60 01-CTAAAGGTT
C61-GAGATWTATKCATATGC-C61 02-CTAAAGGTT
C69-ACAGTATTGGAACCTACAG-C69 04-GATTTCcAA
C70-CAACAGTTACTGCGACG-C70 06-TTATGCATA
C72-GACAGTATTGGAACCTACAG-C70 07-TTATGCATA
S5-GTGTtTTTGcAGGAATGCACTGACCA-S5 08-AATACGTAT
35 010-GTGTATATTGCAAGACAGTATTGGAACCTACAGAGGTATTTGAATTtGCATTtAAAGATTtATTtGTG-010
011-TTATTtGTG
012-TTATTtGTG
013-AATAAACAC
017-CTAAAGGTC
018-CTAAAGGTC
020-GATTTCcAG
40 024-GTGTGTACTGCAAGCAACAGTTACTGCGACGTGAGGTATATGAcTTTGCTTTTCGGGATTtATGCATA-024
025-TTATTtGTG

[illegible]

6 329 ATATAGACACTTTgATTATGCTGgATATGCAaCaACAGTtGAAGAAGAAACtAAaCAAGAcATcTTAg
 11 329 ATATAGACACTTTAATTATGCTGcATATGCACtTACAGTAGAAGAAGAAACcAAtgAAGATATtTTAa
 5 33 333 ATATAGACATTATAATTATtCTGTATATGGAaATACATTAGAACAaAcAgttAAAAACCTTTaaATG
 16 328 gTATAGACATTATtGTTATAGTtTGTATGGAACAACATTAGAACAgaAtacAACAAACCGtTgTGTG
 31 332 ATTTAGAtggTATaGATATAGTGTGTATGGAACAACATTAGAaaaaTgACaAACAAAGGtaTATGTG
 10 18 335 ATTaAGAcAtTATtcAgActcTGTGTATGGAgacACATTgGAAAAcTaActAACActGGgtTATaca
 con aTatAGAcAtTaTaattAt-cTgt-TATGgAacaACAtTaGAA-Aa-aaactAAcaaag-t-Tat-tg
 atatagacatt-JJ1
 GTATAGACATTAT-AUS8
 15 C50-ATAHSACAYATACSTTGTGTMTCTT-C50
 C51-ATAHSACAYATACSTTGTGTMTCT-C51
 C52-ATAHSACAYATACSTTGTGTMTCT-C52
 C53-CTGAGACACATACCTCTGTGTGTAACT-C53
 C54-CTGAGACACATACCTCTGTGTGTAA-C54
 C55-CTGAGACACATACCTCTGTGTGTAA-C55
 20 O10-ATTAAGACATTATTCAGACTCTGTGTATGGAGACACATTGGAAAACTAACTAACACTGGGTTATACA-O10
 O24-GTATAGACATTATTTGTATAGTTTGTATGGAACAACATTAGAACAGCAATACAACAAACCGTTGTGTG-O24
 TATATCTGTGAAATTAATACGAC-S6
 6 397 AcGTGcTAATTCGgTGcTACCTGTGTGCAAAaCCGcTGTGTGAAGTAGAAAA ggTAAAAcAtATAcT
 25 11 397 AAGTGTTAATTCGtTGTTACCTGTGTGCAAAgCCGTTGTGTGAaATAGAAAAA cTAAAgCACATAtT
 33 401 AAaTaTTAATTAGGTGTATTATaTGCAAAgaCCtTTGTGTCTcAAGAAAAaAAcGACATgTGGAT
 16 396 ATTTGTTAATTAGGTGTATTaactGTCAAAagCCacTGTGTCTGAAGAAAAgCAAAGACATcTGGAc
 30 31 400 ATTTGTTAATTAGGTGTATaAcGTGTCAAAgACCGTTGTGTCCAGAAGAAAAACAAAGACATtTGGAT
 18 403 ATTTaTTAATaAGGTGccTgcgGTGcCAgAaACCGTTGaatCCAGcAGAAAAAcTtAGACAccTtaAT
 con AttTgtTAATTaGgTGtat--tgTGTCAaAaaCCgtTGtgTccagaAGAAAAaca-agAcAtct--at
 AUS4-AATTAATCCACATAAT-AUS4 AUS9-GATTATTTG
 35 AUS5-TGTCATAACCTTGAATGTCT-AUS5
 O10-ATTTATTAATAAGGTGCCTGCGGTGCCAGAAACCGTTGAATCCAGCAGAAAACTTAGACACCTTAAT-O10
 O24-ATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCTGAAGAAAAACAAAGACATCTGGAC-O24
 40
 45
 50
 55

6 464 aaccAAGGCGcGgTTCATAAA gCTAAAtgtacGTGGAAGGG TCGcTG
5 11 464 gggAAAGGCaCGcTTCATAAAA CTAATaAcCaGTGGAAGGG TCGTTG
33 469 ttAAAcAAACGATTTCATAATAT TtcGGGTcGtTGGGCAGGGCGcTGTgcGgCgTGTtTG
16 464 AAAAGcAAAGATTCCATAATATA aGGGGTCGGTGGACcGGtCGaTGTATGctcTGTtTG
10 31 468 AAAAGaAAACGATTCCACAACATAG GaGGAAGGTGGACaGgACGtTGcATagCaTGTtTG
18 471 gAAAAacgACGATTtCACAACTAGctgggcactataGAgGccaGtgccattcgtTGctgcaaccGagc
con aaaaAa--acgatTtCataA--atag-----ctaaaggacg-tgGcgaggcg-tgcatggct-Gttg
TGGGTATAGA-AUS9 AUS6-AAATGTATAGATTTTTATTTC-AUS6 C65-CAACCGAGC
15 010-GAAAAACGACGATTTCACAACATAGCTGGGCACTATAGAGGCCAGTGCCATTCTGTGCTGCAACCGAGC-010
024-AAAAAGCAAAGATTCCATAATATA AGGGGTcGGTGGACCGGTGCATGTATGCTGTtTG-024
6 512 CcTACACTGC TGGACAACATGCATG GAAGAcATGT
20 11 512 CtTACACTGC TGGACAACATGCATG GAAGAcTGT
33 528 gaggtcccgACGTAGAGAAATGCactgtgAcgTGTAaaaacgcCATGagagGACACaagcc
16 523 cagatcatcAAGAaCACGTAGAGAAAC CCAgcTGTAa tCATGCATGGAGAtACAC C
25 31 527 GagAAGACctCGTactGAAAC CCAagTGTAa aCATGCgTGCAGaAACAC C
18 539 acgacaGgaAcGAcTcCaacgacgcAgagaaacaCaAgtataAtattAaGtaTGcAtggACctaaggc
con --ga--gagaagaccacgta-aga-Actgca---ccaggtgtAaaacatgcaTGgagagAcacaaggc
C64-GAACACGTAGAGAAAC CCAG-C64
30 ACGACAGGA-C65
C66-GAGGTCCCGACGTAGAGAA-C66
010-ACGACAGGAACGACTCCAACGACGACGAGAAACACAAGTATAATATTAAAGTATGCATGGACCTAAGGC-010
024-CAGATCATCAAGAACACGTAGAGAAAC CCAG-024
6 547 TACCCtAAAGGA TATtGTAtTAGACCTGCAaCCTCCaGACCCTGTAGGGTTACATTGCTATG
35 11 547 TACCCtAAAGGA TATaGTAcTAGACCTGCAgCCTCCTGACCCTGTAGGGTTACATTGCTATG
33 590 aACgTTAAAGGA ATATGtTtTAGA TTTatATCCTGAaCCAACtGAcCTATACTGCTATG
16 579 TACaTTGcAtGA ATATaTGtTAGA TTTGCAACCaGAGaCAACtGAtCTCTACTGTTATG
40 31 577 TACgTTGCAAGAC TATgTGtTAGA TTTGCAACctGAGgCAACtGACCTCCACTGTTATG
18 607 aCaTTGCAAGACattgtaTtgcattTAGAgccccaaaAtgaaattcGggtTGACCTtCtaTGtAcG
con tAC-tT--AgGAc-----at-tgt-tTAGAcctt---catcc-ga-cCa--tGaccTacacTG-tAtG
45 BE16-ACCAGAGACAACXGAXCXACXGX-BE16
BE18-GXXAGAXXXGCAACCAGAGACAACXGAXCXAC-BE18
010-AACATTGCAAGACATTGTATTGCATTAGAGCCCCAAATGAAATTCCGGTTGACCTTCTATGTCACG-010
C89-G
C90-G

con

6 728 CTGGTTGTGcAGTGTACAGAAacAGACATCAGAgAAgTgCAAcAgCTTcTGTGGGcAACACTAAAcAT
 11 728 CTGGTTGTGgAGTGTcACAGAcgGAGACATCAGAcAAcTACAAGAcCTTtTGTGGGCACACTAAATAT
 33 771 TTaTGTGTcaAcACTcACAGcaaGtGACcTaCGAACcaTACAgcAaCTacTtATGGGCACAgTgAATAT
 16 760 TTGTGcGTACAAAGCACACAGTAGACATTcGtACTtTTGgAAGAcCTGTTAATGGGCACAcTaGGAAT
 31 758 TTGTGTGTACAgAGCACAAAGTAGAtATTcGcAtATTGCAAGAGCTGTTAATGGGcTcAtTtGGAAT
 18 809 cTagtaGTAGAAAGCtCAGcAGAcGAccTTCGagcATTcCAGcAGCTGTTtTGaaCaCccTgtcctT
 con -Tg--tGTAcAgAGcACAgaaG-aGAcAttcGaacatTgcAa-AgCTgtT-aTGggcaCacTaaa-aT
 XXG-BE19 BE29-AGCAAGXGACCXACGAACCAAXACA-BE29 C42-CCCGTGTGAYYYDTA
 XXGXGCGXAC-BE20 C43-CTTGTGGGACAGGAA
 CXAGX-BE25
 BE30-AGXACAGCAAGXGACCXACGAACCAAXACAGCAACX-BE30
 010-CTAGTAGTAGAAAGCTCAGCAGACGACCTTCGAGCATTCCAGCAGCTGTTTCTGAACACCCTGTCTT-010
 6 796 aGTGTGTCCCATCTGCGC AC CgAAgaCtTAACAACgATGGCGGACGATTcAGGTACAGAAAAT
 11 796 TGTGTGTCCCATCTGCGC AC CaAAACcATAACAAGGATGGCGGACGATTcAGGTACAGAAAAT
 33 839 TGTGTGCCcTAcCTGTGC ACaAcAAAtAAACATCAtCtAcaATGGCcGATcCTGaAGGTACAAAtGgg
 16 828 TGTGTGCCcCAtCTGTTCT CAgAAACcATAATCTACcATGGCTGATCCTGCAGGTACcAATGGGGAa
 31 826 cGTGTGCCcCAaCTGTTCT aCtAgAcTGTAA CTACAATGGCTGATCCAGCAGGTACAGATGGGGA
 18 877 tGTGTGTCCgtggTGTgC atCccagCaGTAAgCaACAATGGCTGATCCAGaAGGTACAGAcGGGGA
 con tGTGTG-CCcatcTGTgTtaca-aaacaataatcaCaAtg---G-t---g---gg---ta-ag-ggat
 C40-CACACRGGGTAGACRCG-C40 C75-ATGGCKGAYCCTGMAGGTAC-C75
 C41-CACACAGGCACACACG-C41 C76-ATGGCKGAYGATTcAGGTAC-C76
 ACACAC-C42 C77-ATGGCKGAYCCTTCAGGTAC-C77
 ACACAC-C43 C81-TACCGMCTRGGAACKTCCATG-C81
 C82-TACCGMCTRCTAAGTCCATG-C82
 C83-TACCGMCTRGGAAGTCCATG-C83
 010-TGTGTGTCCGTGGTGTGC ATCCAGCAGTAAGCAACAATGGCTGATC-010
 6 859 GAGGGGTcTGGGTGTACAGGATGGTTTATGGTAGAAGCtATAGTgcAaCACcCaACAGG TAC
 11 859 GAGGGGTcGGGTGTACAGGATGGTTTATGGTAGAAGCcATAGTAGAGCACAcTACAGG TAC
 33 906 GctGGGAtGGGTGTACTGGtTGGTTTgAGGTAGAAGCaGTcaTAGAGAgAAgAACAGG aGA
 16 895 GaGGGtACGGGATGTAATGGaTGGTTTTATGTAGAgGcTGTAgTgGAAaAAAAACAGG GGA
 31 891 GGGgACGGGATGcAATGGtTGGTTTTATGTAGAAGCaGTAAttGACAgAcAgACAGG GGA
 18 943 GGGcACGGGtTGtAAcGGcTGGTTTTATGTAcAAGCtaTtgTaGACAAaAaACAGGagatgtaat
 con gagGGgagcGGGTGTa-tGGaTGGTTTTa-GTAgaAGCt-TagTagA-aaaaaaACAGG-----a
 C78-TGTAMWGGMTGGTTTTATGT-C78
 C79-TGTAMWGGMTGGTTTGAGGT-C79
 C80-TGTAMWGGMTGGTTTATGGT-C80
 C84-ACATKWCKKACCAAAATACCA-C84
 C85-ACATKWCKKACCAAACTCCA-C85
 C86-ACATKWCKKACCAAAATACCA-C86

```

6 921 ACAAATATCAGACGATGAGGAtGAGGAGGTGGAGGACAGTGGGTATGACATGGTGGACTTTATTGATG
5 11 921 ACAAATATCAGAAGATGAGGAaGAGGAGGTGGAGGACAGTGGGTATGACATGGTGGACTTTATTGATG
33 968 TaATATtTCAGAAgATGAGGAtGAAAcAGcaGATGACAGTGGcagcGATTtAcTAGAgTTTATAGATG
16 957 TgcTATaTCAGATGACGAGAaCGAAAAtGacAGTGTATACaGGtGaaGATTtGGTAGAtTTTATAGtaA
10 31 951 caacATTTCAGAGGACGAAAATGAAGACAGtAGTGATACtGGGGAGGATATGGTtGacTTTATTGACA
18 1009 atcagaTgacGAGGACGAAAATG caACAG AcACaGGGtcGGATATGGTaGAtTTTATTGAtA
con a-aaat-tcaGA-GA-GAg-AtGaa-a-g-ggatgAcA-tGGgtagGAtaTggTaGAcTTTATtGat-
15 6 989 A CAGcaATATTACA CAcAATTcAcTGGAAAGCACAGGCATTGTTTTAAcAGGCAGGAGGGCG
11 989 A CAGgcATATTACA CAAAATTcTGTGGAAGCACAGGCATTGTTTTAATAGGCAGGAGGGCG
33 1036 ATtCtAtgGAAaATAgTATACAGGCAGAcACAGAGGCAGCcCgGGCATTGTTTTAATaTACAGGAAGgG
20 16 1025 ATgaTAATGAtTATtTaAcACAGGCAGAAACAGAGACAGCACAtGCgTTGTTTAcTGCACAGGAAGCa
31 1019 ATtgTAATGtATAcacAAcCAGGCAGAAgCAGAGACAGCACAGGCATTGTTTCATGCACAGGAAGCg
18 1071 cacaaggaacATtttgtgAaCAGGCAGAgctAGAGACAGCACAGGCATTGTTcCATGCgCAGGAgGtc
25 con attataatgcatatataataCAGgcagA--cagaG-cAGCaCagGCaTTGTTtaat-c-CAGGA-Gcg
6 1048 GAcaCcCATTATGCGACTGTGCAGGACCTAAAACGAAAGTATTTAGGtAGTCCATATGTTAGTCCCTAT
11 1048 GATGCTCATTATGCGACTGTGCAGGACCTAAAACGAAAGTATTTAGGcAGTCCATATGTaAGTCCCTAT
30 33 1104 GAgGATgATTtAaATGCTGTGtGtGcaCTAAAACGAAAGT TTGCCgc
16 1093 aAacAACATagAGATGCaGTaCAGGTTCtAAAACGAAAGT AT TtGGTAGTCCa
31 1087 gAggAACATGCAGAgGCTGTGCAGGTTCtAAAACGAAAGT ATgTaGGTAGTCCt
35 18 1139 cAcaAtgATGCACaAGtGtGTGcAtGTTtAAAACGAAAGT ttgcaggaggcagcacaga
con gA-gatcATt-agaggctgTgcagGttcTAAAACGAAAGTatttagg-agtcca--tgtga-tgcc-t
BE1-XAAAACGAAAGX-BE1
BE2-AGGACCXAAAACGAAAGXAXXXAG-BE2
BE3-AGGXXCXAAAACGAAAGXAXXXGG-BE3
BE4-AXGXXXXAAAACGAAAGXXXGCAG-BE4

```

6 1116 AAaCacTaTAGCcGAgGCAGTgGAAAGTGaaATAAGTCCACGaTTgGACGCCATTAAACTTACAaGAC
 11 1116 AAGCAaTgTAGCTaATGCAGTaGAAAGTGAgATAAGTCCACGgTTaGACGCCATTAAACTTACAaCAC
 5
 33 1151 ATGttcacaAagTGcTGcGgGagGAcgtTGtTGatcGTgCTgcaAacCCgtGtAgAacgtCTATtAaTA
 16 1146 cTtAGTGATATTAG . TGGaTGTGTaGacaATAATATTAGTCCtaGaTTAAAAGCTATATGTA
 31 1141 tTAAGTGATATTAG TaGtTGTGTGGATtATAATATTAGTCCACGgTTAAAAGCTATATGCa
 10
 18 1198 aaAcagtccATTAGgggagcgggctggagGTGGATacagAgtTaAGTCCACGgTTAcAAGaaATATcctt
 con a-aca-tatAtttagaggcagtgga-gtGtggatagt--t-taagtcc--g--taaaagctAa-gta

6 1184 AGCCAAAAAGGTAAAGCGACGGCTGTTTcAAACcaGGGAacTAACGGACAGTGGATATGGCTATTCT
 11 1184 AGCCAAAAAGGTAAAGCGACGGCTGTTTgAAACAcGGGAatTAACGGACAGTGGATATGGCTATTCT
 15
 33 1219 AAaAtAAAgAatGcAcAtacaGAAAacGaAAAATAgATGAgcTAGAAGACAGCGGATATGGCAATACT
 20
 16 1207 TAGAAAAcAAAGTAGAgCtGCAAAAaGgAGAtTATTTGAAagcGAAGACAGCGGGTATGGCAATACT
 31 1202 TAGAAATaAcAGTAAAACaGCAAAAacGaAGACTcTTTGAacTtcCAGACAGCGGGTATGGCAATACT
 25
 18 1266 TaaAtAgTgggcagAAAAagGCAAAAaGgcGgCTgTTTAcAaTatCAGAtAGtGGcTATGGCtgTtCT
 con -a-aaAaaaag-g-Aaa--ag-aaaa-g-a-aatatttgaacta-caGACAG-GGaTATGGC-aT-CT

JJ3-tatggctattct
 C87-ATACCGTTANGA
 C88-ATACCGAYAWGA

6 1252 GAAGTGGAAAGCTGgaacgggAACG CAGGTAGAGAAACA TGCGC
 11 1252 GAAGTGGAAAGCTG caACG CAGGTAGAGAAACA TGCGC
 35
 33 1287 GAAGTGGAAACT CAGCAGAT GGTA CAACA GGTA
 16 1275 GAAGTGGAAACT CAGCAGAT G tTACA GGTA
 31 1270 GAAGTGGAAAC gCAGCAGAT G gTACA GGTA
 40
 18 1334 GAAGTGGAAgC aacaCAGATtcaggtaacTACAaatggcgaacatggcggcaatgtatGTAG
 con GAAGTGGAA-Ctg----gca-caGataggtagag--ACA-----GtaG
 45
 gaagtggaaagctgnnnnncnacagat-JJ3
 CTCACCT-C87
 CTCACCT-C88

```

6 1295      taCCGGAAAAATGG      GGGAGATGGTCAGGAAAaGGA
11 1289 A      cCCGGAAAAATGG      GGGAGATGGTCAGGAAAaGGA
5          |      |||||      |
33 1321 A      AagtcAAAAATGG      cgACAC AaActtaaAtGActtaGA
          |      |||||      |
16 1306 A      A      gggcGccatgagactgAAACACcAtgtagtcAgtAtagtGg
          |      |||||      |
31 1301 A      GGAG      CAAC      AAACA      AC
10          |      |||||      |
18 1396      tggcggcagttacGGAGgctatagaCAACggggggcacagagggcAACA      AC
con      a-----ggag----aacgcaaaatgg----aga--gaaacacgagatggtcaggaaagggg

6 1329      CACAGGaAGGGACATAGAGGG      GGaGGAACATAcAGAGGGCGAAGCgcccacaaACAgTgtac
15          |      |||||      |
11 1323      CACAGGgAGGGACATAGAGGGTgagGgGGTGGAAcATagAGAGGGCGAAGCagtagacGACAGcaccC
          |      |||||      |
33 1358      atCtAGTGGGGtgGGGgATGaTtcaGAaCTaAGctGTgagacaaatGtAGaTagctGTGAAA
          |      |||||      |
16 1349      tggAACTGGCGgtGGTtgcagTcagtAcaGTAGTGGaagtggGGGAGagGgTgtTAGTGAAAGAcAcA
20          |      |||||      |
31 1317      AttAAGT      tgtaATgGTAGTG      ACGGGA      cAcATAGTGAACGAgAga
          |      |||||      |
18 1445 A      gcagtgtagacggTacaAGTG      AC      aAtAgcaatAtaGaaAat
con      a-caagtagggacagaga-ggt-agga-g--agtgataga-cgg--gaagca---agtgaaga-a--

25

6 1391      GgGAGCATGCAGgCACAgCAGGAATAT      TgGAATTgtTAAAATGTAAaGATtTAC      GggCagCATT
          |      |||||      |
11 1391      GaGAGCATGCAGACACAtCAGGAATAT      TAGAATTacTAAAATGTAAgGATATAC      GAtCtACATT
          |      |||||      |
30 33 1420      atgttACgttgCAGGAA AT      TAGtAATGTTCTAcAtAgTAGTAATACAAAAGCAAatAT
          |      |||||      |
16 1417      cTatAtgcCaAACACcacttacAA ATATTTTaATGTaCTAAAACTAGTAATGCAAAgGCAGCaAT
          |      |||||      |
31 1361      aTgAAaCtCCAAcAC      GtA ATATATTgcAaGTGTAAAAACTAGCAATGgtAAAGctGCTAT
          |      |||||      |
35 18 1487      gTaAAtCcaCAAtgtaccataGcAcAatTaaaagActTGTAAAAgtaAaCAATaaacAAGgaGCTAT
con      gtgaa--t-caa-c-ca-caggaAtAtattagaaatggt-tAaaaa--ag-aaTacaaaagcagc-aT

40

6 1455      ACtTGGTAAGTTTAAAGaATGCTTTGGGCTGTCTTTTaTaGATTTAATTAGGCCATTTAAAAGTGATA
          |      |||||      |
11 1455      ACaTGGTAAGTTTAAAGAcTGCTTTGGGCTGTcATTgTtGATTTAATTAGGCCATTTAAAAGTGATA
          |      |||||      |
33 1478      ATTataTAAATTTAAAGAGgcCTATGGaaTaAGTTTtTgGAATTAGTAAGACCATTTAAAAGTGATA
          |      |||||      |
16 1484      GTTAGcaAAATTTAAAGAGTTATAcGGGgTgAGTTTtcaGAATTAGTAAGACCATTTAAAAGTAATA
          |      |||||      |
45 31 1422      GTTAGgtAAATTTAAAGAAtTATATGGtGTAAGTTTtTatgGAaCTAaTTAGgCCATTTcAAAGcAAATA
          |      |||||      |
18 1555      GTTAGcagtATTAAAGAcacATATGGgcTatcaTTAcAGAttTAGTTAGaaatTTTAAAAGtgATA
con      -ttaggtaaaTTTAAAGA-t--TatGGgcT---tTTTataGA-tTA-TtAG-ccaTTTAAAAGtgATA
          JJ4-ttaggttagaccattttaaagtata
50

55

```

[illegible]

6 1795 TGGTTCtGtACAGGtATaTCAAAATGCCAGTACAGTTATAGGGGAaGCaCCaGAATGGATAACaCGCCA
11 1795 TGGTTTAgACAGGcATtTCAAATGCaAGTACAGTTATAGGGGAgGCgCCgGAATGGATAACgCGCCA
33 1818 TGGTTTAgAACAGcAaTgTCAAAcATTAGTGAAtGtaAAGGtacaAcCctGAATGGATAgAtAGAct
16 1824 TGGTATAaAACAGGtATaTCAAAAtATTAGTGAAgTgTATGgaGAcAcgCCGAATGGATAcAAAGACA
31 1762 TGGTAcAGAAcAGGAATgTCAAAcATTAGcGATGTATATGgTGAaAcACCAGAATGGATAgAAAGACA
18 1895 TGGTAtAGAAcAGGAATaTCAAAAtATTAGtGAAGTaatgGGAcACACcTgAgTGGATAcAAAGAct

con TGGT-tagaACAGgaATaTCAAAAtattAGtgaaGTaa-aGG-gaaaCaCCaGaATGGATA-aaaGaCa
BE32-AXAXCAAAXAXXAGXGAAGX-BE32 JJ6-tggataNaaagaca

6 1863 aACaGTTATTGAACAcgGgTTGGcAGAcAGTCagTTTAAATTAAcAGAAATGGTGCAGTGGGcGTATG
11 1863 gACcGTTATTGAACATAGtTTGGCTGACAGTCAATTTAAATTAACTGAAATGGTGCAGTGGGCATATG
33 1886 AACTgTTTTACAACATAGcTTTAATGATaTatATTGAtTTAAgTGAAATGGTACAGTGGGCATATG
16 1892 AACAGTATTACAACATAGTTTTAATGATtgTACATTGAaTTATCaCagATGGTACAATGGGcTAcG
31 1830 AACAGTATTACagCATAGTTTTAATGAcAcaACATTGATTTGTcCCAAATGGTACAATGGGCATATG
18 1963 tACtaTtaTACaACATgGaaTagATgATAgcAaTTTGATTGTGcAgAAATGGTACAATGGGCATtTG
con aACagTt-TacAaCataGttTt-atGA-agtaaaTTTgA-TTa-cagAaATGGTaCA-TGGGcATaTg
aacNgttatacaacatagtttNgatga-JJ6

[illegible][illegible]

6 2067 TTATAAACATGCAGAAATGAggAAGATGCTATaAAACAAATGGATaAAacATAGGGGTtCTAAAaTaG
 11 2067 TTATAAACATGCAGAAATGaaaAAGATGCTATtAAACAAATGGATtAAgtATAGGGGTaCTAAAgTtG
 33 2090 TTATAAAAaAGCAGAAAAAcgtAAAAATGTCaATagGACAAATGGATAcAAagTAGATGTGaaaaaAa
 16 2096 TTATAAACGAGCAGAAAAaaACAAATGagtATGaGtCAATGGATAAAaTaTAGATGTGatAggGTAg
 31 2034 TTATAAACGAGCAGAAAAACGACAAATGtccATGgGACAGTGGATtAAAagTAGATGTGAcAAAGTta
 18 2167 TTATAggCGAGCccAAAAACGACAAATGaataTGtcACAGTGGATacgAttTAGATGTtcaAAAAaTag

con TTATAaac-aGCagAAAAa-ga-AaATGtctATgagaCAaTGGATAaaataTAGatGTg-tAaa-tag
 JJ11-tggataaaaatatagatgtNctaaaatag

6 2135 AagGcacAGGAAAtTGGAAaCCAATTGTaCaATTcCTACGACATCAAAATaTAGAATTcATTCCtTTT
 11 2135 AcaGTGTAGGtAAcTGGAAgCCAATTGTgCAGTtCTtAGACATCAAAACATAGAATTtATTCCATTT
 33 2158 ATGATGGAGGAAATTGGAGaCCAATaGTaCAGTTgTTAAGATATCAAAACATtGAATTtAcagCATTT
 16 2164 ATGATGGAGGTGATTGGAAgCAAAATtGTTtATGTTTTTAAAGgTATCAAggtgTAGAgTTATGTCATTT
 31 2102 gTGACGaAGGTGAcTGGAGGgAcATAGTAAAGTTTTTAAAGATATCAACAAATAGaATTgTGTCATTT
 18 2235 aTGAAgggGGaGAtTGGAGaccaATAGTgcAaTTccTgcGATACCAACAAATAGAgTTTaTaaCATTT
 con atgatggaGG--AtTGGA--ccaAT-GTacagTTt-TaaGatAtCAAAA-aTaGAAtTtat--CaTTT
 atgatggaggaaattgga-JJ11 JJ12-cattt

6 2203 TTAActAAAtTtAAATTATGGCTGCACGGtACGCCaAAAAAAAAAcTGcATAGCCATaGTAGGcCCtCC
 11 2203 TTAAGcAAAcTaAAATTATGGCTGCACGGaACGCCcAAAAAAAAAtTGTATAGCCATTGTAGGgCCACC
 33 2226 TTAgtGTGCATtTAAAAagTTTTTaaAAGGtATACCaaaaaaAgcTGTATgcTAATTTgTGGaCCAGC
 16 2232 TTAaCTGCATTAAAAgaTTTTTgcAAGGcATACcTAAAAAAATTGcATaTTAcTATATGGTGCAGC
 31 2170 TTAAtCTGCATTAAAgctgTTTTTAAAGGAGTgCCaAAgAAAAAcTGTATtTTAaTAcATGGTGCACc
 18 2303 TTAgaGCcTTAAAtcaTTTTTAAAGGaaccCCcAAAAAAATGTtTagTatTttgTGGacCAGc

con TTAA-tgcatTaAAattaTtttT--AaGGaa-gCCaAAAAAAa-TGtaTagtaaT-t-tGG-cCa-C
 ttaagtgcattaaaattatttttgcaggNacNccNaaaaaaa-JJ12

6 2271 aGAtACTGGGAAaTCGTaCTTTTGTaTGAG TTTAATaAgcTTTcTaGGaGGtACAGTTATTAGTcAT
 11 2271 tGAcACTGGGAAGTCGTgCTTTTGcATGAG TTTAATtAAGTTTTTgGGgGGaACAGTTATTAGTTAT
 33 2294 aAAtACAGGaAAGTCATatTTTGGaATGAG TTTAATacAGTTTTTaaAAGGGTgTGTtATATcaTgT
 16 2300 TAaCACAGGTAAATCATtATTTGGtATGAG TTTAATGAAaTTcTgCAAGGGTcTGTAATATgtTtT
 31 2238 TAATACAGGTAAATCATATTTTGAATGAccTTATTGAgCTTTtTACAAGGATgTaTAATATCATaT
 18 2371 aAATACAGGaAAATCATATTTTGAATGAGttTTAT acaCTTTaTACAAGGAgcagTAATATCATtT

con -aAtACaGG-AAATCaTatTTTgGaATGAG-tTTAataaacTTTtTacaaGGatc-gT-ATat--taT

6 2338 GTaAATTCCaGCAGCCATTTtTGGtTgCaaCCgtTAgtAGATGCTAAgGTaGCATTgTTaGATGATGC
 11 2338 GTtAATTCCtGCAGCCATTTcTGGcTaCAGCCAcTaaCgGATGCAAAAGTgGCATTaTTgGATGATGC
 33 2361 GTAAATTCTAAAAGtCacTTTTGGTTgCAGCCATTatCAGATGCAAAATAGGAATGaTAGATGATGt
 16 2367 GTAAATTCTAAAAGcCATTtTTGGTTACAACCATTAGCAGATGCCAAAATAGGtATGTTAGATGATGC
 31 2306 GcAAATTCaAAAAGTCATTtTTGGTTACAACCACtGcCTGATGCTAAAATAGGCATGTTAGATGATGC
 18 2438 GtgAATTCcActAGTCATTtTTGGTTggAACCGtTaaCaGATaCTAAgGTgCcCATGTTAGATGATGC
 con GtaAATTCaaaaAG-CAtTTtTGGtT-cAACCatTagcaGATgCtAAA-TaG-aaTgtTaGATGATGc
 6 2406 aACACaGccATGTTGGAtATATATGGATACATATATGAGAAAtTgTTAGATGGTAATCCTATGAGtA
 11 2406 cACACAACCATGTTGGACATATATGGATACATATATGAGAAAccTaTTAGATGGTAATCCTATGAGcA
 33 2429 aACgCcAatAaGTTGGACATATATAGATGAtTAcATGAGAAATGCgTTAGATGGAAATgaaATTTCAa
 16 2435 TACAgTGCCcTGTGGAAcTAcATAGATGAcAAttTAAGAAATGCATTgGATGGAAATtAGTTTCTA
 31 2374 TACAACGCCaTGTGGcAtTAtATAGAcAAtTAccTAcGAAATGCacTAGATGGCAAcCCTGTATCTA
 18 2506 aACgACCaCgTGTGGAcATActTtGAtAccTAtaTgaGAAATGCgtTAGATGGCAAtCCaaTAagTA
 con aACaccgccatGTTGGAcATAtaTaGata--tAtaTgaGAAAtgc-tTaGATGG-AAccc-aT---tA
 JJ15-gttggacatatatNgatacNtatatgagaaatgcggttagatgg-JJ15
 6 2474 TtGAcAGAAAGcATAaAGCATTgACATTAAATTAaATGTCCACcCTgCTaGTaACgTCCAAcATAGAt
 11 2474 TAGATAGAAAACATAGAGCATTAAcATTAAATTAaGTGCCACCGCTaCTgGTTACaTCAATATAGAc
 33 2497 TAGATGTgAAACATAGgGCATTAGTgCAAtTAAATGTCCACCACTgCTtcTTAcTCAATACAAAT
 16 2503 TgGATGTAAAGCATAGAcCATTgTgTCAAcTAAATGcCCTCCATTATTaATTACATCTAAcAttAAAT
 31 2442 TaGATGTAAAGCATAAAGCtTTAATgCAGtTAAATGTCCCTCctTTATTgATTACATCTAATATAAAT
 18 2574 TtGATagAAAGCacAAAcCaTTAATaCAAcTAAATGTCCCTCCaaTAcTacTaACCaCaAATATACAT
 con TaGAt--aaAgCatA-agCaTTaatacaa-TaAAaTGtCC-CCacTacTa-TtACatCaAAtAtaaAt
 6 2542 ATTActAAAGaAGAtAAATAtAAgTATTtACATAcTAGAGTaACaACATTtACATTtCCAAATCCATT
 11 2542 ATTAGCAAAAGAgGAGAAATAcAAATATTtACATAGTAGAGTtACcACATTtACATTtCCAAATCCATT
 33 2565 GCaGGCACAGAcTCTAGATGGCCATATTtACATAGTAGATTaACaGTATTtgaATTttaaAAATCCATT
 16 2571 GcTGGTACAGATTCTAGgTGGCCtTATTtACATAaTAGATTGGTGGTgTTTACATTtCCtAAATgagTT
 31 2510 GCAGGTAAAGGATgAcAGATGGCCATAccTACATAGcAGAcTGGTGGTtTTTACATTtCCAAATcCATT
 18 2642 cCAGcaAAGGATaAtAGATGGCCATAttTAGAaAGtAGaaTaacaGTaTTTgaATTtCCAAATgCATT
 con gc-ggtAaaGatgatAgaTggccaTAttTAcAtAgTAGA-TaacagtaTTTAcATTtccaAAATccaTT

[illegible]

6 2876 AGCCACATaGGaaTgCAAGTAGTgCCACCATTAAagGTGTcCgAagCaAAAGGACATAATGCcATTGA
 11 2876 AGCCACATcGGgtTaCAAGTAGTaccACCATTAAcTGTGTcAGAGAcTAAAGGACATAATGCcATTGA
 5
 33 2902 tcACATtTatGCCACCagGTGGTGCcttCtTTGttaGcATCAAAGAcCaaAGCATTTCaAGtAATTGA
 16 2908 aAACATATTAAACCACCAaGTGGTGCcAaCacTGgCtGTATCAAAGaAtAAAGCATTACAAGCAATTGA
 31 2847 CAcAgTATTAAACCACCAGGTGGTGCcAGCgTTGtCaGTATCAAAGgCcAAAGCcTTACAAGCTATTGA
 10
 18 2982 CAgAcAtTaAACCACCAGGTGGTGCcAGCcTataacaTtTCAaaaagTAAAGCacataAAGCTATTGA
 con aaccataTaa-ccacCA-GTgGTgCCa-Cattgac-gtaTCaaAgactAAAGCa--t-AaGctATTGA
 JJ18-tcaaagactaaagcacataaagcNattga
 15
 6 2944 AATGCAAATGCATTTAGAATCaTTattAAggACTgAGTATaGTaTGGAAcCgTGGACATTACaAGaaA
 11 2944 AATGCAAATGCATTTAGAATCcTTAgcAAAAAcTCAgTATgTgTGGAAcCtTGGACATTACAgGAcA
 33 2970 ACTaCAAATGgCaTTAGAgACATTaagTAAATCACAGTATAGTAcagcCAaTGGACATTgCAACaaA
 20
 16 2976 ACTgCAAcTaACGTTAGAAACaAtaTATAACTCACAAATATAGTAATGaaAgTGGACATTaCAAGAcg
 31 2915 ACTaCAAATGatGTTgGAAACatTaaATAACACTgAATACAAAAATGAGGAcTGGACaATGCAGcAaa
 18 3050 ACTgCAAATGgcccTAcAAGgcccTgcacAaAgTcgATACAAAccGAGGATGGACAcTGCAagAcA
 25
 con AcTgCAAAgTg-c-tTagAaacatTa---aaaactca-Tatagta--gaaca-TGGACATt-CAagA-a
 actgcaaatgg-JJ18
 30
 6 3012 CaAGTTATGAAATGTGGCaAACACCACC tAAACGcTGtTTTAAAAAACgGGGcAAaACTGTaGaaGT
 11 3012 CcAGTTATGAAATGTGGCTAACACCACC CAAACGgTGcTTTAAAAAACAGGAAAtACTGTgAgGT
 33 3038 CaAGCTTaGAgGTGTGGCTttgTGAACCACC AaaATGTTTTAAAAAACaAGGAgAaACAGTaaCTGT
 16 3044 ttAGCCTTGAAgTGTATTTAACTGCACCAAC AGGATGTaTAAAAAACATGGATATACAGTgGaaGT
 31 2983 CAAGtCTTGAACtGTATTTAACTGCACCTAC AGGgTGTTTTAAAAAACATGGATATACtGTAGAgGT
 35
 18 3118 CATGcgagGAACTaTggaatACaGaACCTAcTcactgcTTTAAAAAA ggTGGccAaCaGTAcAaGT
 con caaG-t-tGaa-TgTggctaac-gcACCaacaa-g-tggttT-AAAAAacatGGA-A-AC-GTagaaGT
 40
 6 3079 tAAATTTGA TGGCTGTGcAaACAATacAATGGAtTATGTGGTATGGACAgAtgTgTatgTGCAGG
 11 3079 aAAATTTGA TGGCTGTGAAGACAATgtAATGGAgTATGTGGTATGGACAcATATATAcCTGCAGG
 33 3105 GCAATaTGA caatGACAAAaAaAATACAATGGATTATACAAACTGGggtgAaATATATATTataG
 16 3111 GCAGTTTGATGG aGACATatgCAATACAATGCATTATACAAACTGGAcAcATATATATATTGTG
 45
 31 3050 GCAaTTTGATGG tGAtGTAcACAACcATGCATTATAcTAACTGGAaAtTTATATAcTatTGTa
 18 3185 atAtTTTGATGGcaacaAaGacaAttgtAtgAcctATgtagCatgggacAgTgTgtatTataTgacTg
 con gcAaTtTGATggcaacgatgaaacaatacaAtggAttat-caaactggacagatataTataTg--tg
 50
 55

```

6 3144 ACAATGACaCtTGGGTAAAgGTgcaTAGTatgGTAGATGcTAAAGGGcATATATTACACATGTGGACAA
5 11 3144 ACAAcGAcTcATGGGTAAAaGTaACTAGTtccGTAGATGccAAGGGcATATATTATACATGTGGACAA
33 3170 AgGAAGAtaCATGtACTATGGTtACaGGgaAAGTAGATTATAtaGGTATgTATTATATACATaActGt
16 3176 AAGAAgcatCAgtaACTGTGGTaGAgGGtCAAGTTGAcTATTtAtGGTtTaTATTATGTtCATGAAGGA
10 31 3115 tAGAtGGccaATGtACTGTtGTgGAaGGgCAAGTTAATTgTAAGGGcaTtTATTATGTACATGAAGGA
18 3253 atGcaGgaacATGggacaaaaccCctacctgtGTaAgTcacAgGGGatTgTATTATGTAAaGGAAGGg
con a-gaaGacacatgg-cta-ggt-g-t-gt-aaGTagattataagGGTaTaTATTAt-tacatgaagga

15 6 3212 TTTAAAACATATTATGTAAAcTTTgtaAAAGAGGCAGAAAAGTATGGgAGcACCAAaCATTGGGAAGT
11 3212 TTTAAAACATATTATGTAAATTTTAAaAAAGAGGCACAAAAGTATGGTAGtACCAATCATTGGGAAGT
33 3238 gaAAAggtATATtTTaaAtATTTTAAAGAgGATGcTcGcAAAGTATtctTAAACacAAaTgTGGGAAGT
20 16 3244 atAcgAACATATTTTGTgcAgTTTAAAGAtGATGCAGAAAAATATaGTAAAAaTAAAgTATGGGAAGT
31 3183 catAtAACATATTTTGTAAAtTTTACAGaAGAGCAaAAAAATATGGGActggTAAAAaATGGGAAGT
18 3321 tAcAacACgTtTTaTaTAGAaTTTAAaAgTGAatgtgAAAAATATGGGAacacaggtAcgTGGGAAGT
25 con t-taaaacaTaTT-TgtaaAtTTTaaa-aaGAggcagaAAA-TATgg-Aa-ac-aaaaa-TGGGAAGT

6 3280 ATGTTATGGCAGCACAGTTAT ATGTTCTCCTGC ATCTGTATCTAGCACTacACaAGAAGTAT
11 3280 ATGTTATGGCAGCACAGTTAT ATGTTCTCCTGC ATCTGTATCTAGCACTgtACgAGAAGTAT
30 33 3306 ACATGtGGGTGGTCAGGTAAT tgTTGTCTCTAC gTCtaTATCTAGCA ACCA AaTAT
16 3312 tCATGCGGGTGGTCAGGTAAT atTaTGTCCTACATCTGTgTTTAGCAGCA ACCA AgTAT
31 3251 gCATGCGGGTGGTCAGGTAATTG TTTtTCCTgaATCTGTaTTTAGCAG TGACGA AaTAT
35 18 3389 aCATtttGGgaaTaAtGTAATTGattgTaaTgactctatgtgcagTACAG TGACGAcacggTAT
con acaT---GGt-gt-agGTaATtg-at-tt-Tcctgcatc-tct-t--c-AGcactgac-aagaagTAT
BE21-CGGTAT

40 6 3342 CCATTcCTGAA tCTACTACATACACCCCGCACAGACC tCcaCCCT tGTGTCCtCaaGC AC
11 3342 CCATTgCTGAA CCTACTACATACACCCCGCACAGACCacCgcCCCTacaGTGTCCgCctGC AC
33 3362 CCACTaCTGAAACTgcTgACATACA gACAGAC AAC gaTaacCGACC AC
16 3371 CCTCTcCTGAAAtTATtaggcagCA cttgGCC AACcACcCCgCCgCGACCcATAC
45 31 3310 CCT tTGCTggGATTGTAcAaAGCTACcaacaGCC AACaACACCcCaCaAtCGaATTC
18 3454 CC gcTaCTcaGcTTGTAAaAcAGCTAC AgcACACCcCCtCacCGtATTC
con CCact-cTgaaa---ttgacatacAcccagcacagacc---c---caacaac-cctcc-Caacc-ataC
CC---GCXACXCAGCXXG-BE21

```

```

6 3403 CA                               aGGAAGACGcaGTGcaaaCGCCGCTAGGAAaCG
5 11 3406 CAC                           GGAAGACGGcGTGtcggCGCCGCTAGGAAgCG
33 3410 CACAAGC                         agcggccAAACgacGACGAC      cTgCAGacACCA
16 3426 CA AAGCCgtCGCCTTGGGCACC      GAAG      AAACacaGACGAC      TATcCAGCGACCAAGA
10 31 3368 CA AAACCTgCGCCTTGGGCACCgAGtGAAGgtgTgCGGCgggcGACGACGTCTActaAGCGACCAAGA
18 3503 CA gcACCgtgtCCgTGGGCACC GcaAAGaccTaCGGC      caGACGTC
BE10-GGCGXGXCGGCGCCGCCXAG-BE10

15 con CACaaaccgtgccttgggcacc-g-gaaggcgtacgaagac-gacgacgtcc-cc-ag--accaaca
6 3439 AGCACGaggagtccaACaGTCCcCTtgCAACgCCtTGTGTGTGGCCcACATtgGacCCGTGGACAGTg
11 3442 AGCACG      tggACCGTCCaCTaaCAACaCCcTGTGTGTGGCCaACATCaGatCCGTGGACAGTA
20 33 3449      CAGACACCGCCcAgCCCCT      taaaaAgcTGTtGTGCA gaCccCgCCTTGGACAaTA
16 3481 tCAGAGCCAGACACCG GAAACCCCTgCCACaCCActAAGTTGTTGCacaGaGACTCaGTGGACAGTG
31 3435 aCAGAGCCAGAGcaC aGAAACcCCCaCCACcCCAacAAGTTGTTGCCagGCGACTCcGTGGACAGTG
25 18 3548      GgctgctAcACgaCCtggACaCtgtggAcTcGcgGaGaaGcagCattGTGGAC cTG
con acaaagccaga--ccgc-aaaCccct-c-acaccatgt-tttggtgcacagcggctccgTGGACagTg
6 3507 gAAACcACAACcTCaTCACTaAC      AATcACgACcAGCACCAAA      GAcGG      AACAACaG
30 11 3504 cAAtCaACAACATCGTCACTgAC      AATtACAACAAGCACCAAA      GAaGG      AACAACtG
33 3506 gAACAgcaCgtACTGCAACTAACTGC      aCAACAAGCAgCGGA      cTgtGTGT      AgTTC
16 3548 cTCCAaTcCtCtACTGCAttTAACAGCT      CACACAAAggACGGA      tTaaCTGT      AaTag
35 31 3502 TCAACTgtggggTTaTcAGTGCAGCT gcatgCACAAAccAAACAA      GGgCTGTcAGTtGTcc
18 3604 TCAAC      ccacTTCtCgGTGCAGCTacacctacaggcaaacAACAAaagacGGaaacTCtGTaGTg
con c--aac-c--cactgc-actaaCagcta-at-c-aacaagcacca-Aa-----gggtgtcaaca-t-g
40 6 3562 TaACAGTtCAGCTACGCCTATAGTGCAAtTtCAAGGTGAaTCCAATTGTTTAAAgTGTtTTAGATATA
11 3559 TcACAGTGcAGCTACGCCTATAGTGCAActgCAAGGTGAAtTCCAATTGTTTAAATGTtTTAGATATA
45 33 3561 TAACgtTGCA      CCTATAGTGcATTTAAAGGTGAaTcAATAGTTTAAATGTtTTAAGATA
16 3603 TAACACTACA      CCcATAGTACATTTAAAGGTGATGcTAAATcTTTAAATGTtTTAAGATA
31 3563 TgcaACTACA      CCTATAATACAcTTAAAGGTGATGCAATataTTAAATGTtTTAAGATA
50 18 3668 TaacACTAC      gCCTATAATACAtTTAAAGGTGAcagAAAcAgTtTAAATGTtTAcGgTA
con TaacacTaCagctacgCCTaTAgT-CAttTaaAAGGTGAttcaAatagtTTAAATGTtTaaGaTata
JJ20-catttaaaaggtgaNtcNaatagtttaaaatgtttaagatata
55

```

6 3630 GgCTaAATGACAgAcAcAgACATTTaTTTGATTTAaATCaTCAACGTGGCacTGGGCTCctCaaAG
 11 3627 GaCTgAATGACaaATATAAACATTTGTTTGAaTTAgcATCtTCAACGTGGCATTGGGCTCacCtgAG
 5
 33 3621 cAGATTaAAACcTtATAAAgAgTTGTATAgTTCtaTGTCaTCcACcTGGCATTGGACCaGtgAcAAc
 16 3663 TAGATTtAAAAAgcATtgtaCATTGTATAcTgCAGTGTcGtCTACATGGCATTGGACAgGacAtAAAT
 31 3623 TAGgcTGtcAAAAAtATAaacAATTGTATgaAcAAGTGTcATCTACATGGCATTGGACAtGtacagAT
 10
 18 3728 cAGatTGcgAAAAAcATagcgAccacTATagAgAtaTaTCATCACCcTGGCATTGGACA ggtgc
 con g-agattt-aaaaa-Ata-aca-ttgTaT-a-t-a-t-TCaTC-AC-TGGCAtTGGaC-tg-cc-aa-
 gcagatt-JJ20
 15
 6 3698 GCACCACATAAA cATGCCaATTGTAACtgTAACAT ATgatAGTGAGGAACAAaGgCAaCagTTTT
 11 3695 GCACCACATAAA ATGCAATTGTAACatTAACAT ATAgcAGTGAGGAACAACGtCagCAaTTTT
 33 3688 aaaaaatagTAAAA ATGgAATTGTAACtgTAACATtTGtaAcTGAACAGCAACAAC AaatgTTTT
 20
 16 3730 GtAAAAACATAAAA gTGCAATTGTtACacTtACATATGatAGTGAATgGCAAC GtGACCaATTTT
 31 3690 GGAaaACATAAAAA TGctATTGTaAcCtTAACATATataAGTAcATCACAA AGAGACgAtTTTT
 18 3791 aGgcAAAtgaAAAAAcaGgaATacTgAcTgTAACATAccatAGTgaAaCACAA AGAacaaATTTT
 25
 con g-a-aacatAAAAaatGcaATTgTaACtgTaACATatgatagt-aa-agcAAcaaag--aascaATTTT
 6 3762 TAGAtgtTGTAaaaaATACCcCctACCATTAGcCA CAAacTGGGaTTTATGTcAcTgCaccTATTGTa
 11 3759 TAAAcAgTGTAaaaaATACCACCcACCATTAGcCAT AAGgTGGGgTTTATGTcATaCATTtATTGTa
 30
 33 3752 TAaggTAaccGTAAAAATACCACC tACTgTgcaAAT AAG TACTGGATTtAT
 16 3794 TgtcTcaaGTTAAAAATACCA AAaACTAtTaCAGT GTC TACTGGATTtAT
 31 3754 TAAATACTGTaAAAAATACC tAAcACagTatCAGT GTCaacaggatatatgactATTTA
 35
 18 3856 TAAATACTGT
 con TaaatactGTaaaaataccaccaaaaca-tagcaat-aagggtcgg-tttatgt-actg-atttattgtgta
 40
 6 3829 AtttgtatatatgtaaAtgtgTaaATATATGgTATtgGTGTaatacaActgTACaTGTATGGAaGTgG
 11 3826 A cCATTAcaccTgtATATATG TATAtGTGTA CATAACATACgTGTATGGAaGTaG
 33 3801 G aCATTA TAaGTGTA CATcACAagCcaaTATG
 16 3843 G tCt
 45
 31 3812 gCc
 18 3866 tgcaattccagatagtgtacaaatattggtgggataCa
 50
 con a-----g--catta----t--atatatggtatatgtgta--cataacaaacatgtatggaagtcg
 55

6 3897 TGCCTGTACAAATaGCTGCGAGgAACAAccAgcACATTcTACTc GCCTGTTTaATTGTCAT
|||||
5 11 3881 TGCCTGTACAAATTGCTGCGAGcAACAACTACaACATTGATATT GCCTGTTGTTATTGTCAT
|||||
33 3833 TGCTGC TaAtTgttATATAACcATGATATTtgTTTTTG taTTAtGTTTTaTaTT
| | | | |
16 3847 atATGA caAAtcTtgatacTgcATccAcAaCATTAcTgGcgTGCTTTTTG CTTTGCTTT GTGTG
| | | | |
10 31 3815 TaATGATTgAActaAatattTcTAcagtaAgCATT gTGCTaTGCTTTTTG CTTTGCTTTTGTGTG
| | | | |
18 3904 TgAcaATgtAAatacAtatgcTgTAgtagccAatATgttatCacTtaTTTTTTtatTTTGCTTTTGTGT
| | | | |
con tgac-atacaa-ttgcctgc-tgaacaaccA-cA--tt-ata-TgctttttggccTtt-cTtttgtgtt
O21-CTGCAGGAACAACCAGCACATTCATACT GCCTGTTATAATTGTCAT
15
6 3957 TTGttGTATGTtTTgTTAGcATcaTACTTATtgTATggATATCTGAGTTTaTtGTgTACaCATCTGTG
| | | | |
11 3941 TTGcaGTATGTaTtTcTTAGtATtgTACTTATaATTAATATCTGATTTTcTaGTaTATACATCTGTG
| | | | |
20 33 3886 gT TTTtaTGctTaTcCtTATTatTACGTCCtTTAATAcTTTCaTTTCTACcTATgCtTggTTG
| | | | |
16 3911 CT TTT GTGTGTCTgCcTATTAATACGTCCgCTgcTttTGTCTGTGTCTACATAcaCATCATTA
| | | | |
31 3880 CTactaTTT GTGTGTCT tgTcATACGTCCaCTtgTgcTGTCTGTGTGcgtATatgCAaCAcTA
| | | | |
18 3971
25
con -tgctgtttg-tgtgt-tgcat--ta-tacgtccatt-atattttct-tttctgtatatacatc--tg
O21-TTGTGTATGTTTTGTTAGCATCATACTTATTGTATGGATATCTGAGTTTATTGTGTACACATCTGTG-O21
30
6 4025 CTaGTACTAACACTgCTTTTATATTTaCTaTTGTGGCTgcTATTAACAACCCCCcTT GCAATTtTTcc
| | | | |
11 4009 CTGGTACTAACACTTCTTTTATATTTGCTTTTGTGGCTtTATTAACAACCCCCTTT GCAATTcTTTT
| | | | |
33 3950 CTGGT gTTGGTATTgcTgcTtTggGtgTTTGTGG gATcTCCTTaaaAATT TTTT
| | | | |
16 3974 aTaaT ATTGGTATT acTaTTgTGGaTAACaGCAgCCTCTgCgTTTaG
| | | | |
35 31 3943 cTAtT ATTaaTtgT gaTtTTaTGGgTtAttGCAaCCTCTcCaTTacG
| | | | |
18 3971
40
con ctagtac-tt-atTTTTTTtatatttgcttttggttttatgaa-aac-cc-ttc-caattttt--
O21-CTAGTACTAACACTGCTTTTATATTTACTATTGTGGCTGCTATTAACAACCCCCCTT GCAATTTTTTCC-O21

6 4092 TACTAACTCTactTGTGTGTACtGTCCcGCaTTgTATATACACTacTAtATTGT taccacA
 |||||
 11 4076 TACTAACaCtGtgTGTGTGCTATTTTCCTGCcTTTATATACACataTACATTGTgcaaacgcAAcaA
 |||||
 5 33 4005 T ~ ttGCTAITTT GTTgtTTTTATAT tTA CCAaTGaTgTgtATtAAAttt
 |||||
 16 4021 gTGTtTtattTGTATATAtaTATTT GTT TATA TA CCATTATTTTAAATaCATAC
 |||||
 31 3990 tTGTtT TTGTATATAT gtTgT GTT TATA TAtattCCATTATTgTAATtCATAC
 |||||
 10 18 3971
 con tactaacactgtatat-tgctattttcgcttc-ttttatatactata-tccattgtttttaat-cata-
 021-TACTAACTCTACTTGTGTGTACTGTCCCGCATTGTATATACACTACTATATTGT TACCACA-021
 |||||
 6 4154 cAgcaaTGATGcTAACaTGTCaAtTtAAATGATGGaGAT ACcTGGcTGggtTtTGTGGTTGTTatgTG
 |||||
 15 11 4144 TAATGgTGATGtTAACcTGTCACtTtAAATGATGGtGAT ACATGGtTGtTcTGTGGTTGTTtacTG
 |||||
 33 4051 TCATGCACAgcaTAtgacacaACaagAgTAATGTATAT ACATGtaTaTATTGTTtGTATATatgTG
 |||||
 16 4075 ACATGCAC gcTTTTTAattacaTAATGTATATGTACATAaTgtaATTGTT ACATATA
 |||||
 20 31 4044 ACATGCA tctTTTTTAA GTCAAcAgTaaCTTTTTT AC
 |||||
 18 3971 AtgcatgtatgtgtgctGcCATgtcccgCTTTGccAtctgtctgta
 con -catgcacatg-taac-t-t-Aattaaataatggagatgtacatggttg-tTtt-tg-t-t-tatgtg
 021-CAGCAATGATGCTAACATGTCAATTTAATGATGGAGAT ACCTGGCTGGGTTGTGGTTGTTATGTG-021
 |||||
 25 6 4220 CcTTTaTTGTAGggaTgtTgGGgTTaTtATT gaTgCACTAtAGaGCTGTACaAGGggaTaAAC
 |||||
 11 4210 CATTtTgTTGTAGcGTacTtGGATTGTTGTT acTaCATTAcAGgGCTGTACATGGTAcTgAAA
 |||||
 30 33 4117 CA caTGGTGgTGTtTTAacATTGTTGTT gTTATTTT AgtTTTTTTTTTTTGTa
 |||||
 16 4132 atTgTTGTATACCaTaActtactaTtTTTctTtTTTATTTTcaTatAtaattTTTTTTTTTGT
 |||||
 31 4081 TtGTGTATAC TgTTgtTTgTatTgGTattggTaTTggTaTTgg
 |||||
 18 4018 tgtgtgcGTaTgcAtgggtatttggtatttgtgtatatTgtggTaataacGTcccctgccacagcaTtc
 |||||
 35 18 4018
 con cathtt-tt-gtg-a-t-ttag--tt-tt-tt-t-tt-ttt--a--g-t-t-tttttt-ttt-t-
 021-CCTTTATTGTAGGGATGTTGGGGTTATTATT GATGCACTATAGAGCTGTACAAGGGGATAAAC-021
 |||||
 40 6 4283 AcACcAAATGTaagAAGTGTAA CAAAC aCAActgTAaTGatGATTATGTaactATGcattATacT
 |||||
 11 4273 AaACTAAATGTgctAAGTGTAAATCAAACcgCAAtacTAcTGTgGATTATGTGTATATGtcacATggT
 |||||
 33 4171 ttACTAA TAAAT AccTTTATaTtttagcaGTGTAT
 |||||
 16 4196 TTgTTTgtTTgTTTTTA
 |||||
 45 31 4124 tattggTATtggTaTaaTaaacTTTTTtACTTtTTTTTA
 |||||
 18 4086 acagtaTATgtaTtTgTttttTaTTgcccCaTgTTacTattgcatatacatgctatatattgtctttaca
 con a-actaaatgtattaagtgtatt-t--cc-t--tttT-atgttgattaagtgtatatg---tatact
 021-ACACCAAATGTAAGAAGTGTAA CAAAC ACAACTGTAATGATGATTATGTAACATATGCACTTATACT-021
 |||||

40

45

50

55

6 4549 CAAATATTAAATGGGGAAGcTTgGGGGTgTTTTTTGGAGGGTTgGGTATaGGcACgGGctCcgGcAc
 11 4540 CAAATATTAAATGGGGAAGcTTAGGGGTTTTTTTGGTGGGTAGGTATTGGtACAGGggCTGGTAg
 33 4336 CAAATtcTAAATATGGcAGTTTAGGGGTTTTTTTGGTGGTtTAGGTATTGGcACAGGcTCTGGTtC
 16 4364 CAAATATTAcAATATGGaAGTATGGGTGTaTTTTTGGTGGGTAGGaATTGGaACAGGgTCgGGTAC
 31 4301 CAAATATTAAaggTATGGtAGTATGGGTGTtTTTTTGGTGGGTgGGtATTGGgtCcGGCTCtGGTAC
 18 4358 acgtTAgcAgataAaatattgcaatGgtcaagccTTGGTataTtttgggTGGacttGGCataGGTAC
 con caaaTattaaaaatattggaagttt-gGggttttttTTGGTgggTTaggtattGG-acaGGctctGGtac
 021-CAAATATTAAATGGGGAAGTTTGGGGGTGTTTTTGGAGGGTTGGGTATAGGCACGGGTTCGGGCAC-021
 6 4617 TGGgGGTCGTaCtGGcTATgTtCCCTTAcAAcTCTgCAAAaCCTtCTATTACTaGtGGGCCctatgG
 11 4608 TGGcGGTCGTgCaGGgTATaTACCCTTgGGAAGcTCTCCcAAGCCTGCTATTACTgGgGGGCCagCaG
 33 4404 AGGtGGAaGgACTGGcTATgTACCTaTtGGtACtgacCCaCCtACAGCTgCAAtccCctTGCagCCTa
 16 4432 AGGcGGACGCACtGGgTATaTtCCatTgGGAaCAaGgCCTCCcACAGCTaCAGAtaCAcTTgctCCTg
 31 4369 TGGgGGTCGCACTGGaTATgTcCCtCtTaGtACACGtCCTtCTACAGtaTCTgAGgCAagTaTaCCTa
 18 4426 TGGCaGTgGtACaGGgggTcgtaCaggggtacAttCcattgggTgggCGtTCCAAtaCAgtgTggaTg
 con tGGCgGtcGtaCtGGgtaTggttcC-ttgggaAct-ctcc--ctacagctactaatacag-gcc-cctg
 BE11-GAAGCXcXCCCAAGCCXGcXAXX-BE11
 BE12-TATATACCCTTGGGAAGCXcXCCCAAGCCXGcXAX-BE12
 021-TGGGGGTCTGACTGGCTATGTTCCCTTACAACTTCTGCAAAACCTTCTATTACTAGTGGGCCTATGG-021
 6 4685 CtCGTCctCctGTGgTgGTGGAGCCTGTgCCCCCTTCgGATCCaTctATTGTGTCTtTAATTGAaGAA
 11 4676 CACGTCCgCCaGTGcTTGTGGAGCCTGTGCCCCCTTCcGATCCcTccATTGTGTCTtTAATTGAaGAG
 33 4472 TACGTCTcCCgTtACTGTAGAcACTGTGGaCCTTtaGActCgTCTATAGTGTcATTAAaGAAGAA
 16 4500 TAAGACcCCcttTaACaGTAGAtCCTGTgGGcCCTTctGAtCCTTCTATAGTtTCTTTAGTgGAAGAA
 31 4437 TTAGACCaCCaGTTAgCaTtGAcCCTGTaGGtCCcTTGGACCCCTCTATAGTAagTcTTGTGAAGAA
 18 4494 TTgGtCCtaCAcGTccCccaGtggtTaTtGaaCCtgTGGgCCCCaCagacccAtcTaTTGTtAcAtta
 con t-cGtCCtcCagttac-gtaGagccTgTtGgcCCtt-gGa-cCctCtatagtgtcttTa-Ttgaagaa
 BE26-CGXCCXCCGXXACGXAGAXA-BE26 JJ22-TCTATTGTGTCNTTAATNGAAGAA
 BE27-GXCCXCCGXXACGXAGACACX-BE27 022-GGATCCATCTATTGTGTCTTTAATTGAAGAA
 BE28-XCCXCCGXXACGXAGACACXGXXGACCXXXAG-BE28
 021-CTCGTCCTCTGTGGTGGTGGAGCCTGTGGCCCTTCGGATCC-021

6 4753 TCgGCaATcATTAAcGCaGGgGCgCC TCgGCaATcATTAAcGCaGGgGCgCC TgCACAAGGTGGgTTTAC
 11 4744 TcLgCTATTATTAAcGctGGTGCACC TGAggTgGTaCCCCC TACACAgGGTGGcTTTAC
 5 33 4540 ACaAGTTTTATaGAgGCaGGTGCACCA GccCCaTCtATTCC TACACcATCAGGtTTTga
 16 4568 ACTAGTTTTATTGATGCTGGTGCACCAaCatCTGtaCCTTCcATTCCcCagatgtATCAGGaTTTag
 31 4505 tCTGGaATtGTTGATGTTGGTGC ccCTGCTCCTAtaCCacacCCTCCTacaACATCTGGGTTTGA
 10 18 4562 ataGaggactccagTGTgGtTaCatcaggTGCaCCTAggCCTacgttTaCTggcACgTCTGGGTTTGA
 con -ctggtattatt-atGctGgtgCacca-ctgctgc-at---c---ccctcct-caccatctGGgTTT-a
 TCTAGTNTTATTAAATGCAGGTGCACC-JJ22
 BE5-CAXXAACGCAGGGGCGCC-----XGAA-BE5
 BE6-GGCAAXCAXXAACGCAGGGGCGC-BE6
 15 BE7-GCAAXCAXXAACGCAGGGGCGCC-----XGAAAXXGXGCC-BE7
 05-GTACCCCC TACACAGGGTGGCTTTAC
 022-TCGGCAATCATTAAcGCAGGGGCGCC TGAAATGTGCCCCC TGCACACGGTGGGTTTAC-022
 6 4812 aATtACATCcTCTGAAaCaACTAcCCTGCaTaTtGATGT aTCaGTT ACTAgTCACACTA
 20 11 4803 TATAACATCATCTGAATcGACTACACCTGCTaTTTTaGATGT gTCTGTT ACcAaTCACACTA
 33 4599 TgTTACTACATCTGCAGATACTACACCTGCaATTATTAATGTTtcaTCTGTTggggAgtcacTATTc
 16 4636 TATTACTAcTtCaaCtGATACcACACCTGC tATATTA GATattaAtAatACTGTTA
 25 31 4570 cATTgCTACaAcTGCaGAcACaACACCTGC aATTTTA GAT gtaACaAgTGTTA
 18 4630 tATaaCatCtgCgGgtacaACTACACCTGCGgtTTTggatatcacaccttcgtctacctCtgtgtcTA
 con taTtaC--CatCtgcag--ActACaCCTGCaatttTt-atgt--catctggt--tac-act--ta-Ta
 05-TATAACATCATCTGAATCGACTACACCTGCTaTTTTAGATGT GTCTGTT ACCAATCACACTA-05
 30 022-AATTACATCCTCTGAAACAACtACCCCTGCAATATTGGATGT ATCAGTT ACTAGTCACACTA-022
 6 4874 CtACTA GTaTaTTTtagAAAATCCTgTcTTTACAGAACCtTCTGTAAcACAaCCCCAACCCcCGTG
 11 4865 CcACTA GTgTgTTTcaAAATCCcTgTTTACAGAACCgTCTGTAAATACAgCCCCAACCCcCGTG
 35 33 4667 aaACTATTtCTACACATtAAATCCCAcATTACTGAACCATCTGTAcTACaCCTCCAgCgCCTGCA
 16 4692 ctACTgTTaCTACACATaAtAAATCCCACTTTcACTGAcCCATCTGTATTGCAGCCTCCAACACCTGCA
 31 4623 gCACACATgAaAATCCTACTTTTACTGATCCATCTGTATTGCAGCCTCCtACACCTGCA
 40 18 4698 tttccacaacCAatttTaccAATCCTgCaTTTtCTGATCCgTCCaTtaTtgAagtTCCacaAaCTGgg
 con ctactatta-taca--TaaaAATCC-ac-TTtaCtGAaCCaTCTgTaatacAgcctCcaccacCtGc-
 05-CCACTA GTGTGTTTCAAAATCCCTGTTTACAGAACCgTCTGTAAATACAGCCCCAACCCcCGTG-05
 022-CTACTA GTATATTAGAAATCCTGTCTTACAGAACCCTTCTGTAAACACAACCCCAACCcCGTG-022
 027-CTGCA

6 4939 GAGGCCAaTGGACATATATaTtTCTGCaCCcActgTAACgTcCaACcTaTAGAgGaaATTCCttT
 |||||
 11 4930 GAGGCCAgTGGcCacATAcTtATaTCTGCCCCaCaAaTAACaTCCcCAACaTgTAGAAGACATTCCAcT
 |||||
 5 33 4735 GAAGCCctcTGGaCATTtTATaTtTCTTCCCCtACTgTTAGcACACAAAgTTATGAAaACATaACCAAT
 |||||
 16 4760 GAAACtggAGGgCATTtTACAcTTTCATCATCcACTATTAGtACACATAATTATGAAGAAAtCCTAT
 |||||
 31 4682 GAAACatCAGGTcATTtAcTACTTTCATCATCcTcTATTAGcACACATAATTATGAGGAAATACCTAT
 |||||
 10 18 4766 GAggtggCAGGTaATgTATtTgTTggtACccCtaCateTgGaACACATgggTATGAGGAAATACCTtT
 |||||
 con GA-gc--c-GGtcAttTa-ta-Tttcttc-cC-aCtattag-aCaCataattatGA-gAaAT-CCtaT
 05-GAGGCCAGTGGTCACATACTTATATCTGCCCCaCAaTAACATCCCAACATGTAGAAGACATTCCACT-05
 022-GAGGCTAATGGACATATATTAATTTCTGCACCcACTGTAAcGTcACACCCTATAGAGGAAATTCCTTT-022
 027-GAAGCCTCTGGACATTtTATATtTCTTCCCCTACTGTGTAGCACACAAAgTTATGAAaACATACCAAT-027
 15
 6 5007 AGAtACTTTTGTgGTATcTCTAGTGATAGcGGtCCTACATCCAGTACcCCTgTTCCTgGTaCTgcaC
 |||||
 11 4998 AGAcACTTTTGTGTATCCTCTAGTGATAGTGGaCCTACATCCAGTAcTcCTcTTCCTcGTgCT-ttC
 |||||
 20 33 4803 GGATAcCtTTGTGTTTCCACAgAcAgTAGTAatGTAACATCaAGCACgCCCATTCcAGGGTCTCGCC
 |||||
 16 4828 GGATACATTtATGTtAgCACAAAcCTAAcAcaGTAACtAGTAGCACACCcATaCCAGGGTCTCGCC
 |||||
 31 4750 GGATACATTtATGTTTCTACTAAtaATGAaAAcaTAACaAGTAGCACACCcATTcCAGGGGTGCGCC
 |||||
 18 4834 acAaACATTtGcTtcTTCtGgTAcggggGAggAaaccAttAGTAGtACCCcATgCCtactGTGCGgC
 |||||
 25
 con -gAtACaTTTgttggtttccactaatgata---aac-aAca--tAG-AC-CCcAtTCC-gg-gctgcgcC
 05-AGACACTTTTGTGTATCCTCTAGTGATAGTGGACCTACATCCAGTACTcCTCTTCTCGTGCCTTTTC-05
 022-AGATACTTTTGTGGTATCATCTAGTGATAGCGGTCTCTACATCCAGTACCCTGTTCCTGGTACTGCAC-022
 027-GGATACCTTTGTGTTTCCACAGACAGTAGTAATGTAACATCAAGCACGCCcATTCCAGGGTCTCGCC-027
 30
 6 5075 CTCGGCCTCGtGTGGGccTaTATAGTCGTGCaTtGcACcAGGTgCAGGTTACaGACCCtGCAtTTcTt
 |||||
 11 5066 CTCGGCCTCGgGTGGGTTTgTATAGTCGTGCcTTaCagCAGGTACAGGTTAcgGACCCcGCgTTTTg
 |||||
 33 4871 CTGTGGCAGCCCTcGGTTTATATAGTCG CAAtAcCCaACAGGTTA AGGTTGTtGACCCTGC
 |||||
 35 16 4896 CaGTGGCAGCCCTAGGaTTATATAGTCG CACaACACAACAGGTTA AAGTTGTaGACCCTGC
 |||||
 31 4818 GTcctGCACGTtTAGGgTTATATAGT AaGGCtACACAACAAGTaa AAGTTaTTGAtCCaaC
 |||||
 18 4902 GTgtAGCAGGTccccGccTtTAcAGT AgGGCctacCAACAAGT gtcAGTggtTaAcCCtga
 |||||
 40
 con ct-tggCacGtct-gG-tTaTATAGTCgtgc-atg---a--caaCagGTtaca-gttgttga-cctgc
 05-CTCGGCCTCGGTGGGTTGTATAGTCGTGCCTTACAGCAGGTACAGGTTACGGACCCCGCGTTTTG-05
 022-CTCGGCCTCGTGTGGGCTATATAGTCGTGCATTGCACCAGGTGCAGGTTACAGACCTGCATTCTT-022
 027-CTGTGGCAGCCCTGGTTTATATAGTCG CAATACCCaACAGGTa AGGTTGTGACCCTGC-027

[illegible]

```

6 5328 GGGGTCTATGcACACTCGCAGcGGAAaGcAcATAGGgGCCCCGcATTcATTATT
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
11 5319 GGGGTCTcATGtACACaCGCAGTGGAcAACAtATAGGtGCCCGCATACATTATT
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
5 33 5130 AGccACACTtaAaaACTCGCAGTGGtAAACAAaAtTGGAcCTAGaATACATTATTATcAgGATTTAAGTc
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
16 5161 ACAAACTTaCGtACTCGTAGTGGaAAAAtCTATaGGTGCtAsGGTACATTATTATTATGATTTAAGTA
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
31 5077 ACAAACTtTGCGcACTCGTAGTGGTgCtaCTATtGGTGCaAGGGTgCATTATTATTATGATATTAGTA
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
10 18 5149 ggcAACTaTGtttACcCGcAGcGGTAcacaaATaGGTGCtAGGGTtCAcTtTTATcATGATATaAGTc
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

con      -g-aaCtaTgcacACTCGcAGtGG--aaacatATaGGtGCtagg-TaCAtTaTTatcatgatataaagta
05-GGGGTCCATGTACACACGcAGTGGACaACATATAGGTGCCCGCATACATTATT(-05)
016-AGCCACACTTAAAACTCGCAGTGGTAACAAATTTGGAGCTAGAATACATTATTATCAGGATTTAAGTC-016
022-GGGGTCTATGCACACTCGCAGCGGAAGACATAGGGGCCCGCATTcATTATT(-022)
15 027-AGCCACACTTAAAACTCGCAGTGGTAACAAATTTGGAGCTAGAATACATTATTATCAGGATTTAAGTC-027
028-AGCCACACTTAAAACTCGCAGTGGTAACAAATTTGGAGCTAGAATACATTATTATCAGGATTTAAGTC-028

6 5381      TTtAtGATATTTcACCTaTTgCACAgGCTGCAGaAGAAATAGAAaTGCACC TCTtGTGG
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
20 11 5372      TTcAgGAcATTTcACcAgTTaCACAGCTGCAGAgGAAATAGAAcTGCACCCTCTAGTGG
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
33 5198 CTATTG      TgcCtttAGAcCACaccgTgCcAAATGaACAAaTaTgAATtAcAgcCTttaCaTgAtacT
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
16 5229 CTATTGATCTGCAGaAGAAatagaatTACAAAcTatAacAccTtCtaCAtAtACTACcACTTCacaT
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
25 31 5145 gTATTaATCCTGCAGgtGAAAgTATTGAAaTGCAaCCTTTAGgggCgTCTGCaACTACTACTTctact
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
18 5217 cTATTgcaCCTtCcccaGAAtaTATTGAaCTGCAGCCTTTAG taTCTGC caCggag

con      ctattgatc-t-c---agaacacat--taca-aagct-caa--g-aatc--aa-ctaccc--tcg---
(05-)TTCAGGACATTTCACCAGTTACACAAGCTGCAG-05
30 016-CTATTG      TGCCTTTAGACCACACCGTGCCAAATGAACAATATGAATTACAGCCTTTACATGATACT-016
022-      TTTATGATATTTcACCTATTGCACAGGCTGCAG-022
027-CTATTG      TGCCTTTAGACCACACCGTGCCAAATGAACAATATGAATTACAGCCTTTACATGATACT-027
028-CTATTG      TGCCTTTAGACCACACCGTGCCAAATGAACAATATGAATTACAGCCTTTACATGATACT-028

6 5441 CTGCACAggATGAtACaTTTGATATTTATGCTGAAtCtTTTGAaCCTggCatTaACCCCTacCCAACAc
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
35 11 5432 CTGCAGaAaaATGAcACGTTTGATATTTATGCTGAACcATTTGAcCCTatCccTgACCCtGtCCAACAT
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
33 5263 tCtaCaTcGtCTtaTaGTATTAATgATGG tTTgTATGATgTTTATGC TgaCgAtGT
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
16 5297 gCAgCcTcAcCTacTTcTATTAAaATGGA TTaTATGATaTTTATGCaGATgacttTattACAGA
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
40 31 5213 ttAAATGAtggCTTaTaTGAcATTATGCAGA CAcTGATtTTaCTGTGGATacACCTgCcACAcA
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
18 5273 gacAATGA CTTgTtTGAtATaTATGCAGAtgaCATgGAcctTgCaGTGccTgtACCAtCgcgttc

con      -t-aa--a-a---tat-T-ttAt-taTg-acag-ac-atgatatt--tgc---taccctt-ccaa---
45 016-TCTACATCGTCTTATAGTATTAATGATGG TTTGTATGATGTTTATGC TGACGATGT-016
027-TCTACATCGTCTTATAGTATTAATGATGG TTTGTATGATGTTTATGC TGACGATGT-027
028-TCTACATCGTCTTATAGTATTAATGATGG TTTGTATGATGTTTATGC TGACGATGT-028

50

55

```

6 5509 cCTGTTACAaatatatcagAtaCaTATtTaActTCCACACCTAATACagTTaCACAACCGTGGGGTAA
 |||||
 11 5500 tCTGTTACA cAgTcTATCTtACcTCCACACCTAATACcTtTcACAAtCGTGGGGTAA
 5
 33 5319 ggaTaaTgtAcaCaCcccAAtgCaacaCTCATacAgtaCgTttgCaaCaacaCgTACCaGcAATGTgt
 |||||
 16 5362 TAcTtcTaCAaCCcCggtAcCatctgtacCCTCtACatCTTtATCAGgtTATaTTCCtGCAAAATACaA
 |||||
 31 5278 TAAgtTTCCcCTtCtAcTgCTgtAcAgTCCaCatCTgCTgTgTCTGCCTATgTAcCTACAAATACcA
 10
 18 5338 TAcTaccTCCtTgCattTttTaaAtAtTCgcCcaCTatatctTCTGCCtTtcctaTAgTAAATgtaA
 con ta-tttt-ca---tctc--attca----tcacctac--c-ttatcagcct--tc-ca-tagtaatgtaa
 016-GGATAATGTACACACCCCAATGCAACACTCATACAGTACGTTTGCAACAACACGTACCAGCAATGTGT-016
 027-GGATAATGTACACACCCCAATGCAACACTCATACAGTACGTTTGCAACAACACGTACCAGCAATGTGT-027
 15 028-GGATAATGTACACACCCCAATGCAACACTCATACAGTACGTTTGCAACAACACGTACCAGCAATGTGT-028

 1 5577 cACCACAGTtCCATTGTCAcTtCCTAaTGACctGTTTTaCAaTCTGGcCCTGatATAACTTTTCCTA
 |||||
 11 5559 tACCACAGTcCCATTGTCAATcCCTAGTGAAGTGGTtTGTgCAGTCTGGgCCTGACATAACTTTTCCTA
 20
 33 5387 CtATACCTTTaaATacaGgATttgATAcTCCTGTTaTGTCtGGcCCTGATATACcTtccCtTTAtTT
 |||||
 16 5430 CaATtCCTTTtgGTggtGcATacaATATTCCTtTagTaTCaGGtCCTGATATACcAttaATAaTaACT
 |||||
 31 5346 CtGTgCCacTAAGTaCaGgTTttGAcATTCCcaTATtTCTGGgCCTGATgTACcTATagAgCATgCA
 25
 18 5406 CgGTcCCTtTAAcctCctcTTggGAtgTgCctgTATacaCgGGtCCTGAT AttacattAcCATtctA
 con ca-taCcttttaatt-tg-aTtcgatat-cCtgt-tt-tc-ggtCctGat-taccataacattt-cta
 016-CTATACCTTTAAATACAGGATTTGATACTCCTGTTATGTCTGGCCCTGATATACCTTCCCCTTTATTT-016
 027-CTATACCTTTAAATACAGGATTTGATACTCCTGTTATGTCTGGCCCTGATATACCTTCCCCTTTATTT-027
 30 028-CTATACCTTTAAATACAGGATTTGATACTCCTGTTATGTCTGGCCCTGATATACCTTCCCCTTTATTT-028

 6 5645 CTGCaCCTATGGGAACACCCCTTTAGTCCTGTAACtCCTGCTTTACCTACAGGCCCTGTTTTcATTACA
 |||||
 11 5627 CTGCAtCTATGGGAACACCCCTTTAGTCCTGTAACtCCTGCTTTACCTACAGGCCCTGTTTTTATTACA
 35
 33 5455 CcCacAtCTaGccCATTtgT TCCTATtCgCCTtTTTTCCTtttGACACcATTgTTGTaGAc
 |||||
 16 5498 gaCcaAgCTccTTCATTaAT TCCTATaGtCCagggTCTCCACAAtAtAcAATTaTTGcTGAT
 |||||
 31 5414 CctaCACAgtTTtCCCAT TCCTtTGGCCCTaCaaCgCCACAAGtGTCTATTtTTGTTGAT
 40
 18 5472 CtacCtCtGtaTggCCCATTTgtatcaCCcacGGCCCTgCctCtaCACA GTaATTggTaTacAT
 con ct-c-act-tgtg-ac-a-ttttagtCctatagetCCTgctt-tcC-caag-c-ctaTTttt-ttgat
 BE22-CCCAXXGXACACCCACGGCCC-BE22
 BE23-CCCAXXGXACACCCACGGCCCCXGCCXACACA-BE23
 45 016-CCCACATCTAGCCCATTTGT TCCTATTTCCGCTTTTTTTCCTTTTGACACCATTGTTGTAGAC-016
 027-CCCACATCTAGCCCATTTGT TCCTATTTCCGCTTTTTTTCCTTTTGACACCATTGTTGTAGAC-027
 028-CCCACATCTAGCCCATTTGT TCCTATTTCCGCTTTTTTTCCTTTTGACACCATTGTTGTAGAC-028

 50
 55

6 5713 GGTTCCTGgaTTtTATTTGCATCCTgCATGGTAtTTTGCACGtAaACGCCGTAAACGTATTCCCTTATT
 11 5695 GGTTCCTGACTTcTATTTGCATCCTACATGGTAcTTTGCACGcAGACGCCGTAAACGTATTCCCTTATT
 33 5518 GGTGCTGACTTTgTtTTTACATCCTAGTTATTtTATTTTACGtcGcaGgCGTAAACGTTTCCATATTT
 16 5561 GcaGGTGACTTTTATTACATCCTAGTTATTacATGTTACGAAAAcGACGTAAACGTTTACCATATTT
 31 5477 GGgGGTGATTTTATTTGCAcCCTAGTTATTATATGTTAaaAcgtCGACGTAAACGTGTatCATATTT
 18 5537 GGtacacATTaTTATTGtgCCattATATTATtTtaTtcctaagaaACGTAAACGTGtCcCtATTT
 con GgtgctgacTtttATTGcatCCtag-TatTat-Ttttacgta-acgaCGTAAACGT-TtcC-TatTT
 JJ25-CGTAAACGTNTTCCCTATTT
 PCR2-CGTTTTCCATATTT
 027-GGTGCTGACTTTGTTTTACATCCTAGTTATTTATTTTACGTGCGAGGCCGTAAACGTTTTCCATATTT-027
 6 5781 TTTTtCAGATGT GGCGGCCTAGCGACAGCACAGTATATGTGCCTCCTCctAACCCCTGTATCC
 11 5763 TTTTACAGATGT GGCGGCCTAGCGACAGCACAGTATATTTGCCTCCTCCcAACCCCTGTATCC
 33 5586 TTTTACAGATGTcGgTgTGGCGGCCTAGTGAGGCCACAGTgTACcTGCCTCCT GTaCCTGTATCT
 16 5629 TTTTtCAGATGTCTCTtTGGctGCCTAGTGAGGCCACTGTCTACTTGCCTCCT GTCCcAGTATCT
 31 5545 TTTTaCAGATGTCTCTGTGGCGGCCTAGcGAGGCTACTGTCTACTTaCCACCT GTCCcAGTGTCT
 18 5605 TTTTgCAGATGgCtTtTGTGGCGGCCTAGtGAcAAACcGTaTAtcTtCCACCT ccttCtGTGgCa
 con TTTTaCAGATGtctctgtGGCGGCCTAG-GA--ccACaGTaTA--TgCCTCCTcc-gtccCtGTatCt
 TTTTNCAGATGTCTNTGTGGCGGCCTAGTGA-JJ25
 PCR1-CAGATGTCTCTGTGGCGGCCTAGTG-PCR1
 TTTTGCAGATG-PCR2
 027-TTTTACAGATGTCCGTGTGGCGGCCTAGTGAGGCCACAGTGTACCTGCCTCCT GTACCTGTATCT-027
 6 5843 AAaGTTGTTGCCACGGATGCTtATGTTAActCGCACCAACATATTTATCATGCCAGCAGTTCTAGACT
 11 5825 AAgGTTGTTGCCACGGATGCGtATGTTAAaCGCACCAACATATTTATCATGCCAGCAGTTCTAGACT
 33 5651 AAaGTTGTcAGCACTGATGAATATGTgtCtCGCACAAgCATtTATTATtATGCTGGtAGTTCAGACT
 16 5694 AAgGTTGTAAGCACGGATGAATATGTtgCACGCACAAACATATATTATCATGCAGGaAcaTCCAGACT
 31 5610 AAAGTTGTAAGCACGGATGAATATGTaACACGaAccAACATATATTATCacGCAGGCAGtgCTAGgCT
 18 5670 AgAGTTGTAAaAtACcGATGAtTATGTgActCccACaAgCATATtTTATCatGCTGGCAGctCTAGatT
 con AAaGTTGTAagcACgGATGaATATGTTac-CgcAC-AaCATaT-TTATcAtGC-gGcAgttCtAGACT
 JJ26-GTTGTNANCACGGATGANTATGTtACTCGCACAA-JJ26
 PCR3-AAGTTGTAAGCACCGATGAATATGT-PCR3
 LCR1A-AAGTTGTAAGCACGGATGAATATGT-LCR1A
 LCR1B-TGCACGCACAAACATATATTATCA-LCRB
 LCR1B'-ACGTGCGGTGTTGTATATAATAGTA-LCRB'
 027-AAAGTTGTcAGCACTGATGAATATGTGTCTCGCACAAAGCATTtATTATTATGCTGGTAGTTCAGACT-027
 6 5911 tCTTGCaGTGGGACATCCTtATTtTcCaTAAAA cggGcTAA C AAAA CtGTTGTgC

11 5893 cCTTGCTGTGGGACATCCATATTactCTATcAAAAA agtTAA C AAAA CAGTTGTAC
 33 5719 tCTTGCTGTGGGcCATCCATATTTTCTATTAAAAAtCCTAcTAA CgctAAAAAAAtTATTgGTAC
 16 5762 aCTTGcAGTTGGaCATCCcTATTTTcCTATTAAAAACCTAACAAAT AAaAAAA TATTaGTtC
 31 5678 gCTTACAGTaGGcCATCCATATTaTtCcATacctAAAAtCTGACAATccTAAAAAAA TAGTTGTaC
 18 5738 atTaAcTGTtGGtaATCCATATT TtagggttcCTGcaggTggTggcAAtAagcagGaTaTtC
 con -cTtgC-GTtGGAcATCCaTATTtttctaTtaaaaaaacctgcta--caacaaaAaa-tagttgTaC
 JJ27-GTTGGACATCCATATTT-JJ27
 027-TCTTGCTGTGGCCATCCATATTTTCTATTAAAAATCCTACTAA CGCTAAAAAATTATTGGTAC-027
 6 5967 CAAAGGTGTcAGGATATCAATAcAGgGTaTTTAAGGTgGTGTTaCCAGATCCTAACAAaTTTGCATTg
 11 5949 CAAAGGTGTcTGGATATCAATATAGaGTgTTTAAGGTaGTGTTgCCAGATCCTAACAAgTTTGCATTa
 33 5784 CcAAAGTATCAGGcTTgCAATATAGGGTtTTTAGGGTcCgTTTACCAGATCCTAATAaTTTGGATTT
 16 5824 CtAAAGTATCAGGATTACAATAcAGGGTATTTAGaaTaCaTTTACCTGAcCCcAATAAgTTTGGtTTT
 31 5743 CaAAGGTgTCAGGATTACAATATAGGGTATTTAGGGTtCgTTTACCAGaTCCAAACAAATTTGGaTTT
 18 5800 CtAAGGTtTCTcGcATacCAATATAGaGTATTTAGGGTgCagTTACCTGAcCCAAAtAAATTTGGtTTa
 con CaAAgGTgTCaGgaT--CAATATAGgGTaTTTAaggT-c--TTaCCAGaTCCtAA-AAaTTTgGaTTt
 JJ28-CAATATAGGGTATTTAGGGTNCNGTTACC-28 30-AATAAATTTGGATTN
 PCR4-GTTATATCCATAAAATCCCATGTTAA-PCR4PCR5-TTATTTAAACCAAAA
 027-CCAAAGTATCAGGCTTGCAATATAGGGTttTAGGGTCCGTTTACCAGATCCTAATAAATTTGGATTT-027
 6 6035 CCTGAcTCgTcTtTtGatCCcACaCaCACAaCGTTTAGTATGGGCaTGCACAGGccTaGAGGTgGG
 11 6017 CCTGAtTCaTCCCTgTTTGACCCCACTACACAgCGTTTAGTATGGGCGTGCACAGGgtTgGAGGTAGG
 33 5852 CCTGACACCTCCTTTTATAACCCtGATACACAaCGaTTAGTATGGGCaTGTGTAGGccTTGAAaTAGG
 16 5892 CCTGACACCTCaTTTTATAATCCaGATACACAgCGgcTgGTTTGGGCCTGTGTAGGTgTTGAGGTAGG
 31 5811 CCTGATACaTCTTTTATAATCCTGAAACtCAACGcTTAGTTTGGGCCTGTGTGGTtTaGAGGTAGG
 18 5868 CCTGATActagTaTTTATAATCCTGAAACaCAACGtTTAGTgTGGGCCTGTGcTGGagTgGAAaTtGG
 con CCTGA-aC-tcttTtTataAtCCTga-ACaCaCGtTtAGTaTGGGCcTGtg-aGG--T-GAggTaGG
 CCTGACACCTCNNTTATAAT-JJ30
 GGACTGTGGA-PCR5
 027-CCTGACACCTCCTTTTATAACCCtGATACACAACGATTAGTATGGGCATGTGTAGGCCTTGAAATAGG-027

55

6 6304 tAATACacCTGTACAggcTGGTGACTGCCCCgCCcTTaGAACCTATTACCAGTGTTATACAGGATGGcG
 11 6289 aAATACctCTGTACaaaTGGTGACTGCCCCcCCgTTgGAACCTATTACCAGTGTTATACAGGATGGgG
 5
 33 6124 TAaTGCAGcACcTgCcaATGATTGTCCACcCTTAGAACTTATAAAaCTaTTATTgAGGATGGTG
 16 6164 cAATgtTGCAGTAAaTCCaGGTGATTGTCCACCATTAGagTTAATAAAcACAGTTATTcAGGATGGTG
 31 6083 tAAcaATGCTaTtACcCCTGGTGATTGTCCcCATTAGAATTAAAAaTtCAGTTATaCAAGATGGgG
 10
 18 6140 atcgcgTcCTtTatCaCagGGcGATTGcCCcCTTTAGAAcTtAAAAaCaCAGTtTggaAGATGGtG
 con -aata-tgCtgtaC--cctgggTgAtTG-CC-CC-TTaGAacTtAtaAacac-gTTaTacAgGATGGtG
 JJ36-GATGGTG
 027- TAATGCAGCACCTGCCAATGATTGTCCACcCTTTAGAACTTATAAAaCTaTTATTgAGGATGGTG-027
 15
 6 6372 AtATGGTTGacACAGGCTTTGGTGCTATGAATTTTGcTgAtTTgCagACCAATAAATCaGATGTTCCt
 11 6357 AcATGGTTGATACAGGCTTTGGTGCTATGAATTTTGcAGAcTTaCAaACCAATAAATCgGATGTTCCc
 20
 33 6189 ATATGGTgGacACAGGaATTGGTtgcATGGATTtTaaAACATTgCAGGCTAATAAAAGTGATGTTCCt
 16 6232 ATATGGTTcATAcTGGCTTTGGTGCTATGGAcTTACTACATTACAGGCTAAcAAAAGTGaaGTTCCa
 31 6151 ATATGGTTGATACaGGCTTTGGaGCTATGGAtTTACTgCtTTACAAGAcACTAAAAGTaATGTTCCt
 25
 18 6208 ATATGGTaGATAcTGGaTaTGGtGCCATGGAcTTAgTaCaTTgCAAGaTACTAAaTgTgAgGTaCCa
 con AtATGGTtgAtACaGGcTtTGGtgctATGgAtTTTact-caTT-CA-gc-AatAAA-gtgAtGTTCCt
 ATATGGTTGATACAGGCTTTGGTGCTATGGA-36 37-CATTNCANGCNAATAAANGTGATGTTCCt
 027-ATATGGTGGACACAGGATTGGTTCATGGATTtTAAaACATTGCAGGCTAATAAAAGTGATGTTCCt-027
 30
 6 6440 aTTGAcATaTGTGGcACTacaTGTAAAATATCCaGATTATTTaCAAAATGGCTGCAGACCCaTATGGTGA
 11 6425 cTTGATATTTGTGGaACTgtcTGCAAAATATCCcGATTATTTgCAAAATGGCTGCAGACCCtTATGGTGA
 35
 33 6257 aTTGATATTTGTGGcAgTAcATGCAAAATATCCAGATTATTTaAAAAATGaCTagtGAgCCTTATGGTGA
 16 6300 cTGGATATTTGTAcATCTATTTGCAAAATATCCAGATTATaTTAAAAATGGTgtCaGAaCCATATGGCGA
 31 6219 TTGGAcATTGTAAaTCTATTTGTAAATATCCAGATTATcTTAAAAATGGTTGCTGAgCCATATGGCGA
 40
 18 6276 TTGGAtATTGTcAgTCTATTTGTAAATATCCcGATTATtTAcAAATGtcTGCAGAcCCTTATGGGGA
 con -T-GATAtTGTg--cTattTG-AAATATCCaGATTATtTa-AAATGgctgcaGA-CC-TATGGtGA
 NTNGATATTTGT-JJ37 JJ38-AAATATCCAGATTATTTANAAATGG-JJ38
 027-ATTGATATTTGTGGCAGTACATGCAAAATATCCAGATTATTTAAAAATGACTAGTGAGCCTTATGGTGA-027
 45
 50
 55

6 6508 TAGaTTaTTTTTTTtTcTaCGgAAGGAACAAATGTTTGCCAGACaTTTTTTAAcAGGGCtGGcgagG
 11 6493 TAGgTTgTTTTTTTAttTgCGAAAGGAACAAATGTTTGCTAGACACTTTTTTAATAGGCCcGGTACTG
 5
 33 6325 TAGtTTATTTTTTcTtTcTtCGAcGtGAACAAATGTTTGTaAGACACTTTTTTAATAGGGCTGGTACat
 16 6368 cAGcTTATTTTTTTATTACGAAGGGAACAAATGTTTGTaAGACATTtATTTAATAGGGCTGGTACTG
 31 6287 TACaTTATTTTTTTATTACGtAGGGAACAAATGTTTGTaAGGCATTTTTTTAATAGatCAGGcACgG
 10
 18 6344 TtCcaTgTTTTTTTgcTTACGgcGtGAgCagcTtTTTGctAGGCATTTTTggAATAGAgCAGGtACTa
 con tag-tTaTTTTTTtTattTaCGaaggGAAcCAaaTgTTTG-tAGaCaTtTtTtAAAGggCtGGTactg
 WO 86/05816-GAGG
 027-TAGTTTATTTTTCTTTCTTCGACGTGAACAAATGTTTGTaAGACACTTTTTTAATAGGGCTGGTACAT-027
 15
 6 6576 TGGGGGAACCTGTGCCTGATacaCTtaTaaTtAAgGGtaGTggaAAAtcGcaCgTCTGTAGggAGTAGT
 11 6561 TGGGGGAACCTGTGCCTGATGACCTGTTgTaaAAAGGggGTaatAAcAGatCaTCTGTAGctAGTAGT
 20
 33 6393 TaGGaGAggCTGtTCCcGATGACCTGTACATTAAAGGtTCaGGaACTACTGCcTCTaTtcaaAGcAGT
 16 6436 TTGGTGAAaaTGTaCCaGAcGatTTATACATTAAAGGCTCtGGgTCTACTGCaAaTTTAGCcAGttca
 31 6355 TTGGTGAAAtCgGTcCCTactGACttATATATTAAAGGCTCcGGTTCaAcAGCTACTTTAGCtAaCaGT
 18 6412 TgGGTGAcAcTGTgCCTcaatcCTTATATATTAAAGGCaCaGGTatgcCtGCTtCacctGgcAgCtGT
 25
 con TgGGtGAa-ctGTgCCtgatgac-Tata-aTtAAaGGctctggtactactgC-tct-tagc-Ag-agt
 TGGGGGAACCTGTGCCTGATACACTTATAATTAAGGGTAGTGGAAATCGCACGTCTGTA-WO86/05816
 LCR2A-ACCTGTTGGTAAAGGGGTAATAA-LCR2A
 LCR2A'-GGACAACCATTtTCCCCCATTATT-LCR2A'
 LCR2B-CAGATCATCTGTAGCTAGTAGT
 LCR2B'-GTCTAGTAGACATCGATCATCA
 30
 LCR3A-ATTTATACATTAAAGGCTCTGGGTC-LCR3A
 LCR3A'-AAATATGTAATTtCCGAGACCCAG-LCR3A'
 LCR3B-TACTGCAAATTTAGCCAGTTCA
 LCR3B'-ATGACGTTTAAATCGGTCAAGT
 LCR4A-CCTTATATATTAAAGGCACAGGTAT-LCR4A
 LCR4A'-GAATATATAATTtCCGTGTCATA-LCR4A'
 35
 LCR4B-GCCTGCTTCACCTGGCAGCTGT
 LCR4B'-CGGACGAAGTGGACCGTCGACA
 027-TAGGAGAGGCTGTTCCCGATGACCTGTACATTAAAGGTTcAGGAACtACTGCCTCTATTCAAAGCAGT-027

6 6644 ATaTATGTtaAcACeCCgAGeGGCTCtTTGGTGTcTcTcGAGGCaCAATTgTTTAATAAgCCATATTG
 11 6629 ATTTATGTaCaAcCaCCTAGTGGCTCATTGGTGTCTTCaGAGGCTCAATTATTTAATAAAaCCATATTG
 5 33 6461 gcTTtTTTCCcAcTcCTAGTGGaTCAATGGTTACTTCcGAatCTCagTTATTTAATAAgCCATATTG
 16 6504 AaTTATTTTCCTACACCTAGTGGtTcTATGGTTACcTcTcGATGCCcAAATATTcAATAAACCTtTATTG
 31 6423 AcaTAcTTTCCTACACCTAGcGGCTCcATGGTTACtTcAGATGCaCAAAATtTTTAATAAACCATATTG
 10 18 6480 gtgTATcTCCcTcTCCaAGtGGCTCtATtGTTACcTcTcGActCcCAgtTgTTTAATAAACCATATTG
 con attTattttcc-aCaCCtAGtGGcTCTaTgGTtaC-TCtGA-gC-CAatTaTTtLAATAAAaCCaTATTG
 AT-LCR2B JJ39-GTTACNTCTGANGCNCAATTATTTAATAAACCATATTG
 TAA-LCR2B'
 AA-LCR3B
 TTA-LCR3B'
 15 GT-LCR4B
 CAC-LCR4B'
 027-GCTTTTTTTCCCACTCCTAGTGGATCAATGGTTACTTCCGAATCTCAGTTATTTAATAAGCCATATTG-027
 6 6712 GCTaCAAAAAaGCcCAGGGACATAACAATGGTATTGtTGGGGtAAcCAaetGTTTGTACTGTGGTAG
 20 11 6697 GCTtCAAAAaGcTcCAGGGACATAACAATGGTATTGcTGGGGaAAcCAcTtGTTTGTACTGTGGTAG
 33 6529 GCTACAACGtGCACaAGGtCATAATAATGGTATTGTTGGGGcAAcCAggtTATTGTACTGTGGTAG
 16 6572 GtTACAACGaGCACAGGGcCACAATAATGGcATTGTTGGGGtAAcCAaetTATTGTACTGTtGtG
 25 31 6491 GaTgCAACGtGcTcCAGGGaCACAATAATGGTATTGTTGGGGcAAcCAgTTATTGTACTGTGGTAG
 18 6548 GtTaCataagGCaCAGGGtCAtAAcAATGGTgTTGcTGGcatAATCAaTTATTGTACTGTGGTAG
 con GcTaCAa---GCaCagGgACaTAA-AATGGtATTGtTGGggtAAcCAaetTATTGTACTGTgGTaG
 GCTACAANNNGCACA-JJ39 J41-AATGGTATTGTTGGGGTAATCAATTATTGTACTGTGGTAG
 30 C6-GCMCAGGGWCATAAAYATGG-C6 C1-CTGTGGTAG
 C7-CTGTGTTG
 C8-CTGTGGTAG
 C10-CAGTTGTAG
 C11-CTGTGGTTG
 C12-CTGTGTGG
 C13-CTGTGTAG
 35 C14-CTGTGGTAG
 C15-CTGTAGTGG
 027-GCTACAACGTGCACAAGGTCATAATAATGGTATTGTTGGGGCAATCAGGTATTGTACTGTGGTAG-027
 40
 45
 50
 55

5
 6 6780 ATACCACACGCGAGTACcAAcATGACAtTATG TGCATCcGTaaCTAcATCTtCcACATACACc
 11 6765 ATACCACACGCGAGTACaAATATGACAcTATG TGCATCtGTgtCTAaATCTgCTACATACACt
 33 6597 ATACCACtCGCAGTACtAATATGACtTTATG caCAcaAGTaaCTAgTGAAGTACATATAAA
 16 6640 ATACtACACGCGAGTACaAATATGTCaTTATGTGCT GCCATAtCtACTtcaGAaACTACATATAAA
 10 31 6559 ATACCACACGtAGTACCAATATGTCTgtTtGTGCT GCAATtgCaAcagtgATACTACATtTAAA
 18 6616 ATACCACtCccAGTACCAATtTaaCaaTaTGTGCTtctaCacagtCtccctgtaccTgggcaATaTgAt
 con ATACCACaCgcAGTACcAAtaTgaCatTaTGTgtct--tgCa---g-aacta-ag-tactacATataaa
 ATACC-JJ41 C16-CATCCGTAACATACATCTTCCA-C16
 15 ATACCACACGCGAGTAC-C1 C17-TCTGTGTCTAAATCTGCTACA-C17
 ATACTACACGCGAGTAC-C7 C20-CACACAAGTAAGTACTAGTGACAG-C20
 ATACCACtCGCAGTAC-C8 C23-CAGTCTCCTGTACCTGGG-C23
 ATACTACTCGCAGCAC-C10 C31-TTGCAAACAGTGATACTACATT-C31
 ATACTACCCGTAGTAC-C11
 ATACTACCAGAAGCAC-C12
 ATACTACTAGAAGCAC-C13
 20 ATACCACACGTAGTAC-C14
 ACACTACCCGCGAGTAC-C15
 027-ATACCACtCGCAGTACTAATATGACTTTATG CACACAAGTAAGTACTAGTGACAGTACATATAAA-027
 25
 6 6842 AATTCTtGATTATAAaGAgTACATGCGtCATGTGGAaGAGTaTGATTTACAaTTTATTTTCAATTaTG
 11 6827 AATTcAGATTATAaGGAATACATGCGcCATGTGGAgGAGTtTGATTTACAGTTTATTTTCAATTgTG
 33 6659 AATgaAAATTTTAAaGAATAtATAaGACATGTtGAaGAATATGATcTACAGTTgTTTTTCAACTaTG
 16 6705 AATAcTAAcTTTAAgGAGTAcTAcGACATGGgGAGGAATATGATTTACAGTTTATTTTCAACTgTG
 30 31 6624 AgTAgtAAATTTTAAaGAGTATtTAAGACATGGTGAGGAATtTGATTTACAaTTTATaTTTCAGTTaTG
 18 6684 gcTAccAAaTTTAAgCAGTATagcAGACATGtTGAGGAATaTGATTtgCAGTTTATtTTTCAGTTgTG
 con aaTactaAtTtTAA-gAgTA-ata-GaCATGt-GAgGAaTaTGATTtTaCAGTTTAtTTTCAaT-TG
 35 027-AATGAAAATTTTAAAGAAATATATAAGACATGTTGAAGAATATGATCTACAGTTTGTTTTCAACTATG-027
 40
 6 6910 TAGCATTACATTgTCTGCTGAAGTaATGGCCTATATtCACACAATGAATCCcTCTGTTTTGGGAaGACT
 11 6895 TAGCATTACATTATCTGCAGAAgTcATGGCCTATATaCACACAATGAATCCcTCTGTTTTGGAgGACT
 33 6727 CAAAgTTACCTTAACTGCAGAAgTTATGACATATATtCATgCTATGAATCCagaTATTTTaGAaGAtT
 16 6773 CAAAATAACCTTAACTGCAGACGTTATGACATAcATaCATtCTATGAATtCcACTATTTTGGAgGAcT
 31 6692 CAAAATAACaTTAtCTGCAGACaTaATGACATATATTCaAGTATGAATcCtgCTATTTTGGGAaGATT
 45 18 6752 tActATtACTTTAACTGCAGAtgTtATGtCcTATATTCAtAGTATGAATagcagTATTTTaGAgGATT
 con -AaaaTtACaTTa-CTGCaGAagTtATGaC-TAtAtTCA-actATGAATccc-cTaTTTTgGA-GA-T
 027-CAAAGTTACCTTAACTGCAG-027
 50
 55

[illegible]

6 7110 TTTGGGAGGTTAAcTTAAAGAAAAGTTTCTAGTGAATTgGATCAGTaTCcTtTgGGACGcAAgTTT
 11 7095 TTTGGGAGGTTAAcTTAAAGAAAAGTTTCAAGTGAATTAGATCAGTTTCcCtTgGGACGtAAgTTT
 5
 33 6927 TTTGGGAAGTggaTTTAAAGGAAAaTTTTcAGCAGAtTTAGATCAGTTTCCTTTgGGACGcAAgTTT
 16 6973 TTTGGGAAGTaaATTAAAGGAAAAGTTTCTGCAGAccTAGATCAGTTTCCTTTaGGACGcAAATTT
 31 6892 TTTGGGAgGTtAAATTAAAGGAAAAGTTTCTGCAGAtTTAGATCAGTTTCcACTgGGtCGcAAATTT
 10
 18 6952 TTTGGaAtGTggaTTTAAAGGAAAAGTTTCTtTAGAcTTAGATCAaTaTCcCtTgGaCGtAAATTT
 con TTTGGGAgGTtAAcTTAAAGGAAAAGTTTCTtgcAGa-tTaGATCAGTtTCcT-TgGGaCGcAA-TTT
 TTTGGGAGGTTAAcTTAAAGGAAAAGTTTCTGCAGANTTAGATCA-JJ46
 C2-GATCAGTTTCcYYTKGGACG-C2
 C3-GATCAGTWTCCYYTKGGACG-C3
 C7-CTAGTCaWAGGRRAMCCTGC-C7
 015-TTTGGAATGTGGATTTAAAGGAAAAGTTTCTTTAGACTTAGATCAATATCCcCTTGGACGTAAATTT-015
 023-TTTGGGAGGTTAAcTTAAAGGAAAAGTTTCAAGTGAATTAGATCAGTTTCcCCTTGGACGTAAgTTT-023
 15
 6 7178 TT gTT aCAAAGTGGATATaGgGGACGGtCcT
 11 7163 TTA TT gCAAAGTGGATATcGAGGACGGaCgT
 33 6995 TTA TTAcagGcAggtcttaaagcAaaAcctaaacttaaACGtgcAGcccccaCAtCcaCCcgCA
 16 7041 TTA cTACAAGCAGGATtgAaGGCcAAACCAAAATTTAcAttAGGaAAACGaaaagCTaCACCcAcCA
 25
 31 6960 TTA tTACAGGCAGGATatAGGGCacgtCCtAAATTTAaAgCAGGtAAACG TagTgCACCC t
 18 7020 TT ggTtCAGGcTGGATtgcGtcgcaagCCcAccaTagggccCtcGcAAACG T tctg
 con TTA--ta--agcaggattgagggcaaaaccaaataa-a-cacgaaaa-gatatag-gcacc-cct
 30 015-TT GGTTcAGGCTGAFTGCGTCGCAAGCCCACCATAGGCCCTCGCAACG T TCTG-015
 023-TTA TT GCAAAGTGGATATCGAGGACGGACGT-023
 35
 6 7209 CTatTCGTACAGGTgTtAAGCGCCCTGCTGTtTCcAAAgCCTCTgCtGCCCCtAAACGtAAgCGGcCC
 11 7194 CTgCTCGTACAGGTaTaAAGCGCCcAGCTGTgTCTAAgcCCTCTaCAGCCCCcAAACGaAAACGTaCC
 33 7059 CaTCgTCTgCAaaacgcAAaaaggTTaAAATAAcAcTtTgTgtaAttgtgtTAtgtTGTgtTttg
 16 7108 CcTCATCTACCTcCTACAACtGctAAACG cAAAAACgTAAGctGTAA GtaTTGTATGTA
 40
 31 7021 CagCATCTACCACTACAcCaGCaAAACGtaAAAAAC TAAAAaGTAAtgGatgTGTATGTAAaCaT
 18 7075 CtcCATCTgCCACTAC gtcttc TAAA ccTGccAagCgT
 con Ct-catcTaC-actacaaa---c--a--t-aat-aa-gtaa-ctg-a-cc-ct-a-c-tgta--tcc-
 45 015-CTCCATCTGCCACTAC GTCTTC TAAA CCTGCCAAGCGT-015
 023-CTGCTCGTACAGGTATAAAGCGCCcAGCTGTGTCTAAGCCCTCTACAGCCCCcAAACGAAACGTACC-023
 50
 55

6 7277 AAAACtAAAAgGTAATATATGTGT aTatGTactGTT
 ||||| ||||| ||||| |||||
 5 11 7262 AAAACcAAAAaGTAATATATGTGTgtcagTGTGTTGTGTT
 ||||| ||||| ||||| |||||
 33 7127 TtcTGtcTatGTactTtgtgTTGT TGTGTTGTGTTgtTGT
 ||||| ||||| ||||| |||||
 16 7167 TgtTGaaTtaGTGT TgtTTGT TGTGT ATATGT
 ||||| ||||| ||||| |||||
 10 31 7088 GTGTctgTatGTGTATGTGCTTGTgctgtattGT ATATGTGTGTGTTtgtgtgtTATATA tg
 ||||| ||||| ||||| |||||
 18 7113 GTG cGTGTACGTGC caGgaagtaATATGTGTGTGT gtatataTATATACat
 con -t-tctataagtgat-tgtttgtg----tgtGtagtgt-tatgtgtgtgt-----tatata---
 015-GTG CGTGTACGTGC CAGGAAGTAATATGTGTGTGT GTATATATATATACAT-015
 15 023-AAAACCAAAAAGTAATATATGTGTGTGTCAGTGTGTTGTGTT-(023)
 6 7313 AT
 |||||
 11 7302 ATtTaTATG T TGTGTA gTGTGT
 ||||| ||||| ||||| |||||
 20 33 7167 TTGT TtTtTgTGTATG TGttacaaTgtATgTTATGTTGTATGTTacTGTGTTG
 ||||| ||||| ||||| |||||
 16 7199 TTGTATGTgctTGTATG TG CTTGTAAATATTAaGTTGTATGT GTGTTG
 ||||| ||||| ||||| |||||
 31 7150 gTATaTGTATGTTTaTGTATG CgTGTGT aCTTGTATATAT GtaTaGTATGT TATGTgTg
 ||||| ||||| ||||| |||||
 25 18 7164 cTATtgtTgTGTT GTATGtCcTGTGTTgtgtTGT TgTAT G aTtgcattgTATG G
 con -tatttgtatgtttttgtatg-c-tgtgt-tgt-cttgtatatattatgttgtatggt-gtgtgtttg
 015-CTATTGTTGTGTTT GTATGTCCTGTGTTTGTGTTTGT TGTAT G ATTGCATTGTATG G-015
 023- ATTTATATG T TGTGTA GTGTGT(-023)
 30 6 7315 aTATATGT
 |||||
 11 7325 aTATGT TtCTTGT atTGTG TATATGT
 ||||| ||||| ||||| |||||
 33 7221 T ttTATGTgTaCTTGTttGTGTGcATGTtTcTATGTacttgt
 ||||| ||||| ||||| |||||
 35 16 7248 TATGTATG gtaTAATAAA cacGTGTGTATGT
 ||||| ||||| ||||| |||||
 31 7209 TATGTATGctatgtaTGTAAATAAatgtgtatatacctgtgtgtTGTGTATGTTGtTcTataTAc
 ||||| ||||| ||||| |||||
 18 7221 TATGTATG gtTGTGTT gtTGTATGTGTatgTtacTAt
 ||||| ||||| ||||| |||||
 40 con tatgtatg-----tgtaataaaa---ttatgt-ttcttggt-gtgtgtatggt-tatgta--tat
 015-TATGTATG GTTGT GTTGTATGTTGTATGTTACTAT-015
 023- ATATGT TCCTTGT ATTGTG TATATGT(-023)
 45
 50
 55

6 7323 GT GTATGTAAGTGT
5 11 7351 GTataTGTtTGTGTATATGT GTAT gtTATGTA TGT
33 7262 cagtTtccTGTtTGTGTATATGTtaataaaaacattgTgTGTATtTgtTaaActATtTgTATGTA TGT
16 7279 GTtTtTaAaTgcTTgtgTAACTATTGT gTcATgcAacATAaAaaacttatt
10 31 7277 AccctaTtagtaacatacTaTtAcTatTTtataAACTATTGTtccTActTgtTcctAcTgttCCTgc
18 7257 AtttgtTggtatgtggcaTtaaAataAaaTatgttttTgtggtTctgTgtgTtaTgtggTgTgcgcCCTag
con a---tat-tgtttgtgtatat-ataatataagaaactatgttttttatgtaatat--Tatgtactgt
O15-ATTTGTTGGTATGTGGCATTAAATAAAATATGTTTTGTGGTTCGTGTGTTATGTGGTTCGCCCTAG-O15
O23- GTATATGTTTGTGTATATGT GTAT GTTATGTA TGT-O23
15
6 7336 TATGT aTATGT GTgTGTGTtTctGTGTGtaagttaAgtTATTTGTGtAATGTGTATGTgTGT
11 7386 TATGTtgtTATGtatGtTGTGTGTtTaGTGTGT gtAaTATTTGTGCAATGTGTATGTATGTT
20 33 7329 TATGT AtatgggtgtaccTataTgaGTAagGagTgTATtGcTtGccctacCcTGCATTgc
16 7331 gtTTCaAcAcctACtaaTgtTgtTgTggtTaTtcAtTGTATaTaAaactaTatTtGctACATcCtgTtt
31 7345 TccTCccaAatagtCATgTacTTaTtTctgccTataAaTTTAGgTgTcacgccTaGTAaAaAgTtgtaca
25 18 7325 TgagtaacAactgtATtTgtgTtTgTggtatggggtTgTgcttgtTgggctatataTtgtccTgtattt
con tatgtaa-aa-gt-attttgt-tttT-tgtgtgtaagtgtattttatttgt-taa-ttgtatgt-tttt
O15-TGAGTAACAACGTGATTTGTGTTTGTGTAAGGTGTTGCTTGTGGGTATATATTGTCCTGTATTT-O15
O23-TATGTTGTTATGTATGTTTGTGTGTTTAGTGTGT GTATATATTTGTGGAATGTGTATGTATGTT-O23
30
6 7400 TaTGTGCAATAAACAAATTAacctcTtgtTacacCCTGT gACTCAGTGgctgttgacgcGTTtTGgT
11 7450 TtTGTGCAATAAACAAATTA TTatgTgtgtCCTGTTACACcCAGTG actaaGTTgTgT
33 7390 aaTGTaCcTAccTtTATtccccTaTatTtgtAGtaCCTACATGTTtaGTattgCtttacCtTTTGaca
35 16 7399 ttgtTTtaTATaTactaTatTtTgTAGcgcCAGgcCCatTTTGTAcGcTcCaAcGaaAttCggTTGcat
31 7413 CccGgTccgtTtTTtgcaACTaaAgctacTCCATTTTgaTTTtatGCagCCAATTTAaaTcccTAACC
18 7393 CaaGtTataaaacTgcacACcTtAcagcaTCCATTTTatccTacaatccCcaTTTtgcTgtgcAACCC
40 con tatgtttcaa-aatt-attaccttata-t-tcc-tt-t-acat-cagtg-c-atttta--cgttt-act
O15-CAAGTTATAAACTGCACACCTTACAGCATCCATTTATCCTACATCCTCCATTTTGTGTGCAACC-O15
O23-TTTGTGCAATAAACAAATTA TTATGTGTGTCCTGTTACACCCAGTG ACTAAGTTGTGTT-O23
O24-GAATTCGGTTGCAT

6 7466 TTGCACGGCCCTTAcacacataagTaATATacaTgcAcaATATATATATtTtTgtTtaaaATACTAT
 11 7508 TTGCACGGCCCGTtTgtgttgccTTCATAT TatAtTATATATATtTgTaataTAcCTATACTATg
 5
 33 7458 TacTAGTgtCCaTATtgtacaaTTTCcTccattTTgTATGcCTAaccgTtTtcggTtACTTgGCAtac
 16 7467 GcTTTtTGgCaCAAAaTgTgtTTTttaAaTAGTTCTATGtCagcaacTaTgGtTtAaacTTGTAcGT
 31 7481 GtTTTCGGTTGcAttgTtTaaacaTgctAgTAcAACTATGctgatgcagtaGTTcTGcggTtTtTgGT
 10
 18 7461 GaTTTCGGTTGC ctttggcTTaTGctgTggTttT
 con -ttt-cgg-ccctat-t-ta-a-ttc-tataa-t-ctatgt-tatat-ttt-tt-T-actttgct-tt
 015-GAATTTCGGTTGC CTTTGGCTTATGCTCTGGTttt-015
 023-TTGCACGGCCCGTTTGTGTTCCTTCATAT TATATTATATATATTGTAATATACCTATACTATG-023
 024-GCTTTTGGCACAAATGTGTTTTTTTAAATAGTTCTATGTGCAACTATGGTTTAAACTTGTACGT-024
 15
 6 7533 aCttttatAtTTGCAACCGTTTCGGTTGCCCTTAgCATACACTTtCCaCcaAATTGTtAcAAC
 11 7573 tTACCCccccCacTTGCAACCGTtTCGGTTGCCCTTA CATACACTTAcCTCaAATTGTtAcAAC
 20
 33 7526 aTACCCcTaTgaCATtGGCAGaacAgTtasTccTTTtCTtCCTGCACTGtgtTgtTcTgTACTtgcTg
 16 7535 TTCCCTG cTtgCcaTGcgtGccaAaTcccTgtTTTcTgaCCTGCACTG cTTgccaACcaTccc
 31 7549 TTCCCTG aaTAcTagTTTtTGcCaacaTTCTggcTtgTagt
 25
 18 7496 cTgCacaatacagtacgctggcactattgcaacttTaaTctTTTggGCactgcTcTacaTatTttg
 con tt-c-ct-tt-catt-gcagcc--tttcg-tt-ctcttacc-T-cact--c-tcttct-tattata-c
 015-CTGCACAATACAGTACGCTGGCACTATTGCAAACTTTAATCTTTGGGCACTGCTCCTACATATTTTG-015
 023-TTACCCCCCCCCACTTGCACCGTTTTCGGTTGCCCTTA CATACACTTACCTCAAATTTGTtATAAC-023
 024-TTCCCTG CTTGCCATGCGTGCCAAATCCCTGTTTCTCTGACCTGCACTG CTTGCCAACCATTC-024
 30
 6 7597 GTGTTTccTctTAATCctATATattTTGTG CcAGGTACAcATTGCCCTGCCAAGTtgCTTGCCAA
 11 7640 GTGTTTtgTACTAATCCcATAT gTTGTgtgcCAAGGTACAtATTGCCCTGCCAAGTatCTTGCCAA
 33 7594 caTTggcaTACatAcCctATgacatTgGCagaaCagTtAAATcctTTtCTTtCTGcacTgtgTttgtc
 35
 16 7598 aTTgTtttTtACACtgCacTatgtgcaAcTActgAaTCacTaTgTaCATTgtgTCataTAAaaTaaaT
 31 7589 tTCCtgccTaACACacCTTgccaCATATAatccAgTCCaacTtTGCAATTAtaCtATgAATCatgtT
 18 7564 aaCaattggcgCgCctCTTtggcgCATATAA ggCgcaccTGgtATTA gtcATtttcCtgtcc
 40
 con -t-ttt--ta-ca-tcCtatat---tt-taa-ccaa-g-aca--Ttgc-tt-c--aatt--ttt--a-
 015-AACAATTGGCGCGCCTCTTTGGCGCATATAA GGCGCACCTGGTATTA GTCATTTTCTGTGCC-015
 023-GTGTTTTGTACTAATCCCATAT G-023
 024-ATTGTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCATATAAAATAAAT-024
 45
 50
 55

6 7662 gtgcatcatatcctgcccacCACACACCTGGCgcCAGGGtGCGGTATTGC cTtactcATAA
 11 7706 CAACACACCTGGC CAGGGcGCGGTATTGCaTgAcTaaTgTAcAATAA
 5 33 7662 tgtacTtgctgcAttgacTCAtatataCatGCAGtgcaATTgcaaaTaCTTaATTgtacTaatAgTT
 16 7666 cacTaTgcgcCAACGgcctTacatACcgCgtgtTAGgcacATatTtTTggcTTgTtTTAactAACcTAAT
 31 7657 tGtTtaaaTACAACtgttagttcaACTATgtgTcatgcAcaTATATTataTTaTCCTACAcAcCTTAAA
 10 18 7626 aGgTgcgcTACAAC aATTgcTtgcatAacTATAT ccactcCCTA AgtaaTAAAA
 con tg-tatg-tacaacgccatc-a-acaactgg-agca-aatt-tata-t-cttt-cta-a--actaaaa
 BE31-XXAGGCACAXAXXX-BE31 hpv16+18+33
 O15-AGGTGCGCTACAAC AATTGCTTGCATAACTATAT CCACTCCCTA AGTAATAAAA-O15
 O24-CACATATGCGCCAACGCCCTTACATACCGCTGTAGGCACATATTTTGGCTTGTTTAACTAACCTAAT-O24
 15 6 7723 ACCTGTC TTTGTgttAtAcTtTTaTGcAcTGTAGCCAActcTTAAAAGCATTTTTGGCTTgTAGCa
 11 7753 ACCTGTCGgTTTGT ACAaTgTTgTGgATTGCAGCCAAAggTTAAAAGCATTTTTGGCTTcTAGCt
 20 33 7730 TaCacATGcTTTtaggcACATAtTTTactTTaCtttCAAaccTTAagtGCAGTTTGGCTT aCa
 16 7734 TgCATATTtGGCAtAaggTTTAAacTTcTAaggCcAaCtAAatgTcAccctAGTTCaTaCaTgaActg
 31 7725 CTGCTTTTAGGCACATATTTT CTagaTTATctaTatCctTgATTGCAGtgctGGCTTTtgcacAtgt
 18 7680 CTGCTTTTAGGCACATATTTTtAGTtTgtTtTtacTtaagcTaATTGCAtactTGGCTT
 25 con --c-tttta---atataaat-tagtttt-tattgct--caaa--tTaaa-gcattt-t-gcttgtagc-
 BE31-XXAGGCACAXAXXX-BE31 hpv16+18+33
 BE31-XXAGGCACAXAXXX-BE31 hpv16+18+33
 O15-CTGCTTTTAGGCACATATTTTAGTtTGTtTTTACTTAAGCTAATTGCATACTTGGCTT-(O15)
 O24-TGCATATTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAATGTCCACCTAGTTCATACATGAAGTG-O24
 30 6 7789 GcACATTTTTtTgCtCTTAcTgTtTggTatACAATAaCataAAAATGAGTAACCTAAGGTCACACACC
 11 7818 GAACATTTTGTACcCTTAgTaTaTtaTgcACAATAcCcacAAAATGAGTAACCTAAGGTCACACACC
 33 7795 cAAttgcTTTGTATgCcaAactaTgcctTTGTAAAgtgagtcActacctggtTaTtAccaGGTGTGga
 35 16 7802 TgtAAagGTTAgTcaTAcATTgTTCATTGTAAAA cTgcAcatgGGTGTGtg
 31 7792 TtaAActGccAaggTTgtgTcaTgCATTaTaaATAagttgTatgttactcaTATAATtaATTgCatAt
 18 7738 gtacaactacTTtcaTgtccaACatTctgTctacccTtaacatgaacTATAAT ATgaCtaAg
 40 con -aa-attttt-tact-ttatt-tt-a-tttaaaaaac-gtaaa-tg--tat--taagga-g--ta--
 O15- GTACAACTACTTTCATGTCCAACATTCTGTCTACCCCTAACATGAACATAAT ATGACTAAG-O15
 O24-TGTAAAGGTTAGTCATACATTGTTTCATTGTAAAA CTGCACATGGGTGTGTG-O24
 45
 50
 55

```

6   7857 TGCgACCGGTTTCGGTTAtCCACACCCTACATATTTCTTCTTTATA
    ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
11  7886 TGCAACCGGTTTCGGTTAcCCACACCCTACATATTTCTTCTTTATA
    ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
5   |      |      |      |      |      |      |      |
33  7863 CtAACCG TTTTaGGTcAtaTTggTCATTtA tAAtcTTTATATAATA
    | ||||| ||||| |      |      |      |      |      |
16  7854 CaAACCGATTTT gGGTTACACATTTACAAGCAActTATATAATAACTaa
    |      |      |      |      |      |      |      |
31  7860 agGTattAcaccgtTTTcGGTTACAGtTTTACAAGCAAtTgtTCTttTTATACT
    ||      ||      ||      ||      ||      ||      ||
10  |      |      |      |      |      |      |      |
18  7800 ctGTgcatacatagTTTatGcaACcGaaaTAGgttgggccaGcaCaTacTATACTtttc

con       cg-aac---ttt-ggttatg--acccat-tA-a-ttc-tt-ttataataact----
O15-CTGTGCATACATAGTTTTATGCAACCGAAATAGGTTGGGAGCACATACTATACTTTTC-(O15)
O24-CAAACCGATTTT GGGTTACACATTTACAAGCAACTTATATAATAATACTAA(-O24)
15

```

Claims

Claims for the following Contracting States : AT, BE, CH, LI, DE, DK, FR, GB, GR, IT, NL, SE

1. A composition useful in LCR for amplifying the DNA of human papilloma virus present in a test sample, said composition comprising a set of four oligonucleotide probes, said probe sets being selected from the group consisting of the following oligonucleotide sets:

LCR5: SEQ ID No.

81 GCTGCAACA ACTATACATG ATATAA,
82 TTATATCATG TATAGTTGTT TGCAGC,
83 TATTAGAATG TGTGTACTGC AAGCA,
84 TGCTTGCACT ACACACATTC TAATA:

LCR6: SEQ ID No.

85 CTTCACTGCA AGACATAGAA ATAA,
86 TTATTTCTAT GTCTTGCAGT GAA,
87 CCTGTGTATA TTGCAAGACA GTAT,
88 TACTGTCTTG CAATATACAC AGG;

LCR7: SEQ ID No.

89 TATATTGCAA GACAGTATTG GAAC,
90 GTTCCAATAC TGTCTTGCAA TTTA,
91 TTACAGAGGT ATTTGAATTT GCATT,
92 AATGCAAATT CAAATACCTC TGTA; and

LCR8: SEQ ID No.

93	GTATGGAACA	ACATTAGAAC	AGCA,
94	TGCTGTTCTA	ATGTTGTTCC	ATAC.
95	ATACAACAAA	CCGTTGTGTG	ATTT.
96	AAATCACACA	ACGGTTTGT	GTAT.

2. A composition according to claim 1 for amplifying the DNA of human papilloma virus type 16 present in a test sample, said composition comprising a set of four oligonucleotide probes, said probe sets being selected from the group consisting of the following oligonucleotide sets:

LCR5 (SEQ ID Nos. 81,82,83 and 84) and LCR8 (SEQ ID Nos. 93, 94, 95 and 96).

3. A composition according to claim 1 for amplifying the DNA of human papilloma virus type 18 present in a test sample, said composition comprising a set of four oligonucleotide probes, said probe sets being selected from the group consisting of the following oligonucleotide sets:

LCR 6 (SEQ ID Nos. 85,86,87 and 88) and LCR 7 (SEQ ID Nos. 89,90,91 and 92).

4. A kit for detecting the presence of human papilloma virus DNA in a test sample, comprising:
a composition according to any of claims 1 to 3; and
further comprising a ligase.

5. A kit according to claim 4, wherein said ligase is thermostable.

6. A composition useful in PCR for amplifying the DNA of human papilloma virus present in a test sample, said composition comprising:

a first nucleic acid primer of sense direction, capable of hybridizing to the antisense strand of HPV DNA, said primer having from 10 to about 30 nucleotides in length and having a sequence selected from the group consisting of the following sequences:

SEQ ID No.

1 CAGATGTCTC TGTGGCGGCC TAGTG.

6 GAATTAGTTA GACCATTAA AAG.

7 GGGGAAACAC CAGAATGGAT A.

81 GCTGCAAACA ACTATACATG ATATAA.

85 CTTCACTGCA AGACATAGAA ATAA.

89 TATATTGCAA GACAGTATTG GAAC and

93 GTATGGAACA ACATTAGAAC AGCA; and

a second nucleic acid primer of antisense direction, capable of hybridizing to the sense strand of HPV DNA, said primer having from 10 to about 30 nucleotides in length and having a sequence selected from the group consisting of the following sequences:

SEQ ID No.

5 AGGTGTCAGG AAAACCAAAT TTATT.

84 TGCTTGCACT ACACACATTC TAATA.

88 TACTGTCTTG CAATATACAC AGG.

92 AATGCAAATT CAAATACCTC GTAA and

96 AAATCACACA ACGGTTTGTG GTAT;

provided said first and second primers hybridize to their respective antisense and sense strands at locations such that their 3' ends do not overlap and, in the direction of extension, the 5' ends of said primers are spaced further apart than the 3' ends of said primers.

7. A composition according to claim 6 wherein said first and second primers are selected from the following pairs of oligonucleotide sequences (identified by Sequence ID No.):

1 and 5, 6 and 5, 7 and 5, 81 and 84,

85 and 88, 89 and 92, and 93 and 96.

8. A kit for detecting the presence of human papilloma virus DNA in a test sample, comprising:
a composition according to claim 6 or 7; and
further comprising a polymerase.

9. A kit according to claim 8 wherein said polymerase is thermostable.

10. A consensus oligonucleotide for hybridizing human papilloma virus types 6, 11, 16, 18, 31, 33 and 61, which oligonucleotide comprises from about 10 to about 60 nucleotides in length and is selected from the group of sequences consisting of:

SEQ ID No.

1 CAGATGTCTC TGTGGCGGCC TAGTG,
5 AGGTGTCAGG AAAACCAAAT TTATT,
6 GAATTAGTTA GACCATTTAA AAG and
7 GGGGAAACAC CAGAATGGAT A;

and their complements.

11. A type-specific oligonucleotide for determining the presence of human papilloma virus type 16, having a sequence selected from the group consisting of:

SEQ ID No.

81 GCTGCAAACA ACTATACATG ATATAA,
82 TTATATCATG TATAGTTGTT TGCAGC,
83 TATTAGAATG TGTGTACTGC AAGCA,
84 TGCTTGCACT ACACACATTC TAATA,
93 GTATGGAACA ACATTAGAAC AGCA,
94 TGCTGTTCTA ATGTTGTTCC ATAC,
95 ATACAACAAA CCGTTGTGTG ATTT and
96 AAATCACACA ACGGTTTGTG GTAT;

and their complements.

12. A type-specific oligonucleotide for determining the presence of human papilloma virus type 18, having a sequence selected from the group consisting of: SEQ ID No.

SEQ ID No.

85 CTTCACTGCA AGACATAGAA ATAA,
86 TTATTTCTAT GTCTTGCACT GAA,
87 CCTGTGTATA TTGCAAGACA GTAT,
88 TACTGTCTTG CAATATACAC AGG,
89 TATATTGCAA GACAGTATTG GAAC,
90 GTTCCAATAC TGTCTTGCAA TTTA,
91 TTACAGAGGT ATTTGAATTT GCATT and
92 AATGCAAATT CAAATACCTC TGTA;

and their complements.

13. A method for determining the presence of any human papilloma virus in a test sample, comprising:

- hybridizing DNA in the test sample with at least one consensus oligonucleotide selected from the group of claim 10, said oligonucleotide being conjugated to a signal generating compound capable of producing a detectable signal; and
- determining the presence of human papilloma virus by detecting the signal generated.

14. A method for determining the presence of human papilloma virus type 16 in a test sample, comprising:

- hybridizing DNA in the test sample with at least one oligonucleotide selected from the group of claim 11, said oligonucleotide being conjugated to a signal generating compound capable of producing a detectable signal; and
- determining the presence of human papilloma virus by detecting the signal generated.

15. A method for determining the presence of human papilloma virus type 18 in a test sample, comprising:

- a. hybridizing DNA in the test sample with at least one oligonucleotide selected from the group of claim 12, said oligonucleotide being conjugated to a signal generating compound capable of producing a detectable signal; and
- b. determining the presence of human papilloma virus by detecting the signal generated.

16. A method according to any of claims 13-15, further comprising a step of amplification prior to or concurrent with said hybridizing step.

17. A method according to claim 16, wherein said amplification step comprises PCR or LCR.

Claims for the following Contracting States : ES

1. A composition useful in LCR for amplifying the DNA of human papilloma virus present in a test sample, said composition comprising a set of four oligonucleotide probes, said probe sets being selected from the group consisting of the following oligonucleotide sets:

LCR5: SEQ ID No.

81	GCTGCAAACA	ACTATACATG	ATATAA,
82	TTATATCATG	TATAGTTGTT	TGCAGC,
83	TATTAGAATG	TGTGTACTGC	AAGCA,
84	TGCTTGCAGT	ACACACATTC	TAATA;

LCR6: SEQ ID No.

85	CTTCACTGCA	AGACATAGAA	ATAA,
86	TTATTTCTAT	GTCTTGCAGT	GAA,
87	CCTGTGTATA	TTGCAAGACA	GTAT,
88	TACTGTCTTG	CAATATACAC	AGG;

LCR7: SEQ ID No.

89	TATATTGCAA	GACAGTATTG	GAAC,
90	GTTCCAATAC	TGTCTTGCAA	TITA,
91	TTACAGAGGT	ATTTGAATTT	GCATT,
92	AATGCAAATT	CAAATACCTC	TGTAA; and

LCR8: SEQ ID No.

93	GTATGGAACA	ACATTAGAAC	AGCA,
94	TGCTGTTCTA	ATGTTGTTCC	ATAC,
95	ATACAACAAA	CCGTTGTGTG	ATTT,
96	AAATCACACA	ACGGTTTGTG	GTAT.

2. A composition according to claim 1 for amplifying the DNA of human papilloma virus type 16 present in a test sample, said composition comprising a set of four oligonucleotide probes, said probe sets being selected from the group consisting of the following oligonucleotide sets:

LCR5 (SEQ ID Nos. 81,82,83 and 84) and LCR8 (SEQ ID Nos. 93, 94, 95 and 96).

3. A composition according to claim 1 for amplifying the DNA of human papilloma virus type 18 present in a test sample, said composition comprising a set of four oligonucleotide probes, said probe sets being selected from the group consisting of the following oligonucleotide sets:

LCR6(SEQ ID Nos. 85,86,87 and 88) and LCR 7(SEQ ID Nos. 89,90,91 and 92).

4. A kit for detecting the presence of human papilloma virus DNA in a test sample, comprising:

a composition according to any of claims 1 to 3; and further comprising a ligase.

5. A kit according to claim 4, wherein said ligase is thermostable.

5 6. A composition useful in PCR for amplifying the DNA of human papilloma virus present in a test sample, said composition comprising:

10 a first nucleic acid primer of sense direction, capable of hybridizing to the antisense strand of HPV DNA, said primer having from 10 to about 30 nucleotides in length and having a sequence selected from the group consisting of the following sequences:

SEQ ID No.

1 CAGATGTCTC TGTGGCGGCC TAGTG,

15

6 GAATTAGTTA GACCATTAA AAG,

7 GGGGAAACAC CAGAATGGAT A,

81 GCTGCAAACA ACTATACATG ATATAA,

20

85 CTTCACTGCA AGACATAGAA ATAA,

89 TATATTGCAA GACAGTATTG GAAC and

93 GTATGGAACA ACATTAGAAC AGCA; and

25 a second nucleic acid primer of antisense direction, capable of hybridizing to the sense strand of HPV DNA, said primer having from 10 to about 30 nucleotides in length and having a sequence selected from the group consisting of the following sequences:

SEQ ID No.

5 AGGTGTCAGG AAAACCAAAT TTATT,

30

84 TGCTTGCACT ACACACATTC TAATA,

88 TACTGTCTTG CAATATACAC AGG,

92 AATGCAAATT CAAATACCTC TGTA and

96 AAATCACACA ACGGTTTGT GTAT;

35

provided said first and second primers hybridize to their respective antisense and sense strands at locations such that their 3' ends do not overlap and, in the direction of extension, the 5' ends of said primers are spaced further apart than the 3' ends of said primers.

40 7. A composition according to claim 6 wherein said first and second primers are selected from the following pairs of oligonucleotide sequences (identified by Sequence ID No.):

1 and 5, 6 and 5, 7 and 5, 81 and 84,
85 and 88, 89 and 92, and 93 and 96.

45 8. A kit for detecting the presence of human papilloma virus DNA in a test sample, comprising:
a composition according to claim 6 or 7; and
further comprising a polymerase.

9. A kit according to claim 8 wherein said polymerase is thermostable.

50 10. A method for determining the presence of any human papilloma virus in a test sample, comprising:

a. hybridizing DNA in the test sample with at least one consensus oligonucleotide selected from the group of sequences consisting of:

55

SEQ ID No.

5
10
1
5
6
7

CAGATGTCTC TGTGGCGGCC TAGTG,
AGGTGTCAGG AAAACCAAAT TTATT,
GAATTAGTTA GACCAITTTAA AAG and
GGGGAAACAC CAGAATGGAT A;

and their complements,

said oligonucleotide being conjugated to a signal generating compound capable of producing a detectable signal; and

b. determining the presence of human papilloma virus by detecting the signal generated.

11. . A method for determining the presence of human papilloma virus type 16 in a test sample, comprising:

15
a. hybridizing DNA in the test sample with at least one oligonucleotide selected from the group of sequences consisting of:

SEQ ID No.

20
25
30
81
82
83
84
93
94
95
96

GCTGCAAACA ACTATACATG ATATAA,
TTATATCATG TATAGTTGTT TGCAGC,
TATTAGAATG TGTGTAAGTC AAGCA,
TGCTTGCACT ACACACATTC TAATA,
GTATGGAACA ACATTAGAAG AGCA,
TGCTGTTCTA ATGTTGTTCC ATAC,
ATACAACAAA CCGTTGTGTG ATTT and
AAATCACACA ACGGTTTGTT GTAT;

and their complements, said oligonucleotide being conjugated to a signal generating compound capable of producing a detectable signal; and

b. determining the presence of human papilloma virus by detecting the signal generated.

12. . A method for determining the presence of human papilloma virus type 18 in a test sample, comprising:

35
a. hybridizing DNA in the test sample with at least one oligonucleotide selected from the group of sequences consisting of:

SEQ ID No.

40
45
85
86
87
88
89
90
91
92

CTTCACTGCA AGACATAGAA ATAA,
TTATTTCTAT GTCTTGCACT GAA,
CCTGTGTATA TTGCAAGACA GTAT,
TACTGTCTTG CAATATACAC AGG,
TATATTGCAA GACAGTATTG GAAC,
GTTCCAATAC TGTCTTGCAA TTTA,
TTACAGAGGT ATTTGAATTT GCATT and
AATGCAAATT CAAATACCTC TGTA;

and their complements,

said oligonucleotide being conjugated to a signal generating compound capable of producing a detectable signal; and

b. determining the presence of human papilloma virus by detecting the signal generated.

13. A method according to any of claims 10-12, further comprising a step of amplification prior to or concurrent with said hybridizing step.

14. A method according to claim 13, wherein said amplification step comprises PCR or LCR.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, LI, DE, DK, FR, GB, GR, IT, NL, SE

1. Zusammensetzung, die für die LCR ("ligase chain reaction", Ligasekettenreaktion) zur Vervielfachung der DNA des humanen Papillomavirus nützlich ist, der in einer Testprobe vorhanden ist, wobei die Zusammensetzung einen Satz von vier Oligonukleotidsonden umfaßt, wobei die SONDENSÄTZE aus der Gruppe gewählt sind, die aus den folgenden Oligonukleotidsätzen besteht:

LCR5: SEQ ID N^o 81 GCTGCAAACA ACTATACATG ATATAA.
 82 TTATATCATG TATAGTTGTT TGCAGC.
 83 TATTAGAATG TGTGTACTGC AAGCA,
 84 TGCTTGCAGT ACACACATTC TAATA;

LCR6: SEQ ID N^o 85 CTTCACTGCA AGACATAGAA ATAA,
 86 TTATTTCTAT GTCTTGCAGT GAA,
 87 CCTGTGTATA TTGCAAGACA GTAT,
 88 TACTGTCITG CAATATACAC AGG;

LCR7: SEQ ID N^o 89 TATATTGCAA GACAGTATTG GAAC,
 90 GTTCCAATAC TGTCTTGCAA TTAA,
 91 TTACAGAGGT ATTTGAATTT GCATT,
 92 AATGCAAAAT CAAATACCTC TGTA; und

LCR8: SEQ ID N^o 93 GTATGGAACA ACATTAGAAC AGCA,
 94 TGCTGTTCTA ATGTTGTTCC ATAC,
 95 ATACAACAAA CCGTTGTGTG ATTT,
 96 AAATCACACA ACGGTTTGTG GTAT.

2. Zusammensetzung nach Anspruch 1 zur Vervielfachung der DNA des humanen Papillomavirus Typ 16, der in einer Testprobe vorhanden ist, wobei die Zusammensetzung einen Satz von vier Oligonukleotidsonden umfaßt, wobei die SONDENSÄTZE aus der Gruppe gewählt sind, die aus den folgenden Oligonukleotidsätzen besteht: LCR5 (SEQ ID N^o 81, 82, 83 und 84) und LCR8 (SEQ ID N^o 93, 94, 95 und 96)
3. Zusammensetzung nach Anspruch 1 zur Vervielfachung der DNA des humanen Papillomavirus Typ 18, der in einer Testprobe vorhanden ist, wobei die Zusammensetzung einen Satz von vier Oligonukleotidsonden umfaßt, wobei die SONDENSÄTZE aus der Gruppe gewählt sind, die aus den folgenden Oligonukleotidsätzen besteht: LCR6 (SEQ ID N^o 85, 86, 87 und 88) und LCR7 (SEQ ID N^o 89, 90, 91 und 92).
4. Kit zum Nachweis der Anwesenheit der DNA des humanen Papillomavirus in einer Testprobe, das folgendes umfaßt:
 eine Zusammensetzung nach einem der Ansprüche 1 bis 3, und des weiteren eine Ligase.
5. Kit nach Anspruch 4, worin die Ligase thermostabil ist.
6. Zusammensetzung, die bei der PCR ("polymerase chain reaction" Polymerasekettenreaktion) zur Vervielfachung der DNA des humanen Papillomavirus nützlich ist, der in einer Testprobe vorhanden ist, wobei die Zusammensetzung folgendes umfaßt:

einen ersten Nukleinsäureprimer, der zur Richtung gleichläufig ist, welcher zur Hybridisierung an den gegenläufigen Strang der HPV-DNA befähigt ist, wobei der Primer 10 bis ungefähr 30 Nukleotide lang ist und eine Sequenz aufweist, die aus der Gruppe gewählt ist, die aus den folgenden Sequenzen besteht:

5
1 CAGATGTCTC TGTGGCGGCC TAGTG,
6 GAATTAGTTA GACCATTAA AAG,
10 7 GGGGAAACAC CAGAATGGAT A,
81 GCTGCAAACA ACTATACATG ATATAA,
85 CTTCAC TGCA AGACATAGAA ATAA,
89 TATATTGCAA GACAGTATTG GAAC und
15 93 GTATGGAACA ACATTAGAAC AGCA; und

einen zweiten Nukleinsäureprimer, der zur Richtung gegenläufig ist, welcher zur Hybridisierung an den gleichläufigen Strang der HPV-DNA befähigt ist, wobei der Primer 10 bis ungefähr 30 Nukleotide lang ist und eine Sequenz aufweist, die aus der Gruppe gewählt ist, die aus den folgenden Sequenzen besteht:

20 SEQ ID Nr

25 5 AGGTGTCAGG AAAACCAAAT TTATT,
84 TGCTTGCACT ACACACATTC TAATA,
88 TACTGTCTTG CAATATACAC AGG,
92 AATGCAAATT CAAATACCTC TGTA und
30 96 AAATCACACA ACGGTTTGTT GTAT;

vorausgesetzt, daß der erste und der zweite Primer an ihre jeweiligen gleich- und gegenläufigen Stränge an solchen Stellen hybridisieren, daß ihre 3'-Enden nicht überlappen, und daß die 5'-Enden der Primer in Verlängerungsrichtung weiter räumlich abgesetzt sind als die 3'-Enden der Primer.

35 7. Zusammensetzung nach Anspruch 6, worin der erste und zweite Primer aus den folgenden Paaren von Oligonukleotidsequenzen (die durch die Sequenz ID Nr bezeichnet sind) gewählt sind:

1 und 5, 6 und 5, 7 und 5, 81 und 84,
85 und 88, 89 und 92, und 93 und 96.

40 8. Kit zum Nachweis der Anwesenheit der DNA des humanen Papillomavirus in einer Testprobe, das folgendes umfaßt:

eine Zusammensetzung nach Anspruch 6 oder 7 und des weiteren eine Polymerase.

9. Kit nach Anspruch 8, worin die Polymerase thermostabil ist.

45 10. Consensus-Oligonukleotid zur Hybridisierung der humanen papillomaviren Typ 6, 11, 16, 18, 31, 33 und 61, wobei das Oligonukleotid ungefähr 10 bis ungefähr 60 Oligonukleotide lang ist und aus der Gruppe von Sequenzen gewählt ist, die aus folgendem besteht:

50 SEQ ID Nr

55 1 CAGATGTCTC TGTGGCGGCC TAGTG,
5 AGGTGTCAGG AAAACCAAAT TTATT,
6 GAATTAGTTA GACCATTAA AAG
7 GGGGAAACAC CAGAATGGAT A; und

und aus deren Komplementen.

11. Typ-spezifisches Oligonukleotid zur Bestimmung der Anwesenheit des humanen Papillomavirus Typ 16, das eine Sequenz aufweist, die aus der Gruppe gewählt ist, die aus folgendem besteht:

SEO ID Nr

81	GCTGCAAACA	ACTATACATG	ATATAA,
82	TTATATCATG	TATAGTTGTT	TGCAGC,
83	TATTAGAATG	TGTGTACTGC	AAGCA,
84	TGCTTGCAGT	ACACACATTC	TAATA,
93	GTATGGAACA	ACATTAGAAC	AGCA,
94	TGCTGTTCTA	ATGTTGTTCC	ATAC,
95	ATACAACAAA	CCGTTGTGTG	ATTT
96	AAATCACACA	ACGGTTTGTT	GTAT;

und

und aus deren Komplementen.

12. Typ-spezifisches Oligonukleotid zur Bestimmung der Anwesenheit des humanen Papillomavirus Typ 18, das eine Sequenz aufweist, die aus der Gruppe gewählt ist, die aus folgendem besteht:

SEO ID Nr

85	CTTCACTGCA	AGACATAGAA	ATAA,
86	TTATTTCTAT	GTCTTGCAGT	GAA,
87	CCTGTGTATA	TTGCAAGACA	GTAT,
88	TACTGTCTTG	CAATATACAC	AGG,
89	TATATTGCAA	GACAGTATTG	GAAC,
90	GTTCCAATAC	TGTCTTGCAA	TTTA,
91	TTACAGAGGT	ATTTGAATTT	GCAAT
92	AATGCAAATT	CAAATACCTC	TGTAA;

und

und aus deren Komplementen.

13. Verfahren zur Bestimmung der Anwesenheit irgendeines humanen Papillomavirus in einer Testprobe, das folgendes umfaßt:

- Hybridisieren der DNA in der Testprobe mit wenigstens einem Consensus-Oligonukleotid, das aus der Gruppe nach Anspruch 10 gewählt ist, wobei das Oligonukleotid an eine signalerzeugende Verbindung konjugiert ist, die zur Erzeugung eines nachweisbaren Signals befähigt ist, und
- Bestimmen der Anwesenheit des humanen Papillomavirus, indem das erzeugte Signal nachgewiesen wird.

14. Verfahren zur Bestimmung der Anwesenheit des humanen Papillomavirus Typ 16 in einer Probe, das folgendes umfaßt:

- Hybridisieren der DNA in der Testprobe mit wenigstens einem Oligonukleotid, das aus der Gruppe nach Anspruch 11 gewählt ist, wobei das Oligonukleotid an eine signalerzeugende Verbindung konjugiert ist, die zur Erzeugung eines nachweisbaren Signals befähigt ist, und
- Bestimmen der Anwesenheit des humanen Papillomavirus, indem das erzeugte Signal nachgewiesen wird.

15. Verfahren zur Bestimmung der Anwesenheit des humanen Papillomavirus Typ 18 in einer Testprobe, das folgendes umfaßt:

- Hybridisieren der DNA in der Testprobe mit wenigstens einem Oligonukleotid, das aus der Gruppe nach Anspruch 12 gewählt ist, wobei das Oligonukleotid an eine signalerzeugende Verbindung konjugiert ist, die zur Erzeugung eines nachweisbaren Signals befähigt ist, und

b. Bestimmen der Anwesenheit des humanen Papillomavirus, indem das erzeugte Signal nachgewiesen wird.

16. Verfahren nach einem der Ansprüche 13-15, das des weiteren einen Vervielfachungsschritt umfaßt, der vor oder in Konkurrenz mit dem Hybridisierungsschritt stattfindet.

17. Verfahren nach Anspruch 16, worin der Vervielfachungsschritt PCR oder LCR umfaßt.

Patentansprüche für folgenden Vertragsstaat : ES

1. Zusammensetzung, die für die LCR ("ligase chain reaction", Ligasekettenreaktion) zur Vervielfachung der DNA des humanen Papillomavirus nützlich ist, der in einer Testprobe vorhanden ist, wobei die Zusammensetzung einen Satz von vier Oligonukleotidsonden umfaßt, wobei die SONDENSÄTZE aus der Gruppe gewählt sind, die aus den folgenden Oligonukleotidsätzen besteht:

LCR5: SEQ ID N r

81 GCTGCAAACA ACTATACATG ATATAA,
82 TTATATCATG TATAGTTGTT TGCAGC,
83 TATTAGAATG TGTGTACTGC AAGCA,
84 TGCTTGCAGT ACACACATTTC TAATA;

LCR6: SEQ ID N r

85 CTTCACTGCA AGACATAGAA ATAA,
86 TTATTTCTAT GTCTTGCAGT GAA,
87 CCTGTGTATA TTGCAAGACA GTAT,
88 TACTGTCTTG CAATATACAC AGG;

LCR7: SEQ ID N r

89 TATATTGCAA GACAGTATTG GAAC,
90 GTTCCAATAC TGTCTTGCAA TTTA,
91 TTACAGAGGT ATTTGAATTT GCATT,
92 AATGCAAATT CAAATACCTC TGTA;

LCR8: SEQ ID N r

93 GTATGGAACA ACATTAGAAC AGCA, und
94 TGCTGTTCTA ATGTTGTTCC ATAC,
95 ATACAACAAA CCGTTGTGTG ATTT,
96 AAATCACACA ACGGTTTGTG GTAT.

2. Zusammensetzung nach Anspruch 1 zur Vervielfachung der DNA des humanen Papillomavirus Typ 16, der in einer Testprobe vorhanden ist, wobei die Zusammensetzung einen Satz von vier Oligonukleotidsonden umfaßt, wobei die SONDENSÄTZE aus der Gruppe gewählt sind, die aus den folgenden Oligonukleotidsätzen besteht: LCR5 (SEQ ID Nrn 81, 82, 83 und 84) und LCR8 (SEQ ID Nrn 93, 94, 95 und 96).

3. Zusammensetzung nach Anspruch 1 zur Vervielfachung der DNA des humanen Papillomavirus TYP 18, der in einer Testprobe vorhanden ist, wobei die Zusammensetzung einen Satz von vier Oligonukleotidsonden umfaßt, wobei die SONDENSÄTZE aus der Gruppe gewählt sind, die aus den folgenden Oligonukleotidsätzen besteht: LCR6 (SEQ ID Nrn 85, 86, 87 und 88) und LCR7 (SEQ ID Nm 89, 90, 91 und 92).

4. Kit zum Nachweis der Anwesenheit der DNA des humanen Papillomavirus in einer Testprobe, das folgendes umfaßt:
eine Zusammensetzung nach einem der Ansprüche 1 bis 3, und des weiteren eine Ligase.

5. Kit nach Anspruch 4, worin die Ligase thermostabil ist.

6. Zusammensetzung, die bei der PCR ("polymerase chain reaction" polymerasekettenreaktion) zur Vervielfachung der DNA des humanen Papillomavirus nützlich ist, der in einer Testprobe vorhanden ist, wobei die Zusammensetzung folgendes umfaßt:

einen ersten Nukleinsäureprimer, der zur Richtung gleichläufig ist, welcher zur Hybridisierung an den gegenläufigen Strang der HPV-DNA befähigt ist, wobei der Primer 10 bis ungefähr 30 Nukleotide lang ist und eine Sequenz aufweist, die aus der Gruppe gewählt ist, die aus den folgenden Sequenzen besteht:

SEQ ID Nr

1 CAGATGTCTC TGTGGCGGCC TAGTG.

6 GAATTAGTTA GACCATTAA AAG.

7 GGGGAAACAC CAGAATGGAT A.

81 GCTGCAAACA ACTATACATG ATATA.

85 CTTCACCTGCA AGACATAGAA ATAA.

89 TATATTGCAA GACAGTATTG GAAC und

93 GTATGGAACA ACATTAGAAC AGCA; und

einen zweiten Nukleinsäureprimer, der zur Richtung gegenläufig ist, welcher zur Hybridisierung an den gleichläufigen Strang der HPV-DNA befähigt ist, wobei der Primer 10 bis ungefähr 30 Nukleotide lang ist und eine Sequenz aufweist, die aus der Gruppe gewählt ist, die aus den folgenden Sequenzen besteht:

SEQ ID Nr

5 AGGTGTCAGG AAAACCAAAT TTATT.

84 TGCTTGCACT ACACACATTC TAATA.

88 TACTGTCTTG CAATATACAC AGG.

92 AATGCAAAT CAAATACCTC GTAA und

96 AAATCACACA ACGGTTTGTG GTAT;

vorausgesetzt, daß der erste und der zweite Primer an ihre jeweiligen gleich- und gegenläufigen Stränge an solchen Stellen hybridisieren, daß ihre 3'-Enden nicht überlappen, und daß die 5'-Enden der Primer in Verlängerungsrichtung weiter räumlich abgesetzt sind als die 3'-Enden der Primer.

7. Zusammensetzung nach Anspruch 6, worin der erste und zweite Primer aus den folgenden Paaren von Oligonukleotidsequenzen (die durch die Sequenz ID Nr bezeichnet sind) gewählt sind:

1 und 5, 6 und 5, 7 und 5, 81 und 84,

85 und 88, 89 und 92, und 93 und 96.

8. Kit zum Nachweis der Anwesenheit der DNA des humanen Papillomavirus in einer Testprobe, das folgendes umfaßt:

eine Zusammensetzung nach Anspruch 6 oder 7, und des weiteren eine Polymerase.

9. Kit nach Anspruch 8, worin die Polymerase thermostabil ist.

10. Verfahren zur Bestimmung der Anwesenheit irgendeines humanen papillomavirus in einer Testprobe, das folgendes umfaßt:

a. Hybridisieren der DNA in der Testprobe mit wenigstens einem Consensus-Oligonukleotid, das aus der Gruppe von Sequenzen gewählt ist, die aus folgendem besteht:

SEQ ID Nr

5

10

```

1   CAGATGTCCTC TGTGGCGGCC TAGTG,
5   AGGTGTCAGG AAAACCAAAT TTATT
6   GAATTAGTTA GACCATTTAA AAG und
7   GGGGAAACAC CAGAATGGAT A;

```

15

und aus deren Komplementen,
wobei das Oligonukleotid an eine signalerzeugende Verbindung konjugiert ist, die zur Erzeugung eines nachweisbaren Signals befähigt ist, und
b. Bestimmen der Anwesenheit des humanen Papillomavirus, indem das erzeugte Signal nachgewiesen wird.

20

11. Verfahren zur Bestimmung der Anwesenheit des humanen Papillomavirus Typ 16 in einer Probe, das folgendes umfaßt:

a. Hybridisieren der DNA in der Testprobe mit wenigstens einem Oligonukleotid, das aus der Gruppe von Sequenzen gewählt ist, die aus folgendem besteht:

25

SEQ ID Nr

30

35

40

```

81  GCTGCAAACA ACTATACATG ATATAA,
82  TTATATCATG TATAGTTGTT TGCAGC,
83  TATTAGAATG TGTGTACTGC AAGCA,
84  TGCTTGCACT ACACACATTC TAATA,
93  GTATGGAACA ACATTAGAAC AGCA,
94  TGCTGTTCTA ATGTTGTTCC ATAC,
95  ATACAACAAA CCGTTGTGTG ATTT und
96  AAATCACACA ACGGTTTGTT GTAT;

```

45

und aus deren Komplementen,
wobei das Oligonukleotid an eine signalerzeugende Verbindung konjugiert ist, die zur Erzeugung eines nachweisbaren Signals befähigt ist, und
b. Bestimmen der Anwesenheit des humanen Papillomavirus, indem das erzeugte Signal nachgewiesen wird.

50

12. Verfahren zur Bestimmung der Anwesenheit des humanen Papillomavirus Typ 18 in einer Testprobe, das folgendes umfaßt:

a. Hybridisieren der DNA in der Testprobe mit wenigstens einem Oligonukleotid, das aus der Gruppe von Sequenzen gewählt ist, die aus folgendem besteht:

55

SEQ ID Nr

5
85 CTTCAGTGCA AGACATAGAA ATAA,
86 TTATTTCTAT GTCTTGCAGT GAA,
87 CCTGTGTATA TTGCAAGACA GTAT,
88 TACTGTCTTG CAATATACAC AGG,
89 TATATTGCAA GACAGTATTG GAAC,
90 GTTCCAATAC TGTCTTGCAA TTTA,
10 91 TTACAGAGGT ATTTGAATTT GCATT und
92 AATGCAAATT CAAATACCTC .TGTA;

und aus deren Komplementen,

15 wobei das Oligonukleotid an eine signalerzeugende Verbindung konjugiert ist, die zur Erzeugung eines nachweisbaren Signals befähigt ist, und

b. Bestimmen der Anwesenheit des humanen Papillomavirus, indem das erzeugte Signal nachgewiesen wird.

13. Verfahren nach einem der Ansprüche 10-12, das des weiteren einen Vervielfachungsschritt umfaßt, der vor oder
20 in Konkurrenz mit dem Hybridisierungsschritt stattfindet.

14. Verfahren nach Anspruch 13, worin der vervielfachungsschritt PCR oder LCR umfaßt.

25 **Revendications**

Revendications pour les Etats contractants suivants : AT, BE, CH, LI, DE, DK, FR, GB, GR, IT, NL, SE

30 1. Composition utile dans la LCR pour amplifier l'ADN de virus du papillome humain présent dans échantillon à doser, ladite composition comprenant un ensemble de quatre sondes oligonucléotidiques, lesdits ensembles de sondes étant sélectionnés dans le groupe constitué par les ensembles d'oligonucléotides suivants :

35 **LCR5 : n° d'identification**

81 GCTGCAAACA ACTATACATG ATATAA,
82 TTATATCATG TATAGTTGTT TGCAGC,
83 TATTAGAATG TGTGTACTGC AAGCA,
40 84 TGCTTGCAGT ACACACATTC TAATA;

45 **LCR6 : n° d'identification**

85 CTTCAGTGCA AGACATAGAA ATAA,
86 TTATTTCTAT GTCTTGCAGT GAA,
87 CCTGTGTATA TTGCAAGACA GTAT,
50 88 TACTGTCTTG CAATATACAC AGG;

55

LCR7 : n° d'identification

89 TATATTGCAA GACAGTATTG GAAC
 90 GTTCCAATAC TGTCTTGCAA TTTA,
 91 TTACAGAGGT ATTTGAATTT GCATT,
 92 AATGCAAATT CAAATACCTC TGTA ; et

LCR8 : n° d'identification

93 GTATGGAACA ACATTAGAAC AGCA,
 94 TGCTGTTCTA ATGTTGTTCC ATAC,
 95 ATACAACAAA CCGTTGTGTG ATTT,
 96 AAATCACACA ACGGTTTGTT GTAT.

2. Composition selon la revendication 1, destinée à amplifier l'ADN de virus du papillome humain de type 16 présent dans un échantillon à doser, ladite composition comprenant un ensemble de quatre sondes oligonucléotidiques, lesdits ensembles de sondes étant sélectionnés dans le groupe constitué par les ensembles d'oligonucléotides suivants :

LCR5 (n° d'identification 81, 82, 83 et 84) et LCR8 (n° d'identification 93, 94, 95 et 96).

3. Composition selon la revendication 1, destinée à amplifier l'ADN de virus du papillome humain de type 18 présent dans un échantillon à doser, ladite composition comprenant un ensemble de quatre sondes oligonucléotidiques, lesdits ensembles de sondes étant sélectionnés dans le groupe constitué par les ensembles d'oligonucléotides suivants :

LCR6 (n° d'identification 85, 86, 87 et 88) et LCR7 (n° d'identification 89, 90, 91 et 92).

4. Kit de détection de la présence d'ADN de virus du papillome humain dans un échantillon à doser, comprenant : une composition selon l'une quelconque des revendications 1 à 3, et en outre une ligase.

5. Kit selon la revendication 4, dans lequel ladite ligase est thermostable.

6. Composition utile dans la PCR pour amplifier l'ADN de virus du papillome humain présent dans un échantillon à doser, ladite composition comprenant :

une première amorce d'acide nucléique de direction sens, capable de s'hybrider au brin antisens de l'ADN de HPV, ladite amorce ayant de 10 à environ 30 nucléotides de long et une séquence sélectionnée dans le groupe constitué par les séquences suivantes :

N° d'identification

1 CAGATGTCTC TGTGGCGGCC TAGTG,
 6 GAATTAGTTA GACCATTTAA AAG,
 7 GGGGAAACAC CAGAATGGAT A,
 81 GCTGCAAACA ACTATACATG ATATAA,
 85 CTTCACTGCA AGACATAGAA ATAA,
 89 TATATTGCAA GACAGTATTG GAAC et
 93 GTATGGAACA ACATTAGAAC AGCA ; et

une deuxième amorce d'acide nucléique de direction antisens, capable de s'hybrider au brin sens de l'ADN

EP 0 477 972 B1

de HPV, ladite amorce ayant de 10 à environ 30 nucléotides de long et une séquence sélectionnée dans le groupe constitué par les séquences suivantes :

N° d'identification

5	5	AGGTGTCAGG	AAAACCAAAT	TTATT,
	84	TGCTTGCACT	ACACACATTC	TAATA,
	88	TACTGTCTTG	CAATATACAC	AGG,
10	92	AATGCAAATT	CAAATACCTC	TGTAA et
	96	AAATCACACA	ACGGTTTGTT	GTAT ;

pour autant que lesdites première et deuxième amorces s'hybrident à leurs brins respectifs antisens et sens à des emplacements tels que leurs extrémités 3' ne se chevauchent pas et que, dans la direction d'extension, les extrémités 5' desdites amorces soient plus espacées que les extrémités 3' desdites amorces.

7. Composition selon la revendication 6, dans laquelle lesdites première et deuxième amorces sont sélectionnées parmi les paires suivantes de séquences oligonucléotidiques (identifiées par leur numéro d'identification) :

1 et 5, 6 et 5, 7 et 5, 81 et 84,
85 et 88, 89 et 92, et 93 et 96.

8. Kit de détection de la présence d'ADN de virus du papillome humain dans un échantillon à doser, comprenant :
une composition selon la revendication 6 ou 7 et en outre une polymérase.

9. Kit selon la revendication 8, dans lequel ladite polymérase est thermostable.

10. Oligonucléotide consensus pour hybridation du virus du papillome humain des types 6, 11, 16, 18, 31, 33 et 61, lequel oligonucléotide a d'environ 10 à environ 60 nucléotides de long et est sélectionné dans le groupe de séquences constitué par :

N° d'identification

	1	CAGATGTCTC	TGTGGCGGCC	TAGTG,
	5	AGGTGTCAGG	AAAACCAAAT	TTATT,
35	6	GAATTAGTTA	GACCATTTAA	AAG et
	7	GGGGAAACAC	CAGAATGGAT	A ;

et leurs compléments.

11. Oligonucléotide spécifique d'un type, destiné à déterminer la présence du virus du papillome humain de type 16, ayant une séquence sélectionnée dans le groupe constitué par :

N° d'identification

	81	GCTGCAAACA	ACTATACATG	ATATAA,
45	82	TTATATCATG	TATAGTTGTT	TGCAGC,
	83	TATTAGAATG	TGTGTACTGC	AAGCA,
	84	TGCTTGCACT	ACACACATTC	TAATA,
	93	GTATGGAACA	ACATTAGAAC	AGCA,
50	94	TGCTGTTCTA	ATGTTGTTCC	ATAC,
	95	ATACAACAAA	CCGTTGTGTG	ATTT et
	96	AAATCACACA	ACGGTTTGTT	GTAT ;

et leurs compléments.

12. Oligonucléotide spécifique d'un type, destiné à déterminer la présence du virus du papillome humain de type 18, ayant une séquence sélectionnée dans le groupe constitué par :

N° d'identification

	85	CTTCACTGCA	AGACATAGAA	ATAA,
5	86	TTATTTCTAT	GTCTTGCAGT	GAA,
	87	CCTGTGTATA	TTGCAAGACA	GTAT,
	88	TACTGTCTTG	CAATATACAC	AGG,
	89	TATATTGCAA	GACAGTATTG	GAAC,
	90	GTTCCAATAC	TGTCTTGCAA	TTTA,
10	91	TTACAGAGGT	ATTGAATTT	GCATT et
	92	AATGCAAATT	CAAATACCTC	TGTAA ;

et leurs compléments.

- 15 13. Procédé de détermination de la présence d'un virus quelconque du papillome humain dans un échantillon à doser, comprenant :

- 20 a. l'hybridation de l'ADN dans l'échantillon à doser avec au moins un oligonucléotide consensus sélectionné dans le groupe selon la revendication 10, ledit oligonucléotide étant conjugué à un composé émetteur d'un signal, capable de produire un signal détectable, et
b. la détermination de la présence du virus du papillome humain par détection du signal émis.

- 25 14. Procédé de détermination de la présence du virus du papillome humain de type 16 dans un échantillon à doser, comprenant :

- 30 a. l'hybridation de l'ADN dans l'échantillon à doser avec au moins un oligonucléotide sélectionné dans le groupe selon la revendication 11, ledit oligonucléotide étant conjugué à un composé émetteur d'un signal, capable de produire un signal détectable, et
b. la détermination de la présence du virus du papillome humain par détection du signal émis.

- 35 15. Procédé de détermination de la présence du virus du papillome humain de type 18 dans un échantillon à doser, comprenant :

- 40 a. l'hybridation de l'ADN dans l'échantillon à doser avec au moins un oligonucléotide sélectionné dans le groupe selon la revendication 12, ledit oligonucléotide étant conjugué à un composé émetteur d'un signal, capable de produire un signal détectable, et
b. la détermination de la présence du virus du papillome humain par détection du signal émis.

- 45 16. Procédé selon une quelconque des revendications 13 à 15, comprenant en outre une étape d'amplification avant ou pendant ladite étape d'hybridation.

17. Procédé selon la revendication 16, dans lequel ladite étape d'amplification comprend la PCR ou la LCR.

45 **Revendications pour l'Etat contractant suivant : ES**

- 50 1. Composition utile dans la LCR pour amplifier l'ADN de virus du papillome humain présent dans échantillon à doser, ladite composition comprenant un ensemble de quatre sondes oligonucléotidiques, lesdits ensembles de sondes étant sélectionnés dans le groupe constitué par les ensembles d'oligonucléotides suivants :

LCR5 : n° d'identification

	81	GCTGCAAACA	ACTATACATG	ATATAA,
	82	TTATATCATG	TATAGTTGTT	TGCAGC,
55	83	TATTAGAATG	TGTGTACTGC	AAGCA,
	84	TGCTTGCAGT	ACACACATTC	TAATA ;

LCR6 : n° d'identification

85 CTTCACTGCA AGACATAGAA ATAA,
 86 TTATTTCTAT GTCTTGCAGT GAA,
 87 CCTGTGTATA TTGCAAGACA GTAT,
 88 TACTGTCTTG CAATATACAC AGG ;

LCR7 : n° d'identification

89 TATATTGCAA GACAGTATTG GAAC
 90 GTTCCAATAC TGTCTTGCAA TTTA,
 91 TTACAGAGGT ATTTGAATTT GCATT,
 92 AATGCAAATT CAAATACCTC TGTA ; et

LCR8 : n° d'identification

93 GTATGGAACA ACATTAGAAC AGCA,
 94 TGCTGTTCTA ATGTTGTTCC ATAC,
 95 ATACAACAAA CCGTTGTGTG ATTT,
 96 AAATCACACA ACGGTTTGTT GTAT.

2. Composition selon la revendication 1, destinée à amplifier l'ADN de virus du papillome humain de type 16 présent dans un échantillon à doser, ladite composition comprenant un ensemble de quatre sondes oligonucléotidiques, lesdits ensembles de sondes étant sélectionnés dans le groupe constitué par les ensembles d'oligonucléotides suivants :

LCR5 (n° d'identification 81, 82, 83 et 84) et LCR8 (n° d'identification 93, 94, 95 et 96).

3. Composition selon la revendication 1, destinée à amplifier l'ADN de virus du papillome humain de type 18 présent dans un échantillon à doser, ladite composition comprenant un ensemble de quatre sondes oligonucléotidiques, lesdits ensembles de sondes étant sélectionnés dans le groupe constitué par les ensembles d'oligonucléotides suivants :

LCR6 (n° d'identification 85, 86, 87 et 88) et LCR7 (n° d'identification 89, 90, 91 et 92).

4. Kit de détection de la présence d'ADN de virus du papillome humain dans un échantillon à doser, comprenant : une composition selon l'une quelconque des revendications 1 à 3, et en outre une ligase.

5. Kit selon la revendication 4, dans lequel ladite ligase est thermostable.

6. Composition utile dans la PCR pour amplifier l'ADN de virus du papillome humain présent dans un échantillon à doser, ladite composition comprenant :

une première amorce d'acide nucléique de direction sens, capable de s'hybrider au brin antisens de l'ADN de HPV, ladite amorce ayant de 10 à environ 30 nucléotides de long et une séquence sélectionnée dans le groupe constitué par les séquences suivantes :

N° d'identification

5	1	CAGATGTCTC	TGTGGCGGCC	TAGTG,
	6	GAATTAGTTA	GACCATTTAA	AAG,
	7	GGGGAAACAC	CAGAATGGAT	A,
10	81	GCTGCAAACA	ACTATACATG	ATATAA,
	85	CTTCACTGCA	AGACATAGAA	ATAA,
	89	TATATTGCAA	GACAGTATTG	GAAC et
	93	GTATGGAACA	ACATTAGAAC	AGCA ; et

15 une deuxième amorce d'acide nucléique de direction antisens, capable de s'hybrider au brin sens de l'ADN de HPV, ladite amorce ayant de 10 à environ 30 nucléotides de long et une séquence sélectionnée dans le groupe constitué par les séquences suivantes :

N° d'identification

20	5	AGGTGTCAGG	AAAACCAAAT	TTATT,
	84	TGCTTGCACT	ACACACATTC	TAATA,
	88	TACTGTCTTG	CAATATACAC	AGG,
25	92	AATGCAAATT	CAAATACCTC	TGTAA et
	96	AAATCACACA	ACGGTTTGTT	GTAT ;

30 pour autant que lesdites première et deuxième amorces s'hybrident à leurs brins respectifs antisens et sens à des emplacements tels que leurs extrémités 3' ne se chevauchent pas et que, dans la direction d'extension, les extrémités 5' desdites amorces soient plus espacées que les extrémités 3' desdites amorces.

7. Composition selon la revendication 6, dans laquelle lesdites première et deuxième amorces sont sélectionnées parmi les paires suivantes de séquences oligonucléotidiques (identifiées par leur numéro d'identification) :

35 1 et 5, 6 et 5, 7 et 5, 81 et 84,
85 et 88, 89 et 92, et 93 et 96.

8. Kit de détection de la présence d'ADN de virus du papillome humain dans un échantillon à doser, comprenant :
une composition selon la revendication 6 ou 7 et
en outre une polymérase.

9. Kit selon la revendication 8, dans lequel ladite polymérase est thermostable.

10. Procédé de détermination de la présence d'un virus quelconque du papillome humain dans un échantillon à doser, comprenant :

45 a. l'hybridation de l'ADN dans l'échantillon à doser avec au moins un oligonucléotide consensus sélectionné dans le groupe de séquences constitué par :

N° d'identification

50	1	CAGATGTCTC	TGTGGCGGCC	TAGTG,
	5	AGGTGTCAGG	AAAACCAAAT	TTATT,
	6	GAATTAGTTA	GACCATTTAA	AAG et
	7	GGGGAAACAC	CAGAATGGAT	A ;

55 et leurs compléments, ledit oligonucléotide étant conjugué à un composé émetteur d'un signal, capable de produire un signal détectable, et

b. la détermination de la présence du virus du papillome humain par détection du signal émis.

11. Procédé de détermination de la présence du virus du papillome humain de type 16 dans un échantillon à doser, comprenant :

a. l'hybridation de l'ADN dans l'échantillon à doser avec au moins un oligonucléotide sélectionné dans le groupe de séquences constitué par :

N° d'identification

81	GCTGCAAACA	ACTATACATG	ATATAA,
82	TTATATCATG	TATAGTTGTT	TGCAGC,
83	TATTAGAATG	TGTGTACTGC	AAGCA,
84	TGCTTGCAGT	ACACACATTC	TAATA,
93	GTATGGAACA	ACATTAGAAC	AGCA,
94	TGCTGTTCTA	ATGTTGTTCC	ATAC,
95	ATACAACAAA	CCGTTGTGTG	ATTT et
96	AAATCACACA	ACGGTTTGTT	GTAT ;

et leurs compléments,

ledit oligonucléotide étant conjugué à un composé émetteur d'un signal, capable de produire un signal détectable, et

b. la détermination de la présence du virus du papillome humain par détection du signal émis.

12. Procédé de détermination de la présence du virus du papillome humain de type 18 dans un échantillon à doser, comprenant :

a. l'hybridation de l'ADN dans l'échantillon à doser avec au moins un oligonucléotide sélectionné dans le groupe de séquences constitué par :

N° d'identification

85	CTTCACTGCA	AGACATAGAA	ATAA,
86	TTATTTCTAT	GTCTTGCAGT	GAA,
87	CCTGTGTATA	TTGCAAGACA	GTAT,
88	TACTGTCTTG	CAATATACAC	AGG,
89	TATATTGCAA	GACAGTATTG	GAAC,
90	GTTCCAATAC	TGTCTTGCAA	TTTA,
91	TTACAGAGGT	ATTTGAATTT	GCATT et
92	AATGCAAATT	CAAATACCTC	TGTAA ;

et leurs compléments,

ledit oligonucléotide étant conjugué à un composé émetteur d'un signal, capable de produire un signal détectable, et

b. la détermination de la présence du virus du papillome humain par détection du signal émis.

13. Procédé selon une quelconque des revendications 10 à 12, comprenant en outre une étape d'amplification avant ou pendant ladite étape d'hybridation.

14. Procédé selon la revendication 13, dans lequel ladite étape d'amplification comprend la PCR ou la LCR.




FIG. 1

1 2 3 4 5 6 7 8 9 10 11 12 13



FIG. 2

Best Available Copy




FIG. 3

Best Available Copy

FIG. 4




FIG. 5




FIG. 6




FIG. 7

